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Abstract
The chromosomal region 2p23.3 contains the candidate type 2 diabetes genes encoding
glucokinase regulator protein (GKRP) and ketohexokinase (KHK) and is also the location of
the non-syndromic recessive sensorineural deafness gene DFNB9. Both GKRP and KHK
have previously been shown to be metabolically connected and with the co-localisation of
GCKR and KHK to a 500 kb region of human chromosome 2p23.3, the possibility of co¬
ordinate regulation by common as-acting regulatory elements has been raised. Several
genes on 2p, such as PPP1CB and KIF3C, map to mouse chromosome 12, but mapping of
both GCKR and KHK has shown them to co-localise to mouse Chr 5 (gene order PPP1CB-
KHK-GCKR-KIF3C). A detailed investigation of transcripts within this genomic region was
carried out with the aim of identifying and characterising other transcripts that may encode
proteins involved in carbohydrate metabolism and provide evidence for the involvement of
this genomic region in the pathogenesis of type 2 diabetes. In addition, the localisation of
the DFNB9 gene to the same region, 2p22-23, provided additional interest in transcripts that
were identified in this region and also expressed in the inner ear.
A 2 Mb physical contig that spanned both the KHK-GCKR genomic region and the DFNB9
interval was constructed using YACs, BACs, PACs and cosmids and assembled by a
combination of STS content analysis and cosmid fingerprinting. This physical contig was
used as the basis for transcript mapping by a combination ofPCR screening of genomic
clones for cDNA markers mapping to the 2p23 region and direct sequencing of genomic
clones with computer analysis of sequences to search for similarity to ESTs. A total of 14
known genes and 15 ESTs were mapped to the physical contig. Several ESTs were chosen
for further investigation based upon the involvement of their predicted encoded proteins in
various biochemical pathways with potential roles in the pathogenesis of type 2 diabetes or
deafness. Genes that were cloned included eIF2B4, the gene that encodes the delta subunit
of the guanine nucleotide exchange factor eIF2B, which plays a key role in protein synthesis
initiation and has been shown to be stimulated by both glucose and sugar phosphates. The
genomic structure was characterised, two different isoforms identified and tissue specific
splice forms identified. A gene called KIAA0064 was also characterised due to its intimate
location upstream to eIF2B4. An EST showing homology to ribokinase was investigated as
it belonged to the same family of kinase proteins as KHK. Three genes were identified as
candidate DFNB9 genes: MPV17, KIF3C, and KCNK3. The KIF3C gene was cloned,
genomic structure characterised and the mouse homologue mapped.
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A adenosine residue in a DNA sequence
ATP adenosine triphosphate
BAC bacterial artificial chromosome
bp base-pairs
BSA bovine serum albumin
C cytidine residue in a DNA sequence
°C degrees centigrade
Ca2+ calcium ion
cDNA complementary deoxyribonucleic acid
CEPH Centre d'Etude du Polymorphisme humain
Ci Curie


















E. coli Escherischia coli
EDTA ethylenediaminetetra-acetic acid disodium salt
eIF2 eukaryotic initiation factor 2 (substrate of eIF2B)
eIF2B eukaryotic initiation factor 2B (guanine nucleotide exchange factor eIF2B)
eIF2B4 the gene encoding the delta subunit of eIF2B
EMBF European Molecular Biology Laboratory
EST expressed sequence tag
F1 first generation offspring
FISH fluorescent in situ hybridisation
g grams or relative centrifugal force
G guanosine residue in a DNA sequence
GCK glucokinase
GCKR glucokinase regulator gene
GKRP glucokinase regulatory protein
GTP guanosine triphosphate
HGMP human genome mapping proj ect
ICRF Imperial Cancer Research Fund
IDDM insulin-dependent diabetes mellitus




KIF3C kinesin-related protein, member of the KIF3 family
KHK ketohexokinase
1 litres






MODY maturity onset diabetes of the young
mM millimolar
v
mRNA messenger ribonucleic acid
N2 backcross mice
NIDDM non-insulin-dependent diabetes mellitus
NSHI non-syndromic hearing impairment
nt nucleotides
p human chromosome short arm
PAC P1 artificial chromosome
PBS phosphate buffered saline
PCR polymerase chain reaction
PFGE pulsed field gel electrophoresis
q human chromosome long arm
RBSK ribokinase
RFLP restriction fragment length polymorphism
RNA ribonucleic acid
RNase ribonuclease
rpm revolutions per minute
RT-PCR reverse transcriptase polymerase chain reaction
SDS sodium dodecyl (lauryl) sulphate
SSC saline sodium citrate
SSCP single strand conformation polymorphism
STS sequence tagged site
T thymidine residue in a DNA sequence
Ta annealing temperature
TEMED NNNTSf tetramethylethylenediamine
TIGR The Institute ofGenomic Research
Tm melting temperature
tRNA transfer ribonucleic acid
tRNAMet methionyl-tRNA
Tris tris hydroxymethyl aminomethane
U units
UTR untranslated region
w/v weight for volume
YAC yeast artificial chromosome
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1 Chromosome 2p23.3 - a region of interest for
diabetes and deafness
1.1 Chromosome 2p23.3
The research described in this thesis examines in detail a genomic region of chromosome
2p23.3, within which are located the candidate type 2 diabetes genes encoding the
glucokinase regulatory protein (GKRP)and fructokinase (KHK), and also a locus for
non-syndromic recessive sensorineural deafness, DFNB9. The chromosomal region 2p23.3
first became of interest to us when the genes encoding GKRP and KHK were shown to
co-localise to a 500 kb region of 2p23 (Warner et al., 1995). GKRP and KHK had
previously been shown to have a close metabolic relationship with each other, since
fructose-1-phosphate is both the KHK end-product and an allosteric inhibitor ofGKRP.
Although the intimate location of their encoding genes GCKR and KHK could be a
coincidence, the possibility of common cis-acting regulatory elements has been raised
(Hayward et al., 1996). An investigation of the GCKR-KHK genomic region might therefore
also reveal other transcripts that encode proteins involved in carbohydrate metabolism and
provide evidence for the involvement of this genomic region in the pathogenesis of type 2
diabetes. Finally, the localisation of a gene for non-syndromic recessive sensorineural
deafness, DFNB9, to the same small genomic region in chromosome 2p22-p23 (Chaib et al.,
1996), provided additional interest in transcripts found in this region that are expressed in the
inner ear.
1.2 Type 2 diabetes
1.2.1 Classification and prevalence
Non-insulin-dependent (type 2) diabetes mellitus (NIDDM) is characterised by
hyperglycaemia due to defects in insulin secretion and/or action (Sacks & McDonald, 1996).
It is a common disorder especially in developed countries where it affects 10-20% of the
population older than 45 years of age (King & Rewers, 1993). In some populations such as
the Pima Indians, NIDDM is achieving epidemic proportions (Bennett, 1999). Left
untreated, NIDDM is a leading cause of death and morbidity. NIDDM differs from the
much less common insulin-dependent (type 1) diabetes mellitus (IDDM) in genetic basis,
2
age of onset (mainly in adults than juveniles), cellular manifestations (peripheral insulin
resistance rather than autoimmune destruction of pancreatic islet (3-cells), and treatment
(often by diet, not by insulin injections).
1.2.2 Genetic aetiology of type 2 diabetes
The genetic aetiology of type 2 diabetes was first investigated by examining type 2 diabetes
in older identical (monozygotic) twins. This revealed concordance rates approaching 100%
inmonozygotic twins but much lower in dizygotic (non-identical) twins (with estimates of
concordance ranging from 3% to 37% )(Barnett et al., 1981a; Barnett etal., 1981b). As
twins usually share the same environment early on in life, concordance could be the result of
genetic or environmental similarity, but the fact that they usually live apart in later life does
suggest, for a later-onset disorder such as type 2 diabetes, that this is a genetic disease.
Furthermore, a recent study investigating concordance rates for type 2 diabetes in
monozygotic twin pairs, initially ascertained as discordant for diabetes, reveals a
concordance rate of 76% 15 years of the initial type 2 diabetes in one member of the twin
pair (Medici et al., 1999). In addition, the concordance rate for any abnormality of glucose
metabolism (either type 2 diabetes or impaired glucose tolerance) at 15 years' follow-up was
96%. However, in another study of type 2 diabetes in twin pairs, concordance was only 26%
for type 2 diabetes but 61% for abnormal glucose tolerance (Poulsen et al., 1999). Although
different twin populations and experimental methods make it difficult to compare these
studies, generally they agree that genetic predisposition is important for the development of
abnormal glucose tolerance and that although environmental factors play an important part in
the pathogenesis of type 2 diabetes, genetic factors also play a crucial role.
1.3 The search for type 2 diabetes loci
1.3.1 Linkage studies
Although genetic factors have been shown to play a crucial role in determining susceptibility
to type 2 diabetes, the search for late onset NEDDM susceptibility loci has proven largely
unsuccessful. This can mainly be attributed to the multifactorial nature ofNIDDM
pathogenesis in which this highly genetic heterogeneous disorder is also further modulated
by environmental factors. Linkage studies have to overcome several problems, such as the
fact that the mean age at diagnosis is approximately 50 years, making it difficult to identify
complete nuclear families in which segregation events can be observed. Often one or both
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parents are not available, due both to the high mortality rate of the disorder and to the fact
that children of affected individuals may not yet have developed the condition. Without a
genetic model that reflects the clear familial aggregation of the disorder, new methods such
as genome-wide linkage screening forNIDDM susceptibility genes using affected siblings
without parents have had to be employed.
So far, three loci have been identified in two different populations using such approaches
(see Table 1.1). TheNEDDMl locus near to D2S125 was identified using non- and
quasi-parametric linkage analysis in a genome-wide search forNIDDM genes in Mexican
Americans (Hanis et al., 1996). This data suggests that in this population studied, late onset
NIDDM results from the action of at least one relatively major susceptibility gene.
However, in two other populations (non-Hispanic whites and Japanese), no evidence for
linkage ofD2S125 with NIDDM was found. Similarity, in the Finnish population two other
NIDDM loci, on chromosome 12 (Mahtani et al., 1996) and chromosome 20 (Ghosh et al.,
1999) have been identified, but when other populations with late onset NIDDM have been
analysed, no linkage was found to these chromosomal regions. These results suggest that
different racial and ethnic populations may have different NIDDM susceptibility loci or
perhaps susceptibility loci within different populations play stronger or weaker roles in the
multistep process leading to the onset ofNIDDM.
NIDDM locus Gene Chromosomal location Population
NIDDM 1 unknown 2q37 Mexican Americans
NIDDM 2 HNF1A 12q24.2 Finnish
NIDDM3 unknown 20 Finnish
Table 1.1 NIDDM loci.
1.3.2 The candidate gene approach
Genome-wide screening of populations withNIDDM has identified only a limited number of
candidate loci, and even these have not been shown to be of central importance in disease
pathogenesis in different populations. Therefore, to identify other genes involved in the
pathogenesis of type 2 diabetes, the candidate gene approach has been frequently adopted.
For the successful identification ofNIDDM candidate genes, an understanding of the
biochemical pathways underlying both insulin secretion and action is required. One of the
first successes was the detection ofmutations in the insulin-receptor gene in patients with
NIDDM (Orahilly et al., 1991). However, mutations in the insulin-receptor gene account for
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a very small proportion ofNIDDM cases. The insulin-receptor gene was identified by its
role in insulin action, but other candidate genes were identified by their role in insulin
secretion.
1.4 Maturity onset diabetes of the young (MODY)
1.4.1 Identification of MODY genes
The main successes in identifying NIDDM susceptibility loci have arisen using linkage
studies in families with maturity onset diabetes of the young (MODY), a monogenic form of
NIDDM characterised by onset usually before 25 years of age and autosomal dominant
inheritance. The genetic analysis ofMODY families has identified 5 different genes
involved in the pathogenesis ofMODY (see Table 1.2). Mutational screening studies in
MODY families has also shown that several do not contain mutations in any of these 5
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Table 1.2 MODY genes and chromosomal location.
1.4.2 Function of MODY genes
Although the exact function of the proteins encoded by MODY genes is unknown, four out
of the five MODY genes encode transcription factors (the exception being glucokinase - see
Section 1.5). Clinical physiological studies indicate that mutations in these genes are
associated with abnormal patterns of glucose-stimulated insulin secretion by pancreatic
P-cells. HNF4A (encoded by HNF4A, the MODY1 gene) is a key regulator of hepatic gene
expression and is a major activator ofHNF1A (the MODY3 gene) expression. HNF1, in turn
activates the expression of a large number of genes specifically in the liver, for example
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albumin, alpha-1-antitrypsin, and pyruvate kinase (Courtois et al., 1987). Both HNF4A and
HNF1A are also expressed in other tissues including the pancreas. The interaction between
HNF4A and HNF1A demonstrates the existence of a complex transcriptional regulatory
mechanism for the expression of genes in both liver and the pancreas.
Studies investigating the cellular consequences ofmutations inMODY genes will reveal
important information concerning the pathogenesis of type 2 diabetes. The HNF1A rat
homologue encodes a transcription factor that binds a sequence required for
hepatocyte-specific transcription of several genes (Courtois et al., 1987). It is also
suggested, though, that mutations in human HNF1A might lead to diabetes by causing
abnormal pancreatic islet development during fetal life or by impairing transcriptional
regulation of genes that play a key role in normal [3-cell function (Vaxillaire et al., 1997).
The gene underlying MODY5 encodes another hepatic transcription factor (TCF2).
Mutations in either TCF2 or HNF1A can cause MODY by affecting [3-cell function and
interestingly, deficiency of either TCF2 or HNF1A also affects renal function; individuals
with TCF2 mutations show susceptibility to severe non-diabetic renal disease (Horikawa et
al., 1997; Nishigori et al., 1998), while HNF1A mutations are associated with reduced renal
thresholds for glucose (Menzel et al., 1998).
The MODY4 gene (IPF1), is a homeodomain-containing transcription factor and is critically
required for the embryonic development of the pancreas and for the transcriptional
regulation of endocrine pancreas-specific genes in adults, such as insulin, glucose
transporter-2 (GLUT2) and glucokinase in [3-cells, and somatostatin in 8-cells (reviewed in
Habener & Staffers, 1998)). The finding that four out of five MODY genes encode
transcription factors suggests that the proper transcriptional regulation of glucose
homeostasis-specific genes is crucial for maintaining normal blood glucose levels.
Understanding the complex transcriptional regulatory mechanisms in both liver and pancreas
may reveal novel candidate type 2 diabetes genes.
1.4.3 The role of MODY genes in late onset type 2 diabetes
Interestingly, the MODY3 and MODY4 genes have now also been linked to late onset type 2
diabetes. The NIDDM2 and MODY3 loci co-localise, and NIDDM2 and MODY3 families
are both characterised by a reduced insulin secretory response that subsequently progresses
to diabetes. It is suggested that both forms ofNIDDM are due to allelic mutations in the
HNF1A gene (Lehto et al., 1997). Mutations in the MODY4 gene, IPF1, have now also
6
been demonstrated in late onset type 2 diabetes (Hani et al., 1999). IPF1 mutations that
result in a profound alteration of IPF1 function cause MODY 4 but less severe mutations
cause a late-onset form of type 2 diabetes. This demonstrates that the identification of genes
underlyingMODY may also lead to the discovery of genes involved in late-onset type 2
diabetes.
1.5 Glucokinase (GCK)
1.5.1 GCK- a good candidate type 2 diabetes gene
The glucokinase (GCK) gene encodes the major enzyme that phosphorylates glucose on
entry into the liver and pancreatic islet P-cells. The gene encoding GCK was considered a
good candidate as a type 2 diabetes gene when it was discovered that GCK played an
important role in determining the rate of glucose uptake and thereby acting as a key
component in "glucose-sensing" in pancreatic islet [3 -cells, controlling insulin release.
1.5.2 Evidence for glucokinase as the "glucose-sensor"
Glucose metabolism is initiated by phosphorylation of the sugar to glucose-6-phosphate by
hexokinases. In all cells except hepatocytes and insulin-secreting pancreatic cells ((3-cells),
glucose is phosphorylated by hexokinases I, II or III, all of which have a Michaelis constant
(Km) for glucose in the 0.01 to 0.1 mM range. Glucose metabolism rates depend on the
concentration of glucose within the cell, and in all cells except hepatocytes and pancreatic
P-cells, this is controlled by the activity of plasma membrane glucose transporters (GLUT) 1,
3, and 4 (Burant et al., 1991).
However, investigation of glucose transport into hepatocytes revealed that these cells appear
freely permeable to glucose (Cahill, 1958a; Cahill, 1958b) and that their rate of glucose
phosphorylation is dependent on glucose concentration across the physiological range (4-9
mM). Further investigation revealed that glucose transport into hepatocytes and pancreatic
P-cells is facilitated by glucose transporter 2 (GLUT2). Therefore, unlike the other glucose
transporters, GLUT2 is non rate-limiting for glucose metabolism (Johnson et al., 1990), it
facilitates rapid equilibrium between extracellular and intracellular glucose so that the
concentration of glucose in hepatocytes and pancreatic P-cells is within the physiological
range (4-9 mM).
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In all tissues except liver and pancreas, hexokinases I, II, and III phosphorylate glucose for
entry into the glycolytic pathway. However, in hepatocytes and pancreatic P-cells, a
different hexokinase was identified with different kinetic properties to that of hexokinases I,
II, and III (DiPietro, 1962). This hexokinase was named glucokinase (hexokinase IV or
GCK) and its properties included a much lower affinity for glucose than the other
hexokinases, a sigmoid glucose concentration-reaction velocity relationship, and no
inhibition by the reaction product glucose-6-phosphate (Vinuela, 1963).
Investigation of insulin secretion by P-cells shows that only sugars which are substrates for
hexokinases and for glycolysis elicit insulin release, suggesting a link between sugar
metabolism and insulin release (German, 1993). It was also found that the insulin output of
cultured P-cells is regulated by glucose according to a sigmoidal curve (Liang et al., 1992),
with a threshold for insulin production around the physiological glucose concentration of
4mM (Figure 1.1). The resemblance of this sigmoidal curve to the glucose
concentration-reaction velocity curve ofGCK suggested that GCK might play a key role in
this homeostatic process of sensing glucose and modulation of insulin release (Matschinsky,
1990; Randle, 1993). The functional characteristics ofGCK allow it to increase glucose
phosphorylation in response to hyperglycaemia and it is this variable flux into glycolysis that
is thought to determine insulin output. Thus, in effect, the extracellular glucose
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Figure 1.1 Sigmoidal relationship between glucose concentration and insulin output in the
pancreatic P-cell. (Chen et al., 1994). The threshold for insulin production is around
physiological glucose concentration of 4mM. A) "normal" glucose homeostasis (green line);
B) postulated effect ofmutations in GCK that "reset glucose sensing"(red line), causing
insufficient insulin release in response to high levels of glucose, as seen in mild type 2
diabetes (MODY2).
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The downstream mechanism between "glucose sensing" by GCK and insulin release
involves a complex series of steps that presently are still poorly defined. Until recently, the
level ofATP in the pancreatic (3-cell, which affects cell membrane potential through
ATP-dependent K+ channels, was thought to be the main mechanism for insulin release.
Briefly, enhanced glucose metabolism in the (3-cell leads to an increased ATP/ADP
concentration ratio and closure ofATP-dependent K+ channels. This causes membrane
depolarisation and opening of voltage-dependant Ca2+ channels. The influx of (3-cell Ca2+
triggers the release of insulin into the blood stream through exocytosis of insulin secretory
granules in the (3-cell (Ashcroft & Gribble, 1999). This is an example of a glucose-induced
ionic event.
It is now thought that "non-ionic" glucose actions in the (3-cell also play an important role in
insulin secretion. This hypothesis is based upon evidence showing (3-cell insulin secretion
that is independent of potassium ion channel function (Aizawa et al., 1994) and insulin
release even during Ca2+ deprivation (Macfarlane et al., 2000). It should also be noted that
in pancreatic (3-cells, while glucose is the major insulin secretagogue, there are a host of
other physiological regulators that stimulate insulin release from pancreatic (3-cells. These
include neurotransmitters, neuropeptides, circulating hormones, and amino acids (Dunne,
2000). Whereas glucose must be metabolised in the [3-cell for insulin secretion,
neuromodulators influence the insulin secretory process following their interaction with
specific cell-surface receptors.
It is clear that the sensing mechanisms for insulin secretagogues and corresponding signal
transduction pathways required for insulin release are highly complex. Much research is
now being focused on "non-ionic" glucose action in the (3-cell and also how
neuromodulators influence the insulin secretory process. The elucidation and understanding
of signal transduction pathways involved in insulin release in the (3-cell will almost certainly
identify novel type 2 diabetes candidate genes.
1.5.3 Mutations in GCK can cause MODY
Linkage ofMODY to the GCK locus in chromosome 7 (MODY2) and subsequent
demonstration ofmutations in GCK (Froguel et al., 1992), confirmed that in this case, the
candidate gene approach had been successful. The cDNA encoding GCK was first cloned
from liver (Andreone et al., 1989) and later an islet-specific glucokinase was isolated from a
rat insulinoma cDNA library. This, differs from the liver cDNA at its 5' end (Magnuson &
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Shelton, 1989). Analysis of the GCK genomic structure reveals that both isoforms originate
from the same gene. Both are, encoded by 10 exons, and differ in their first exons only, the
liver and islet isoforms both sharing exons 2-10. In addition, a further, less abundant liver
splice form exists, that is produced as result of inclusion of a "cassette" exon between exons
1 and 2 (reviewed in Iynedjian, 1993). The mutations in GCK that cause MODY2 have been
shown to reduce glucokinase activity (to approximately 50% of normal, since only one allele
is mutated) (Gidhjain et al., 1993). This reduction in GCK activity then appears to "reset the
glucose homeostat", resulting in the threshold of circulating glucose levels which induce
insulin secretion to be raised (Figure 1.1).
1.5.4 Regulation of GCK activity
1.5.4.1 Effectors of GCK activity
As mutations in GCK underlie MODY2, genes that encode modulators ofGCK activity such
as regulatory proteins, could also be considered as good candidate genes for type 2 diabetes.
Possible mechanisms that could alter the rate of glucose phosphorylation by GCK would be
changes in cellular content ofGCK and/or GCK catalytic activity (Chen et al., 1994).
Studies of cellular GCK protein levels reveal increased levels ofGCK only after a long time
period of sustained high glucose concentration (Chen et al., 1994). However, in studies of
possible GCK allosteric effectors, GCK activity was shown to increase fivefold in cultured
rat islets under high glucose concentrations despite little change in mRNA levels. This
suggests that regulation of glucokinase is mostly post-transcriptional (Liang et al., 1992).
The metabolite fructose has also been shown to increase uptake and phosphorylation of
glucose and its conversion to glycogen, lactate, CO2 and amino acids (reviewed in
Vanschaftingen & Vandercammen, 1989). Further investigation into the effect of fructose
revealed that hepatic glucokinase is inhibited by fructose-6-phosphate (F-6-P), that this
inhibition is relieved by fructose-1-phosphate (F-l-P) and that these effects of fructose
phosphates require a specific regulatory protein called glucokinase regulatory protein
(GKRP) - see Figure 1.2 (Van Schaftingen, 1989).
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Figure 1.2 The effect of fructose phosphates on glucokinase regulatory protein (GKRP)
inhibition ofglucokinase (GCK). Abbreviations: KHK, Ketohexokinase; F-l-P,
fructose-1-phosphate; F-6-P, fructose-6-phosphate; G-6-P, glucose-6-phosphate. In the
presence of F-6-P, GKRP interacts non-covalently with GCK causing its inhibition. F-l-P
(the product of fructose phosphorylation by KHK), relieves inhibition ofGCK by GKRP.
F-6-P concentrations can passively reflect those ofG-6-P via G-6-P isomerase. As insulin
secretion by the pancreatic P-cell depends on the rate of glycolytic flux, effectors ofGCK
activity such as the action of fructose phosphates through GKRP may play an important role
in the pathogenesis of type 2 diabetes.
1.5.4.2 Glucokinase regulatory protein (GKRP)
The investigation of the 65 kDa glucokinase regulatory protein (GKRP) in rat liver reveals
that in the presence ofF-6-P, GKRP interacts non-covalently with GCK causing its
inhibition (Van Schaftingen, 1989). However, F-l-P prevents the association ofGCK and
GKRP, thus antagonising the inhibition exerted by F-6-P and upregulating GCK activity
(Malaisse et al., 1990). The fructose effect (Figure 1.2) has also been shown to exist in the
pancreatic islet which also contains both GKRP and KHK (Malaisse et al., 1990). The
F-1-P/F-6-P ratio is probably mainly alterable through variation in F-l-P concentration,
because F-6-P will passively follow G-6-P (via G-6-P isomerase), suggesting F-6-P as a
mediator of indirect end-product inhibition ofGCK (Randle, 1993). This important
regulatory role ofGKRP and fructose phosphates on GCK was confirmed by the restoration
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of fructose phosphate responsiveness of purified GCK by recombinant rat GKRP (Detheux
& Vanschaftingen, 1994). Further investigation of the inhibitory function ofGKRP on GCK
has also subsequently revealed the importance of subcellular localisation of both GKRP and
GCK in controlling the activity of this system.
1.5.4.3 Subcellular localisation of GCK and GKRP
Studies into the mechanism by which glucose stimulates GCK activity reveal the importance
of the subcellular location ofGCK and the essential role that GKRP plays in controlling this
subcellular localisation ofGCK. One study shows that in livers of fasted rats, GCK is found
predominantly in the hepatocyte nuclei bound to GKRP, forming an inactive complex.
However in livers of re-fed rats, GCK is translocated to the cytoplasm where it is unbound
and active (Fernandez-Novell et al., 1999). A diagrammatic model ofGCK
nuclear-cytoplasmic translocation and the role ofGKRP is shown in Figure 1.3. Apart from
high glucose, both fructose-1-phosphate and sorbitol can also stimulate translocation ofGCK
from nuclei to cytoplasm (Mukhtar et al., 1999). The important role ofGKRP in GCK
subcellular localisation is shown in studies usingmutant GCK that are unable to bind GKRP.
In this case, GCK is unable to accumulate in the hepatocyte nuclei even at low glucose
concentration (de la Iglesia et al., 1999).
Although all these studies show that GKRP sequesters GCK in the hepatocyte nuclei, there
are conflicting reports concerning the subcellular localisation ofGKRP during levels of high
glucose. This conflict may be due to the different techniques used to observe subcellular
localisation GKRP during high and low levels of glucose. Research using specific
antibodies against GKRP and laser confocal fluorescence microscopy suggest no
translocation ofGKRP from nuclei to the cytoplasm at any level of cellular glucose (Brown
et al., 1997). However, other confocal microscopic studies using quantitative imaging show
that GKRP is translocated with GCK from the nuclei during high levels of glucose (Mukhtar
et al., 1999; Toyoda et al., 1995). The latter study indicated that GKRP translocation out of
the hepatocyte nuclei with GCK results in only a fractional decrease in total nuclei GKRP.
As this results in only small changes in nuclear/cytoplasmic ratios ofGKRP compared to
that for GCK, changes in GKRP can only be seen using quantitative imaging. This suggests
that in addition to the role in nuclear retention ofGCK, GKRP may also be involved in
nuclear export or import of glucokinase (Mukhtar et al., 1999). The involvement ofGKRP
in the subcellular localisation ofGCK, coupled to the sigmoidal kinetics ofGCK, confers a
markedly extended responsiveness and sensitivity to changes in glucose concentration in the
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hepatocyte. The full implications of this regulatory mechanism for both glycogen synthesis
in the liver and insulin release by the pancreatic P-cell have still to be understood.
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Figure 1.3 Model showing a nuclear-cytoplasmic translocation cycle for hepatic glucokinase
(GCK), and the role that the glucokinase regulatory protein (GKRP) plays in this cycle.
During low levels of cellular glucose, GCK is bound in an inactive complex with GKRP in
the hepatocyte nuclei. High levels of glucose stimulate GCK translocation from the
hepatocyte nuclei to the cytoplasm where it is unbound and active. There are conflicting
reports as to whether GKRP is or is not translocated with GCK from the hepatocyte nuclei.
This diagram is adapted from (Shiota et al., 1999).
1.5.4.4 Mice mutant for glucokinase regulatory protein
Further evidence for an important role for GKRP in glucose homeostasis has recently been
obtained by the creation of a mouse knockout of Gckr, the gene encoding gkrp (Farrelly et
al., 1999; Grimsby et al., 2000). Before the creation of this mouse knockout, it was thought
that gain of function mutations in GCKR would most likely lead to enhanced glucokinase
inhibition and the development ofMODY phenotype. Loss of function mutations in GCKR
would be predicted to result in higher glucokinase activity. However, the mouse Gckr
knockout revealed that loss ofGkrp causes a secondary loss of glucokinase protein and
activity in mutant mouse liver. This loss is shown to be primarily because of
post-transcriptional regulation of glucokinase, indicating a positive role for GKRP in
maintaining glucokinase levels and activity.
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As discussed previously (see Section 1.5.4.3), GKRP plays an important role in the
subcellular localisation ofGCK by sequestering GCK in hepatocyte nuclei until high levels
of glucose stimulate GCK translocation to the cytoplasm where it is unbound and active (see
Figure 1.3). In the hepatocytes ofGckr -/- mice, Gck is not found in the nucleus under any
conditions. This result is similar to that seen in experiments using mutant Gck that cannot
bind Gkrp, showing that mutant Gck is unable to accumulate in hepatocyte nuclei (de la
Iglesia et al., 1999). Therefore, the Gckr -/- mice confirm the function ofGkrp as an anchor
to sequester and inhibit glucokinase in the hepatocyte nucleus.
In the Gckr-mutant mice, the disruption of the GKRP sequestration mechanism on GCK in
hepatocyte nuclei results in a subsequent decrease in GCK activity (Farrelly et al., 1999;
Grimsby et al., 2000). Interestingly, although glucose and insulin levels in Gckr -/- mice
(both fasting and fed) were relatively unchanged compared to Gckr +/+ mice, total liver
glycogen concentration was decreased (33% lower in -/- mice compared to +/+ mice). This
suggests impaired glucose metabolism and is consistent with impaired liver glycogen
synthesis observed in MODY2 patients with defective GCK activity (Velho et al., 1996).
Other physiological changes observed in the Gckr -/- mice were elevated levels of the
gluconeogenic enzyme phosphoenolpyruvate carboxykinase (expression negatively regulated
by insulin) and higher glucose levels after a glucose challenge. These additional effects
suggest that the Gckr -/- mice develop resistance to insulin.
To summarise (see Figure 1.3), during the fasting state, GKRP maintains a reserve pool of
GCK in the hepatocyte nucleus. After feeding, the GKRP/GCK association is disrupted, and
GCK is rapidly released and mobilised into the cytoplasm to provide phosphorylation
activity. After glucose levels lower, GCK moves back into the nucleus where it is
sequestered until required. This process ensures that glucose phosphorylation is minimal
when the liver is in the fasting, glucose-producing phase. It also enables hepatocytes to
rapidly mobilise glucokinase into the cytoplasm to phosphorylate and store or metabolise
glucose after the ingestion of dietary glucose. Before this regulatory process was discovered,
the level of hepatic glucose output was thought to be regulated only by the relative rates of
glucose phosphorylation and dephosphorylation by GCK and glucose-6-phosphatase,
respectively. The additional level of regulation by GKRP on GCK allows the rapid response
to glucose or fructose in hepatocytes resulting in a rapid on/off switch for glucose sensing by
GCK in the liver.
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Although the exact mechanism by which GKRP regulates GCK activity has still to be fully
characterised, the creation of the Gckr -/- mouse reveals that GKRP plays a pivotal role in
determining GCK localisation in hepatocyte nuclei and controlling GCK translocation to the
cytoplasm in response to high levels of glucose and fructose. Interestingly, the mouse Gckr
knockout also shows subtle biochemical changes such as decreased total liver glycogen
concentration. This is consistent with impaired liver glycogen synthesis found in
individuals with MODY2 and confirms GCKR as an excellent candidate type 2 diabetes
gene.
1.6 Characterisation of GCKR
To investigate a possible role ofGKRP in the pathogenesis of type 2 diabetes, the human
gene encoding GKRP (called GCKR) was cloned so that a search for diabetogenic mutations
in GCKR could be performed. The full length human GCKR cDNA (2194 bp) was cloned
(Warner et al., 1995) by first designing degenerate oligonucleotide pools from regions of
amino acid sequence conserved between rat and Xenopus GKRP for use in PCR screening a
hepatoblastoma cDNA library (HepG2). Two HepG2 PCR products of expected size were
amplified showing close homology to rat GCKR and these were used to re-screen the HepG2
library by hybridisation. One full length cDNA clone was sequenced and this revealed an
open reading frame encoding 625 residues that is 88% identical to the rat GKRP (627
residues) but only 59% identical to the fructose phosphate-insensitive Xenopus GKRP (619
residues). To obtain genomic clones, a primer pair was designed that amplified a 258 bp
PCR product that included a 187bp intron at position 558-559 of the cDNA sequence
(Genbank accession number Z48475) and this was used to PCR screen the ICI YAC library
(Anand et al., 1990). Two non-chimeric YACs, 26BA11 and 29IH8 were obtained (sizes
300 kb and 500 kb respectively) and these were each used to perform chromosomal
localisation by in situ hybridisation. Both GCKR-containing YACs localised to chromosome
2p23 (Warner et al., 1995) confirming a previous localisation to 2p22.3-p23 (Vaxillaire et
al., 1994).
The analysis of the GCKR genomic structure (see Chapter 2, Figure 2.2) reveals the gene to
consist of 19 exons and 18 introns, spanning 27 kb, and investigation of the GCKR mRNA in
the liver and pancreatic islet reveals no tissue specific alternative splice forms (Hayward &
Bonthron, 1998). Initial screening of GCKR by SSCP analysis revealed a common
polymorphism in the Scottish population within exon 15, which alters residue 446 from
proline, conserved in rat and Xenopus, to leucine. Identification of other polymorphisms and
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introduction of these mutations into recombinant human GKRP may indicate whether they
possess any pathophysiological significance. Further investigation of the possible role of
GCKR in the pathogenesis of type 2 diabetes by amplification of individual exons and
mutational analysis by SSCP (Orita et al., 1989) or sequencing has still to be carried out.
1.7 Fructokinase (KHK)
1.7.1 Characterisation of KHK
The stimulation of glucose phosphorylation in the liver by fructose can be explained by the
presence of fructokinase (KHK). This enzyme catalyses the first step ofmetabolism of
dietary fructose by phosphorylating fructose to F-l-P (Figure 1.2). The fructose effect has
also been shown to exist in the pancreatic islets, where in mouse and rat islets in the presence
of glucose (5.5 mM), a concentration of 20 pM fructose doubles the rate of insulin release
(Ashcrofit et al., 1972).
The phosphorylation of fructose to F-l-P by KHK and the role of F-1-P/F-6-P ratio in the
GKRP regulation ofGCK activity in both the liver and pancreatic islet, suggests that KHK
could play a role in the pathogenesis of type 2 diabetes. To investigate this possible role, the
gene encoding KHK was characterised (Bonthron et al., 1994). The KHK cDNA was
isolated by screening a HepG2 cDNA library by low-stringency hybridisation with the entire
rat KHK coding region. The longest cDNA clone (pHKHK3a\ Genbank accession number
X78677) contains an open reading frame encoding 298 residues but two other shorter cDNA
clones were also identified (pHKHK3d andpHKHKl-2). These two shorter clones were
derived frommRNA that had utilised an upstream polyadenylation site resulting in a shorter
3TJTR. It was also noticed thatpHKHKl-2 is an alternative splice form that differs from the
other two clones by containing an alternative exon (Genbank accession number X78678).
Inspection of the two alternative exons reveals that they show enough similarity to suggest
that they may have arisen from an intragenic duplication event within KHK.
To characterise the KHK genomic structure, a PI clone (J0788) was isolated from the ICRF
P1 reference library 700 (Francis et al., 1994). KHK was shown to consist of 9 exons
spanning 14 kb (see Chapter 2, Figure 2.4), with two alternative splice forms arising from a
pair of homologous exons (3a and 3c). The functional significance of these two different
KHK splice forms is unknown but there is some evidence that they may perform different
functions. The two KHK isoforms are evolutionary conserved between human, mouse and
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rat, suggesting distinct conserved functions, and the alternative splicing has been shown to
be tissue specific (Hayward & Bonthron, 1998). In both human and rat, the 3c isoform is
exclusively expressed in tissues expressing high levels ofKHK (liver, kidney, and
duodenum), while other tissues use only the 3a isoform. There is also a developmental
splicing shift from the 3a isoform to the 3c form when comparing foetal and adult tissues.
As KHK is thought to act as a dimer, the tissue specificity ofKHK isoforms suggests that the
dimer consists ofA-A or C-C isoforms but not a mixture of both.
1.7.2 Molecular basis of essential fructosuria
An inherited deficiency ofKHK was first shown to cause the benign metabolic disorder
essential fructosuria using a biochemical assay for fructokinase (Schapira, 1961-1962). To
genetically confirm this, the gene encoding KHK was screened for mutations in a well
characterised family, in which three out of eight siblings were known to have essential
fructosuria (Bonthron et al., 1994). The finding ofKHKmRNA in lymphoblastoid cells
allowed the analysis by RT-PCR ofRNA from a lymphoblastoid cell line from one essential
fructosuria patient. Cloning and sequencing ofRT-PCR products (the coding region was
amplified in two overlapping segments), revealed several single base substitutions. Using a
PCR/restriction digest assay, it was shown that all the affected individuals were compound
heterozygotes for two mutations Gly40Arg and Ala43Thr. An additional conservative amino
acid change (Val49Ile) was present on the KHK allele bearing Ala43Thr but this is found to
be a common polymorphism in normal Europeans. Both Gly40Arg and Ala43Thr lie in a
conserved region of the protein (in both alternative splice forms), produce non-conservative
amino acid changes, and were not present in >100 control alleles. Therefore it was
concluded that these amino acid changes were responsible for the fructosuric phenotype.
1.8 Co-localisation of GCKR and KHK
The isolation from the ICRF PI reference library 700 of a PI clone (J0788) that contains the
whole ofKHK, and then the isolation ofYACs (26BA11 and 29IH8) and a PAC (J16101)
which contain GCKR (Warner et al., 1995), allowed refinement of the genomic localisations
of GCKR and KHK by fluorescent in situ hybridisation (FISH). This showed that both genes
map to chromosome 2p23.2-23.3 and furthermore, two-colour interphase FISH suggested
that the two genes lie within 500 kb of each other (Hayward et al., 1996). This is an
intriguing finding and although this physical proximity could be a coincidence, it is
noteworthy because of the intimate metabolic links between the two genes' products.
17
Although the clustering of non-homologous genes by function is rare in vertebrates,
exceptions do exist such as the immunoglubulin recombination activating genes RAG1 and
RAG2 (Oettinger et al., 1992). It is also conceivable that the intergenic region between
GCKR and KHK could contain regulatory elements that are common to both genes.
1.9 Other known candidate type 2 diabetes genes at
chromosome 2p23.3
Another candidate type 2 diabetes gene, the protein serine/threonine phosphatase 1 beta
subunit (PPP1CB), also maps to chromosome 2p23 (Saadat et al., 1994). Insulin resistance
is associated with decreased rates of insulin-mediated glycogen synthesis in skeletal muscle
(DeFronzo et al., 1992). Type 1 protein phosphatase (PP1), which activates insulin
stimulation of glycogen synthase, is decreased in insulin-resistant subjects (Kida et al.,
1990). Because the PP1 catalytic (3 subunit is part of the PP1 major isoform in the glycogen
bound PP1 complex, its gene (PPPICB) is also a good candidate for type 2 diabetes
(Prochazka etal., 1995).
In a study involving 19 candidate genes (including GCKR and PPPICB), whose products are
implicated in insulin secretion or action, no evidence for linkage of these candidate genes to
NIDDM was found by non-parametric methods in affected sib pairs from the French
population (Vionnet et al., 1997). This suggests that in these French families, none of the
genes investigated are major contributors to the pathogenesis ofNIDDM. However, these
negative linkage results do not exclude the possibility that mutations in these genes may play
smaller roles in the polygenic background ofNIDDM or a major role in other populations.
1.10 The DFNB9 interval
It became apparent during the course of this work that the GCKR-KHK interval on
chromosome 2p23 also coincided very closely with the location of a gene for non-syndromic
recessive sensorineaural deafness (DFNB9) (Chaib et al., 1996). Consideration was
therefore given during our characterisation ofnovel genes in this region, to whether any of
these genes would be good candidate DFNB9 genes. The identification of candidate deafness
genes was based primarily on the location of the gene within the DFNB9 interval and
putative function of the encoded function.
18
1.11 Aim of this investigation
This thesis describes a detailed examination and characterisation of a genomic region of
2p23.3, the location of the candidate type 2 diabetes genes GCKR and KHK, and the gene for
non-syndromic recessive sensorineural deafness, DFNB9. Chapter 2 describes the mapping
of Gckr and Khk in the mouse genome that reveals information about the genetic linkage of
these two genes through evolution. The creation of a detailed transcript map of the
GCKR-KHK intergenic region and DFNB9 interval is described in Chapter 3. This was
aided by the construction of a YAC, BAC, PAC and cosmid physical contig spanning 2 Mb
across this genomic region. Chapter 4 describes the investigation and characterisation of
transcripts with possible roles in biochemical pathways relating to carbohydrate metabolism.
The search, identification and characterisation of candidate DFNB9 genes on chromosome
2p23.3 is described in Chapter 5. Chapter 6 describes future work that could be carried out
to further investigate the function of the genes identified by the research described in this




2 Mapping of the genes encoding glucokinase
regulatory protein and ketohexokinase in the
mouse
2.1 Introduction
2.1.1 Co-localisation of the glucokinase regulatory protein and
ketohexokinase to human chromosome 2p23
The mapping of GCKR and KHK genes by fluorescent in situ hybridisation using the KHK PI
clone J0788 and the GCKR PI clone J16101 reveals that both genes co-localise to human
chromosome 2p23.2-23.3 (Hayward et al., 1996). The intimate metabolic connection between
GKRP and KHK, added to the close proximity of the GCKR and KHK genes may suggest a
genetic regulatory factor (see Chapter 1). Mapping of the Gckr and Khk genes in the mouse
would provide an interesting insight into their genetic relationship and may add further
circumstantial support to the possibility of their co-ordinate regulation. Also, if these two genes
were found to reside in a region of conserved synteny between human and mouse chromosomes,
this may facilitate the identification of other human transcripts located in chromosome
2p23.2-23.3 that have mouse orthologues near Gckr and Khk.
2.1.2 Comparative genomics
The divergence of the various mammalian lineages approximately 70 million years ago led to
chromosomal rearrangements resulting in alteration of the original order of genes and, in some
cases, the exchange of segments among chromosomes (Ohno, 1973). However, the number of
rearrangements has been sufficiently few to allow the comparison ofmammalian genome
organisation and detailed mapping has enabled the creation of comparative maps. Although
these comparative maps provide an interesting insight of genome organisation and evolution, it
is their use in disease gene identification, for example by the accurate cross referencing ofmodel
organism genes with mapped mammalian phenotypes that can help facilitate the identification of
genes mutated in human disease states via the positional candidate approach. By identifying
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homologous human disease genes in other organisms such as mouse, puffer fish, fruit fly,
nematode, yeast, and bacteria, the investigators can take advantage of the experimental systems
available for each organism permitting the rapid elucidation ofmolecular mechanisms involved
in the human disease process. The existence of cross-reference databases like XREFdb
(http://www.ncbi.nlm.nih.gov/XREFdb/), designed to establish cross-references between model
organism genes and mammalian phenotypes will also increase the rate at which these
cross-species connections will be established (Bassett et ah, 1997).
While studies in organisms such as fruit fly and nematodes have advantages such as ease of
handling and genetic manipulation coupled with a short life cycle and large numbers of progeny,
for the study of human disease phenotypes the mouse has advantages because it is evolutionarily
closer to humans and as both organisms are mammalian, the pathogenic mechanisms of diseases
may be similar in both organisms. Therefore, mutations in orthologues ofhuman genes in the
mouse is more likely to produce phenotypes similar to that seen in the mutation of the human
gene. The mouse is also relatively cheap to maintain, easy to handle, and has large numbers of
progeny.
The mouse is a primary model organism for the Human Genome Project and considerable
emphasis has been placed on the genetic and physical mapping of the mouse genome
world-wide. Both the mouse and human genomes have now been characterised sufficiently to
identify all the large chromosomal regions showing conserved synteny (DeBry & Seldin, 1996).
However, as the number of markers mapped in both the human and mouse genomes increases,
many smaller regions of conserved synteny may yet be identified. The identification ofmouse
genetic loci which may be homologous to human mutations that cause genetic disease often
provides powerful animal models for the disease process. In addition, the ability in the mouse to
target new mutations to genes that may be involved in the human genetic disease has opened up
vital avenues for the exploration of the mammalian gene function. Many mouse models of
human disease phenotypes using gene "knock-outs" and "knock-ins"* have now been produced
*Mouse gene "knock-out" models involve the investigation of gene function by disruption of a gene and the
examination of the resultant mouse phenotype, for example by gene replacement or insertion of a selectable marker.
Mouse gene "knock-in" experiments involve trying to reverse a mouse disease phenotype by the insertion of a
functional gene sequence (often to correct a gene disrupted during a "knock-out" experiment).
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and this can reveal much information involving the pathogenic mechanisms of genetic diseases
which could not be revealed by the study of the disease in either human patients or other model
organisms. More information on mouse models can be found at the "Mouse knockout mutation
database" web-site (http://www.biomednet.com/db/mkmd).
2.1.3 Genetic mapping in the mouse
The first genetic linkages in the mouse were established by analysing the genetic linkage
relationship between loci that could be analysed by visually scoring the segregation of alleles
based on pigmentation, morphological or behavioural phenotypes, for example the pink-eye
dilution (p) and albino locus (c) (Haldane, 1915). With the progress of research into
biochemistry and molecular biology, many more markers have now become available for genetic
mapping and these include protein and enzyme polymorphisms, immunological responses,
antigenic determinants, endogenous retroviruses and DNA sequences (reviewed in Rowe et al.,
1994). It is the recent rapid expansion of known DNA sequences that has allowed many new
loci to be mapped in the mouse. Molecular biology techniques such as cDNA cloning, isolation
ofmini- and microsatellite markers, and anonymous DNA sequences derived from genomic and
chromosome specific libraries now provide a substantial pool of useful markers for the creation
of genetic maps.
2.1.4 Recombinant inbred (Rl) strains
The production of homozygous inbred strains by the systematic inbreeding of the progeny of a
cross of two progenitor founder strains (Bailey, 1971; Taylor, 1978) has been ofmajor
importance in the genetic mapping of the mouse genome. Once genetically homogeneous lines
are produced, each line is typed with a variety of biochemical and molecular markers to produce
haplotype information for each line. New markers that contain a DNA sequence polymorphism
between the 2 progenitor founder strains are typed in the RI lines as either one type or the other.
By comparing haplotype information for a new marker with existing haplotype information, the
marker in question can be placed on the genetic map. Although RI strains provide an unlimited
DNA resource, and all haplotype information is additive, this method ofmapping can be limited




The difficulty encountered in identifying allelic differences among laboratory mouse strains has
been largely overcome by using interspecific backcrosses, which exploit the genetic diversity
inherent among wild mouse species (Avner et al., 1988). The crosses involve 2 mouse species
whose evolutionary distance has allowed accumulation of differences at the DNA sequence level
and yet interbreed under laboratory conditions. An example of a breeding scheme used to
generate an interspecific backcross between the laboratory inbred strain C57BL/6J and Mus
spretus (Copeland & Jenkins, 1991) is shown in Figure 2.1.
Although this cross produces fertile female animals and can be used to establish the backcross
generation, the F1 males are sterile. This means that only recombinational data from the female
F1 mice can be obtained. To overcome the problem of no male genetic map for this interspecific
cross, other wild mouse species that are more closely related to laboratory strains and produce
fertile F1 hybrids of both sexes are used, for example Mus musculus castaneus or molossinus.
One disadvantage of interspecific crosses is the limited amount ofDNA that can be obtained
from each backcross animal. However, the increasing use ofPCR to type the backcross panel
instead ofmethods such as Southern blotting, should allow an unlimited number of loci to be
mapped from each backcross panel. Immortal cell lines from the backcross animals is another
method to ensure enough DNA is available for typing but as these lines can be unstable, other
methods are preferable. As the number of backcross animals and number of loci typed increase,
the mapping ofmarkers and determination of gene order will become more accurate. Although
combining mapping data from different interspecific backcrosses cannot be done directly,
mapping of a common set of anchor loci on each panel allows the mapping data to be combined
with respect to the anchor loci.
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Figure 2.1 Breeding scheme used to generate an interspecific mouse backcross mapping panel
(taken from Copeland and Jenkins, 1991) NB. Only one pair of chromosomes is shown for each
parent. Only recombination events occurring in the F1 parent can be scored in the N2 backcross
mice.
2.1.6 Mapping using the Jackson interspecific backcross DNA panel
The Jackson laboratory established two mouse interspecific backcross DNA panels to be used as
a resource for the generation of a high-resolution (<1 Centimorgan) genetic map of the mouse
genome (Rowe et al., 1994). The two backcross DNA panels consist of (C57BL/6JEi x
SPRET/Ei)Fi x C57BL/6JEi and the reciprocal backcross (C57BL/6JEi x SPRET/Ei)F! x
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SPRET/Ei, each containing 94 animals. Initial characterisation of the genetic maps was carried
out by mappingMIT simple sequence length polymorpism (SSLP) markers (Dietrich et al.,
1992), proviral loci (Stoye & Coffin, 1988), and several other sequence-defined genes (Ko et al.,
1994) so that the Jackson map could be anchored to other published maps such as the European
Collaborative Interspecific Backcross (EUCIB) map (Breen, 1994). Many restriction fragment
length polymorphisms (RFLPs) between inbred mouse strains have been typed using molecular
probes and Southern blot analysis. However, the use ofPCR as a mapping tool has accelerated
the assignment of new markers to the mouse genetic map.
Various types of loci can be mapped by PCR. Oligonucleotide primers can be designed within
variant sequence from cDNA sequences, or from sequence flanking VNTRs (variable numbers
of tandemly repeated mini-satellites) -including polymorphic dinucleotide repeats; (Weber &
May, 1989) (Love et al., 1990). To produce a high density ofmarkers located on the Jackson
mouse genetic maps, both arbitrarily-primed PCR (AP-PCR) and motif-primed PCR (MP-PCR)
have been employed to "fingerprint" the panel DNAs. In AP-PCR , PCR primers are designed
from arbitrary nucleotide sequence irrespective of coding potential (Serikawa et al., 1992). In
MP-PCR, PCR primers are derived from conserved promoter elements and protein motifs
(Birkenmeier et al., 1992). One advantage of using MP-PCR over AP-PCR is that the loci
mapped relate to actual gene sequences.
2.1.7 Other mapping methods
AlthoughMus domesticus and Mus spretus have a high degree ofDNA sequence difference,
some regions of the genome may not contain polymorphisms useful for genetic mapping. In
such cases, mapping can be carried out using radiation hybrid mapping, for example the T31
Mouse Radiation Hybrid Panel of 100 cell lines supplied from Research Genetics (McCarthy et
al., 1997). Radiation hybrid mapping does not require sequence difference between mouse
strains, but only differences between mouse and hamster (the host cell line). One draw back
may occur if mapping coding sequences, as the evolutionary closeness ofmouse and hamster
may result in the co-migration of hamster and mouse PCR fragments in a given assay.
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2.1.8 Aims
This chapter describes the mapping of the mouse Gckr and Khk genes using the Jackson
Laboratory interspecific backcross mapping panel ((C57BL/6JEi x SPRET/Ei) x SPRET/Ei). To
map Gckr and Khk, I identified novel sequence variants between the two mouse species
C57BL/6JEi and SPRET/Ei for both genes. These sequence variants were used to design
PCR/restriction digest assays that could distinguish between the presence or absence of the
C57BL/6JEi alelle and SPRET/Ei allele for Gckr and Khk in each interspecific backross animal.
The haplotype information obtained for Gckr and Khk was compared to the haplotypes of known
chromosomal markers and this used to place each gene onto the Jackson (C57BL/6JEi x
SPRET/Ei) x SPRET/Ei interspecific backcross map.
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2.2 Methods
2.2.1 Method of mapping
The Jackson Laboratory Backcross DNA panel Mapping Resource which consists of 94
backcross animals from the interspecific cross (C57BL/6JEi x SPRET/Ei) x SPRET/Ei, was
typed using a PCR/restriction digest assay to reveal the variants.
2.2.2 Mapping of Gckr
2.2.2.1 Molecular reagents
Comparison of the mouse and human GCKR cDNA sequences (Genbank accession numbers
X68497 and Z48475) reveals a similarity of 83.9%. It was also noticed that that there are
regions of exact identity corresponding to sequences that have previously been used to design
primers for the cloning of the human GCKR cDNA (Hayward et al., 1997). Therefore, primer
pairs could be chosen that would be predicted to amplify GCKR PCR products from both human
and mouse DNA. Two primers were chosen (Gre2f
(5'-dGATATTCCAGGAGGAGGGGCA-3') and Gre7r
(5'-dGCTCACTGGATTGAAGCCAACC-3')) and used in a long range hot start PCR program:
5 min 94°; 2 x (94°C,20 s; 63°C,30 s; 68°C, 4 min); 8 x (94°C,20 s; 65°C,30 s; 68°C, 4 min);
20 x (94°C,20 s; 65°C,30 s; 68°C, 4 min + 10 s per cycle). The long range PCR was carried out
in long range buffer #1 (Materials and Methods, Chapter 6), a final concentration of 350 pM
dNTPs, thin wall PCR tubes and a final reaction volume of 30 pi.
Gre2f and Gre7r were found to amplify a ~4 kb PCR product corresponding to GCKR exons 2-8
from both C57BL/6Ei and SPRET/Ei mouse strains (predicted size from human GCKR genomic
structure: -3.7 kb - see Figure 2.2). The PCR product ends were sequenced using the
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Figure 2.2 Genomic structure of human GCKR. Boxes 1-19 represent exons. Exon sizes (bp)
are indicated above the exon boxes and intron sizes (kb) are also shown. The 3.7 kb region
between exons 2-8 corresponding to the region amplified in mouse Gckr using primer Gre2f and
Gre7r is indicated. This figure was adapted from (Hayward et al., 1998).
Although no sequence variants were found in GCKR IVS2 between C57BL/6Ei and SPRET/Ei,
the C57BL/6Ei and SPRET/Ei sequences were found to diverge 145 bp upstream of the
IVS7-exon 8 splice junction, where a poly(A) sequence (on the sense strand) was found in
C57BL/6Ei but the start of a B1 repetitive element-like sequence was present in SPRET/Ei
(Figure 2.3). It was also noticed that the C57BL/6JEi PCR product was overall 200-300 bp
larger than that of SPRET/Ei. A single nucleotide variant 55 bp upstream of the IVS7-exon 8
splice junction was shown to alter a Xcml cutting site (present in SPRET/Ei but absent in
C57BL/6JEi - see Figure 2.3). To type this polymorphism, a new primer GreSB
(5'-dCTTGGTTGAGGAATCTATTTCTAG-3') within intron 7 was used with the exon 8 primer
Gre7r to generate a PCR product from both C57BL/6JEi and SPRET/Ei. Standard buffers (1.5
mM MgCl2) and a hot start PCR program: 5 min 94°C; 30 x (94°C,45 s; 55°C,45 s; 72°C, 1 min)
were used.
2.2.2.2 Gckr allele detection
The primers GreSB and Gre7R were used to amplify a -200 bp Gckr fragment that, if derived
from a SPRET/Ei allele, cuts with Xcml to yield fragments of size -150 bp and -50 bp.
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10 bp to a poly(A) sequence
CAGGTGGTGGTGGCGCAAACCTTTAACCCAGCA
+ + -- + + 180
► B1 repetitive element
Figure 2.3 Comparison of C57BL/6JEi (B6) and SPRET/Ei (Spr) GCKR intron 7 sequences
(anti-sense strand). Restriction enzyme sites are indicated above the sequences; a C/A variant
found at nucleotide 74, creating a Xcml site in Mus spretus.
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2.2.3 Mapping of Khk
2.2.3.1 Molecular reagents
As only partial mouse Khk cDNA sequence was available at the time of this study, the human
and rat KHK cDNA sequences (Bonthron et al., 1994) (Donaldson et ah, 1993) were compared
to identify conserved regions of sequence which may also be conserved in the mouse. This
revealed some highly conserved regions (the overall similarity between human and rat KHK was
87%) from which the primer KhkM4 (5'-dTGAGGGGCTTGTACAGTCGTCGAG-3') was
designed. Another primer KhkR9 (5'-dCCACCTGGCACCCGAATCTC-3'), that was designed
from the partial mouse Khk cDNA sequence, was used with KhkM4 to PCR amplify a -400 bp
genomic fragment corresponding to exons 6-8 (predicted size from human KHK genomic
structure was 451 bp - see Figure 2.4). Standard PCR reaction conditions were used with a hot
start PCR program: 5 min 94°; 30 x (94°C,45 s; 64°C,45 s; 72°C, 1 min).
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Figure 2.4 Genomic structure of human KHK. Boxes 1-8 represent exons. Exon sizes (bp) are
indicated above the exon boxes and intron sizes are also shown (intron sizes are bp unless
indicated as kb). Corresponding 451 bp region amplified in mouse Khk using primers KhkM4
and KhkR9 is indicated.
2.2.3.2 Khk allele detection
As the amplified mouse Khk PCR product was small (-400 bp), various restriction enzymes
were used on the C57BL/6JEi and SPRET/Ei PCR products, to look for differences in cutting
sites between the two mouse strains which could subsequently be used to reveal the variants and
type the interspecific backcross. The restriction enzymes tried were:- EcoBl, HinhtiM, Mbol,
Sacl, Xbal. Out of the restriction enzymes tried, only Mbol was found to reveal a variant
sequence between the C57BL/6JEi and SPRET/Ei mouse strains. It was found thatMbol
restriction enzyme digestion of the -400 bp genomic fragment amplified using the primers
KhkM4 and KhkR9 produces a fragment of 300 bp from the C57BL/6JEi Khk allele and 220 bp




The Gckr and Khk alleles were typed as described in the methods section and the products from
the PCR/restriction digest assay visualised by electrophoresis through agarose gel (Figures 2.5
and 2.6).
2.3.2 Map position of Gckr and Khk
Analysis of the typing data for both Gckr and Khk reveals complete concordance between
genotypes, with both genes mapping to the proximal part ofmouse chromosome 5 and
co-segregating with a number of other loci including D5MU149. The relative positions of Gckr
and Khk compared to other genes and markers located on the same region of the mouse
chromosome 5 genetic map were estimated by statistical analysis of the typing data (summarised
in Figure 2.7). This places Gckr and Khk at the following genetic location (marker-map distance
between marker and next closest marker (Centimorgans) ± standard error(Centimorgans):
D5Mitl-3A9 ± \ M-D5Bir5-\.()6 ± 1.06-Nos3/Dpp6/Fgl2-1.06 ± 1.06-
Htr5a/Gbxl/En2/Nkxl-l/Plk-ps/D5Mitl49/D5Xrf391/D5Bir6/Znt3/Gckr/Khk-\.06 ± 1.06-
D5Mit351/D5Xrf47-\.06±\.06-Crmpl/D5Bir7/Msxl-2A3 ±\A9-Bapxl. D5Mit and D5Bir are
anonymous mouse chromosome 5 markers, D5Xrf47 is a marker designed from an anonymous
cDNA clone, all the other markers are genes that co-localise with or map near to Gckr and Khk.
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Figure 2.5 Gckr allele typing. The typing of each interspecific backcross animal is indicated
above each gel image (B:heterozygote C57BL/6JEi / SPRET/Ei type; S: homozygous
SPRET/Ei type). Lane 1A contains parental C57BL/6JEi homozygous alleles (BB) and lane IB
contains parental SPRET/Ei homozygous alleles (SS). The size of each allele is shown
(C57BL/6JEi:200 bp and SPRET/Ei: 150 bp). The end lanes of each gel contain 1 kb ladder
(fragment sizes (bp) shown are 506, 396, 344, 298, 220, 201, 154, and 134).
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Figure 2.6 Khk allele typing. The typing of each interspecific backcross animal is indicated
above each gel image (Brheterozygote C57BL/6JEi / SPRET/Ei type; S: homozygous
SPRET/Ei type. Lane 1A contains parental C57BL/6JEi homozygous alleles (BB) and lane IB
contains parental SPRET/Ei homozygous alleles (SS). The size of each allele is shown
(C57BL/6JEi: 300 bp and SPRET/Ei: 220 bp). The end lanes of each gel contain 1 kb ladder
(fragment sizes (bp) shown are 1018, 506, 396, 344, 298, 220, 201, 154, and 134). The 1018 bp
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Figure 2.7 Co-localisation ofGckr and Khk on mouse chromosome 5.
A: map figure showing the proximal part of chromosome 5, with markers linked to Gckr and
Khk. The map is depicted with the centromere (black circle) toward the top. The gene order
and relative positions ofmarkers used in this study are shown. Map distances in
centimorgans are shown on the left.
B: Haplotype figure showing loci linked to Gckr and Khk on chromosome 5. Loci are listed
in order with the most proximal on top. The black boxes represent the C57BL/6J allele, and
the white boxes the SPRET/Ei allele. The number of animals with each haplotype is given at
the bottom of each column of boxes. The percentage recombination (R) between adjacent
loci is given to the right of the figure, with the standard error (SE) for each R.
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2.4 Discussion
2.4.1 Co-localisation of Gckr and Khk
The mapping of the Gckr and Khk genes reveals that they co-localise to the proximal region
ofmouse chromosome 5 (see Figures 2.7 and 2.8). In addition, the mapping of GCKR and
KHK in both human and mouse genomes reveals a new region of conserved synteny between
human chromosome 2 and mouse chromosome 5. As both rat GCKR (Detheux et al.,
1993)and KHK (Hayward & Bonthron, 1998) map to rat chromosome 6, this suggests that
GCKR and KHK are highly closely linked genes that have remained linked during evolution.
GCKR encodes the regulatory protein of glucokinase, which binds to and inhibits
glucokinase in liver and probably pancreatic islet (Malaisse et al., 1990; Van Schafitingen,
1989). This inhibitory interaction is promoted by fructose-6-phosphate and relieved by
fructose-1-phosphate, the product of ketohexokinase (KHK). The postulated metabolic link
between KHK and GKRP therefore makes the co-localisation of their genes in human, rat,
and as shown here also in mouse, noteworthy.
The present localisation defines a new region of conserved synteny (Figure 2.8), which has
since been supported by the mapping of other genes located on human chromosome 2p to
mouse chromosome 5 (Table 2.1). To date, there is not a physical and transcript map for this
proximal region ofmouse chromosome 5, therefore it is not known whether the gene order is
the same within the regions of conserved synteny on human chromosome 2p23.3 and the
proximal region ofmouse chromosome 5. In the next chapter (Chapter 3), a detailed
physical and transcript map of human chromosome 2p23.3 is described (Figures 3.5 and 3.8)
that shows relative gene order at the GCKR-KHK genomic region. The analysis of two
mouse genomic clones reveals that the two pairs of genes Ucn-Mpvl7 (Zhao et al., 1998),
and EIF2B4-KIAA0064 (see Chapter 4, Figure 4.18 in Sections 4.2), are in the same intimate
genomic arrangement in both the human and mouse genome. Although this is not proof that
the relative gene order is the same at the region of conserved synteny between human
chromosome 2p23.3 and mouse chromosome 5, it does emphasise the that these two
genomic regions are highly evolutionary conserved.
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Figure 2.8 Comparative map ofA/ human chromosome 2 showing homologous mouse
chromosomes, and B/ mouse chromosome 5 showing homologous human chromosomes.
Localisation of GCKR and KHK is indicated. This information shown in this figure was
gathered from the Davis human/mouse homology map at the NCBI web-site
(http://www.ncbi.nlm.nih.gov/Homology).
The region of conserved synteny between human chromosome 2 and mouse chromosome 5
must be relatively small, as other genes near GCKR and KHK, like the mouse homologue of
the human phosphatase gene PPP1CB, map to the distal region ofmouse chromosome 12
(Saadat et al., 1994). The human K1F3C gene, a member of the kinesin family (see Chapter
5, Section 5.3), which resides on the other side ofKHK and GCKR compared to PPP1CB
(see Chapter 3, Figures 3.5 and 3.8), also maps to mouse chromosome 12 (Figure 2.9 shows
the relative gene order on chromosome 2p23.3 and mapping ofmouse gene orthologues).
Located near K1F3C is the KCNK3 gene whose mouse homologue also maps to chromosome
5 (Fujita etal., 1998).
37
1 1 H—H—I—I—h
PPP1CB KHK MPV17 EIF2B4 GCKR KCNK3 KIF3C
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Figure 2.9 Relative gene order on human chromosome 2p23.3. Mapping ofmouse gene
orthologues is indicated if known. The estimated physical distance between PPP1CB and
KIF3C according to YAC contigs is <2 Mb. This diagram is not drawn to scale.
It is only possible at present to make an imprecise estimate of the physical size of the region
of conserved synteny between human chromosome 2p23.3 and mouse chromosome 5. YAC
contig mapping indicates PPP1CB and KHK to be <400 kb apart (Hayward et ah, 1996;
Hayward et al., 1997). The physical size of the region between KIF3C and PPP1CB
indicated by YAC, BAC, and PAC contig mapping is <2.0 Mb. Therefore the region of
conserved synteny between human chromosome 2p23.3 and mouse chromosome 5 must also
be <2.0 Mb in size. The co-localisation of Gckr and Khk in the mouse despite their
non-syntenic relationship with Ppplcb and Kif3c, which are adjacent in man, adds
circumstantial support to the possibility of co-ordinate regulation of GCKR and KHK.
2.4.2 Other genes that co-localise with Gckr and Khk
The Gckr and Khk genes co-localise to the proximal part of the Jackson chromosome 5 BSS
map, co-segregating with a number of other loci (Figure 2.7). Several of these markers were
designed from ESTs or gene sequences and therefore it is possible that the human
homologues are located in the region of synteny on human chromosome 2p23.3. The
mapping ofmarkers flanking the mouse chromosome 5 Gckr/Khk locus show that towards
the centromere, for example dpp6maps to human chromosome 7 while towards the
telomere, for example Crmpl, maps to human chromosome 4. The mapping of flanking
markers to mouse Gckr and Khk to human chromosomes 7 and 4 confirms that the region of




(< 2.2 cM from the mouse genetic maps and <2.0 Mb from human YAC contigs).
Examination of the loci co-segregating with Gckr and Khk, reveals that several genes map
either to human chromosome 7 or chromosome 4 and several ESTs including one showing
homology to a zinc transporter gene (Znt3), show homology to a human ESTs that map to
human chromosome 2p23.
The Jackson interspecific backcross BSS panel provides a useful tool in the search for novel
genes that map close to GCKR and KHK on human chromosome 2p23. Any genes/ESTs that
co-localise with Gckr and Khk in the mouse are worth further investigation as there is a good
chance that the human homologue maps to human chromosome 2p23. Good candidate
mouse genes that could map to human chromosome 2p23 include Znt3 and several mouse
cDNA clones that have not been mapped in the human genome. These include: D5Ertd260e,
a mouse cDNA clone showing similarity to human KIAA0064 cDNA sequence (see Chapter
4, Section 4.3); D5Xrf391, an EST (Genbank F13207) showing homology to S.cerevisiae
YJR072C gene; and several anonymous cDNA clones D5Ertd422e (J0214A03), D5Ertd477e
(J0239B08), D5Wsul78e (C0034C05). (For further information, see the Jackson web-site at
http: II]ax.org/resources/documents/cmdata/bkmap/BSS5refs).
A more recent search of the literature reveals that there are now several other genes that have
been mapped to human chromosome 2p23 and mouse chromosome 5 - see Table 2.1 for a
full list. As the glucokinase regulatory protein (GKRP) and ketohexokinase (KHK) are
metabolically connected and their genes co-localise in both human and mouse genomes, an
investigation of transcripts near GCKR and KHKmight reveal other genes that encode
proteins that are either functionally related to or interact with GKRP and KHK. Examination
of the proteins encoded by the genes co-localising with GCKR and KHK (see Table 2.1),
does not immediately reveal any such related genes as there seems to be a wide variety of
protein functions and tissue expression patterns. However, it is probable that this is not an
exhaustive list of the genes that reside at human chromosome 2p23 and mouse chromosome
5. Indeed, studies described elsewhere in this thesis show that this region of chromosome
2p23 is extremely gene-dense, so that only a detailed transcript map of chromosome 2p23.3
might reveal other genes encoding proteins with related functions to GKRP and KHK.
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Mouse gene Gene name/function
Expression profile based upon cDNA
clones
Gckr Glucokinase regulator protein Liver, Pancreas, Testis.
Khk Ketohexokinase Brain, Colon, Kidney, Liver, Spleen,
Tonsil, colon, connective tissue
Znt3 Zinc transporter gene Testis, head and neck.
Mpvl7 Peroxisomal protein
A potential glomerulosclerosis
and deafness gene in the
mouse
Aorta, Bone, Brain, CNS, Heart, Kidney,
Lung, Ovary, Prostate, Skin, Stomach,
Testis, Tonsil, Uterus, Whole embryo,
lung.
Ucn Urocortin
A neuropeptide related to
urotensin I and
corticotrophin-releasing factor
Brain, Colon, Germ Cell, Kidney, Lymph,
Muscle, Prostate, Testis, Uterus, Whole
embryo, lung, ovary.
Kcnk3 Potassium ion channel Brain, Foreskin, Kidney, Lung, Neural,
Pancreas, Placenta, Pooled, Prostate,
Uterus, brain.
Fosl2 Fos-related antigen 2 Breast, Colon, Foreskin, Heart, Liver,
Pancreas, Prostate, Skin, Uterus, colon,
head_neck, lung, ovary.
Cenpa Centromeric protein A Adrenal gland, Brain, Breast, Colon, Germ
Cell, Pooled, Testis, Tonsil, Uterus, Whole
embryo.
Table 2.1 Genes that map to human chromosome 2p23 and mouse chromosome 5. For








To aid the search for transcripts and mapping of chromosomal markers located in the
GCKR-KHK genomic region and DFNB9 interval on chromosome 2p23.3, a detailed
physical contig spanning this genomic region was constructed. At the start of this physical
contig construction, BAC sequences produced as part of the human genome project were not
available and only YAC and PAC libraries were available for screening. However, the
recent availability ofBAC clone sequence within this chromosomal region as part of the
human genome project, although not complete and consisting of unordered contigs ofDNA
sequence, has been used to supplement the physical contig that I have constructed.
To search for transcripts within the physical contig spanning the GCKR-KHK genomic
region and DFNB9 interval, the genomic clones that were used to construct the contig were
PCR screened using ESTs that mapped to chromosome 2p23.3 by radiation hybrid mapping
according to Genemap'99 (http:/www.ncbi.nlm.nih.gov/genemap). Alternatively, the
analysis ofDNA sequence obtained by direct sequencing ofPAC and cosmid clones also
allowed the identification of transcripts located in this genomic region. Although other
methods of transcript identification were contemplated such as cDNA selection and exon
trapping (see Section 3.1.3), they were found not to be required, largely because of the high
gene density that became apparent within this genomic region.
3.1.2 Contig Assembly
3.1.2.1 Identification of YAC and P1 clones
The original physical contig constructed at the GCKR-KHK genomic locus by Hayward et
al., 1996, is shown in Figure 3.1. The YACs 29IH8 and 26BA11 were identified by the PCR
screening of a YAC library (Anand et al., 1990) using primers designed from within GCKR
(Warner et al., 1995). The YACs 18AG7 and 3AG3 were identified by PCR screening the
same YAC library using primers from within KHK and STS D5, respectively (STS D5 is a
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STS designed from sequence at one of the ends ofYAC 26BA11; STS D3, designed from
the other end ofYAC 26BA11, lies within GCKR intron 7). The PI clone J0788 which
contains the whole ofKHK was identified by hybridisation screening 40 000 clones of the
ICRF PI reference library 700 (Francis et al., 1994) using a 2.0 kb KHK cDNA insert
(Bonthron et al., 1994). The PI clone J16101, which has been shown to contain GCKR
exons 1-7, was identified by screening the same PI library with a cloned 623 bp RT-PCR
product that corresponded to GCKR codons 7-214 (Hayward et al., 1996).
The EST content analysis of the physical contig shown in Figure 3.1 reveals none of the
YACs to contain both GCKR and KHK. This meant that STS content analysis of the YAC
clones had to be used to establish the GCKR-KHK physical linkage. This was carried out by
PCR screening of the YAC clones 3AG3, 18AG7, 26BA11 and 29IH8 using STSs created
from sequence at the ends ofYAC 26BA11 (STSs D3 and D5 - STS D3 is located within





YAC 18AG7 03 60kb
P1 J0788 P1 J16101
5.3/5.4
KHK GCKR
Figure 3.1 The original YAC and PI clone physical contig at the KHK-GCKR genomic
locus constructed by Hayward et al., 1996. The distance between KHK and GCKR was
estimated from FISH experiments to be -500 kb. The examination of the STS markers
mapping to these YAC clones reveals that it is not possible to assemble an internally
consistent contig. This was later found to be due to a deletion in YAC 26BA11 - indicated
by a dashed line. The lack of chromosomal markers that had been mapped to the physical
contig meant that at this time the contig orientation with respect to the centromere was not
known.
The results of this STS content analysis showed the A7/A'-containing YAC 18AG7, and YAC
3AG3, to both contain the YAC 26BA11 STS D5 (YAC 26BA11 contains part of GCKR).
Also, the STS J0788 5.3/5.4, an STS from one end of the A7/AT-containing PI clone J0788,
is positive for YAC 26BA11. Although these results established a physical linkage between
GCKR and KHK, examination of the STS markers mapping to these YAC clones reveals that
it is not possible to assemble an internally consistent contig . This was later proved to be due
to a deletion within YAC 26BA11 (see Discussion section 3.4.1.1).
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Although FISH analysis suggests GCKR and KHK to be less than 500 kb apart (Hayward et
al., 1996), the deletion within YAC 26BA11 meant that it was impossible to estimate the
distance between GCKR and KHK using the existing physical contig. The identification of
this aberration within YAC 26BA11 also meant that other genomic clones would have to be
identified to span the deletion within YAC 26BA11. This would be essential for an accurate
estimation of the physical distance between GCKR and KHK, and also would be required for
a detailed investigation of transcripts that resided within the GCKR-KHK intergenic region.
As part of this project was to identify candidate deafness genes within the DFNB9 interval
(see Chapter 5), a genomic region also located on chromosome 2p23, it was decided to
extend the GCKR-KHK physical contig to span the DFNB9 interval. This would be
performed by identifying YAC clones by PCR screening YAC libraries for chromosomal
markers and ESTs that were known to map to chromosome 2p23 by radiation hybrid
mapping.
3.1.2.2 Contig construction strategy
To produce a more detailed contig between KHK and GCKR, YAC clones containing GCKR
were subcloned into cosmids. For cosmid contig assembly, a high resolution, fluorescence
based semi-automated technique for DNA fingerprinting was used (Carrano et al., 1989) -
see Methods Section 3.2.2. One of the advantages of subcloning the YAC inserts into
cosmid vectors is that the cosmid DNA could be directly sequenced for gene identification
without the need for further subcloning into plasmid vectors. Also, a detailed contig would
allow the rapid elucidation of the relative order and orientation of transcripts located on the
contig.
For the identification of new genomic clones at the GCKR-KHK interval, the cosmid STSs
(shown in Table 3.1) were used to either PCR screen the RCPI1 PAC library, or screen
chromosome 2-specific PAC and cosmid libraries by radioactive hybridisation, - see Figure
3.2 for a general outline of the contig construction strategy. To confirm clone overlap and
for further library screening, the insert ends of the PAC clones initially identified were
sequenced using the "T7" and "SP6" universal primers. STSs were designed from these
sequences only if they were non-repetitive elements. New STSs were used to screen all the
genomic clones used in the physical contig to confirm clone overlap. Also, to aid contig
assembly, STSs that did not "hit" any of the genomic clones in the physical contig were used
to re-screen the PAC library. This strategy was used to extend the physical contig with the
aim of spanning the deletion within YAC 26BA11.
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GCKR-containing YACs26BA11 and 29IH8
I
Subclone YAC inserts into cosmid vector (-40-50 kb inserts)
to create cosmid library (-100 clones)
i
Grow cultures of each clone
Extract cosmid DNA using mini-prep procedure
/ \
Sequence cosmid insert ends
using vector primers SC2 and SC3 Contig assembly
1 ^ \
Cosmid fingerprinting STS and EST
Analyse sequences (see Section 3.2.2) content analysis
\ \ \
Repetitive DNA Unique A1. ,







Screen chromosome 2 cosmid library
LL02NCC02 (38 496 clones) by
hybridisation using radioactively
labelled oligonucleotide
Screen chromosome 2 PAC library LL02NP04
(5760 clones) by hybridisation using
radioactively labelled oligonucleotide
Figure 3.2 General strategy employed for contig construction at the GCKR-KHK interval.
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3.1.3 Approaches for identifying transcripts
Once a genomic region has been cloned, for example the physical contig spanning the
GCKR-KHK genomic region and DFNB9 interval, the next step is to identify transcripts for
further identification. This section describes five methods for identifying transcripts.
3.1.3.1 cDNA selection
The method of direct selection allows rapid amplification of coding sequences within large
genomic regions. It is based upon the hybridisation of cDNAs to an immobilised genomic
clone/library and "enrichment" of specific hybrids (Lovett et al., 1991). For example, a
partial Sau3A genomic clone digest is labelled with biotin linkers and immobilised on
streptavidin coated paramagnetic beads. A high quality cDNA library is also partially
digested with Sau3A and hybridised to the immobilised genomic library (it is important to
use a complex cDNA library - if the gene of interest is not represented in the cDNA library,
it cannot be cloned by direct selection). Several rounds of washing are performed to remove
non-specific hybrids to leave the specific cDNA-genomic DNA hybrids. The specific
cDNAs can be eluted and utilised for PCR amplification using the linker oligonucleotide
sequences that were attached to the partially digested cDNA before hybridisation. The
advantages of this method are that it is a relatively quick procedure once all the conditions
have been optimised. However, this technique is susceptible to several problems. Repeat
elements within the cDNA genomic sequences must be blocked successfully to prevent
non-specific hybridisation. The use of a high quality cDNA library is essential as some
libraries may contain contaminants or may not contain a good representation of sequences.
Also, the basis of this technique relies upon the hybridisation of cDNA to genomic DNA.
This means the homology is "patchy" and may cause hybridisation problems especially if the
gene only contains short exons.
3.1.3.2 Exon trapping
Exon trapping facilitates the capturing of exons from genomic DNA by relying on the
cellular splicing machinery (Duyk et al., 1990). Various exon trapping strategies have been
devised but all rely on the in vivo selection for splice sites flanking exon sequences in
genomic DNA. One strategy (Heiss et al., 1996) involves the cloning of the genomic DNA
of interest for example from a cosmid or YAC, into an exon trap vector containing splice
sites, a promoter and polyadenylation signals. The purified recombinant DNA is transfected
into COS-7 cells which allows any exons within the genomic DNA to be transcribed and
spliced. After the total RNA is isolated, cDNA synthesis with vector specific primers is
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performed and the products cloned to generate an exon trap library, or alternatively, are used
as complex probes on cDNA libraries. The advantages of using an exon trapping strategy
are that unlike in techniques such as cDNA selection, genes whose expression patterns are
tissue specific or developmentally regulated will be isolated with the same efficiency as
ubiquitously expressed genes. Exon trapping is only limited by its requirement for the
presence of functional 3' and 5' splice sites flanking a target exon. Therefore intronless or
single intron genes would be missed using this approach.
3.1.3.3 CpG island positional cloning
CpG islands are relatively short stretches (~1 kb) of G+C-rich (60-70%) genomic DNA in
which the frequency of non-methylated CpG dinucleotides is substantially higher than
elsewhere in genomic DNA (Cross & Bird, 1995). A large proportion of genes with a tissue-
specific pattern of expression have been found with CpG islands at their 5' ends, often as
part of the promoter sequence (Bird et al., 1987). Because of their location, CpG islands are
frequently used as markers for the presence of genes in uncharacterised genomic DNA.
Although it is still largely unclear what the exact function ofCpG islands is, DNA
methylation has been shown to repress transcription and has been implicated in alterations of
gene expression. Methylation ofCpG islands and subsequent silencing of associated
transcription units have been found to occur in genes located on the inactive X chromosome
(Pfeifer et al., 1990), genes silenced by genomic imprinting (Razin & Cedar, 1994), and
genes silenced in transformed cell lines and tumours (Antequera & Bird, 1993; Bird, 1996).
CpG islands have also been shown to often contain multiple binding sites for transcription
factors (Pfeifer et al., 1990) and an open chromatin conformation (Antequera et al., 1989).
One mechanism by which DNA methylation can cause transcriptional repression is by the
binding ofmethyl-CpG binding proteins to methylated CpG islands, directly interfering with
the binding of sequence-specific transcription factors (Hendrich & Bird, 1998). CpG islands
have now also been associated with replication origins (Delgado et al., 1998).
The identification within genomic DNA of rare cutting restriction enzyme sites for example
As vHII, Eagl, and Shell, suggests a high "GC" content and the possible presence of a CpG
island. If cloning and sequencing of these restriction fragments reveals a CpG island, there
is a high likelihood that the CpG island may be adjacent to a gene sequence. This method of
CpG island identification has been used successfully to identify a number of gene sequences.
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3.1.3.4 Sequencing of genomic clones
Once genomic clones have been mapped to the chromosomal region of interest, the
sequencing of these clones and sequence analysis may reveal transcript sequences. While
BACs, PACs and cosmids may be sequenced directly, it is more efficient to create a plasmid
subclone library from the larger genomic clones to allow rapid sequencing of a large number
of novel DNA sequences. Two types of subclone library can be created: 1/ a restriction
digest subclone library produced by cloning restriction fragments, and 2/ a shotgun library
produced by cloning DNA fragments created by physical dismption or use ofDNAse I. A
shotgun library is preferable, as it will provide a much greater variety of subclone inserts and
more random sampling of the sequence of the large-clone insert.
The computer analysis of subclone sequences using programs such as BLAST (Altschul et
al., 1990) can identify possible gene sequences by looking for similarity to sequences found
in cDNA databases. Although this method requires much time and resources, once enough
unique sequences have been obtained, they can be used to produce a contig of sequences.
This valuable resource can be used for characterisation of genomic structures once a gene
sequence has been identified. Gene sequences not found in cDNA libraries can be identified
by use of gene prediction programs, for example GRAIL (Roberts, 1991), that identify exons
on the basis of common structural features. The use of the nucleotide identification (NIX)
computer program interface (based at HGMP) which encompasses a group of sequence
similarity search programs and gene prediction programs (commercially available from
Genscan and the Sanger Centre) was found to be a highly useful aid to the analysis of
genomic sequence in the search for transcripts.
3.1.3.5 PCR screening for ESTs
Many EST primer pairs have been designed from cDNA clones and their position on human
chromosomes mapped by radiation hybrid mapping. This EST mapping information has
been gathered to produce a transcript map, allowing ESTs and genes to be placed in relation
to chromosomal markers -see Genemap'99 at theNCBI web-site
(http://www.ncbi.nlm.nih.gov/genemap). Once the chromosomal location of a genomic
clone is known (for example a YAC clone), ESTs mapping to the same genomic region can
be used to PCR screen the YAC clone. The screening of genomic clones using ESTs is
quick and easy to perform but for this method to be successful, the location of the genomic
clone on genetic maps must be accurately known.
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3.1.4 Identification and analysis of transcripts
During the course of the physical contig construction at the GCKR-KHK and DFNB9
intervals, the insert ends of cosmid and PAC clones had been sequenced for the design of
novel STSs. Further sequence analysis of the generated sequences turned out to be a highly
useful method for searching for transcripts. The mapping of chromosomal markers to the
YAC clones in the chromosome 2p23.3 physical contig allowed the selection of ESTs
(mapped by radiation hybrid mapping) for PCR screening the clones within the physical
contig. This again turned out to be a successful method for transcript identification at the
GCKR-KHK and DFNB9 intervals. A search for CpG islands by searching for rare
restriction enzyme sites within the cosmid genomic clones was also performed. Due to the
success of searching for transcripts by direct sequencing and EST PCR screening of genomic
clones, the other methods such as cDNA selection and exon trapping were found not to be
required. Once transcripts had been identified, they could be accurately placed onto the
physical contig and in many cases the relative gene order and orientation could be deduced.
Sequence analysis of the transcripts identified was performed to look for clues to the
encoded protein's function and this was used to choose transcripts for further investigation
(the investigation of individual transcripts is described in Chapters 4 and 5).
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3.2 Methods
3.2.1 YAC contig assembly
The chromosomal marker D2S1237 had previously been mapped to the genomic YAC clone
3AG3 (Hayward et al., 1996; Prochazka et al., 1995) near to the GCKR-KHK region. The
examination of radiation hybrid maps for chromosomal markers mapping near to D2S1237
was carried out to identify other possible chromosomal markers for PCR screening of the
YACs 29IH8, 26BA11, 18AG7 and 3AG3. With the identification of new chromosomal
markers mapping to the GCKR-KHK YAC contig, a search of the Genome Database (GDB)
was performed to identify other YACs, for example CEPH mega-YACs and Whitehead
YACs that also contained these chromosomal markers.
Once YACs had been identified and obtained (CEPH mega-YACs were obtained from the
HGMP resource centre, Hinxton), further STS and EST content analysis was performed by
PCR to identify overlapping YAC clones. To extend this contig to include the DFNB9
interval, YACs mapping between GCKR and KIF3C (a gene known to reside in the DFNB9
interval), were identified by PCR screening YAC libraries using STSs and ESTs that were
known to map to the chromosome 2p23.3 by radiation hybrid mapping. Identification of
YACs mapping to the DFNB interval was carried out by Dr J. Leek. All primer sequences
for chromosome 2 polymorphic markers were obtained from GDB
(http://www.hgmp.mrc.ac.uk/gdb/).
3.2.2 Cosmid fingerprinting and cosmid contig assembly
For more detailed mapping of the GCKR-KHK interval and gene identification, the YACs
26BA11 and 29IH8 were subcloned by Dr J. Warner into the Supercosl vector. Once
cosmid DNA had been extracted by the alkaline lysis technique (Section 6.2.1.2), the method
of cosmid fingerprinting was used to assemble the cosmid clones into a contig (summarised
in Figure 3.3).
Briefly, a universal primer labelled with one of three fluorescent dyes
(FAM/HEX/ROX-5'-dTCCCAGTCACGACGTTGT-3') was annealed to a complementary
synthetic oligonucleotide to create a double-stranded oligonucleotide linker with a
5'-overhang complementary to one produced by a restriction enzyme. The complementary
oligonucleotides were designed with HindWl, EcoRl and BamHl overhangs
(5'-dAGCTACAACGTCGTGACTGG-3', 5'-dAATTACAACGTCGTGACTGG-3',
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5'-dGATCACAACGTCGTGACTGG-3respectively). The cosmid DNA was digested with
the appropriate restriction enzyme and ligated to the fluorescent dye-labelled oligonucleotide
linker. A second digestion step using a different restriction enzyme, for example Hinfl, was
performed to create smaller restriction fragments and an alternative fingerprint. To size the
dye-labelled restriction fragments, the restriction products were electrophoresed through a
polyacrylamide gel and run using the Genscan software package on the ABI 377 fluorescent
DNA sequencer. The cosmid fragments were sized by comparison to an internal lane size














Dye TCCCAGTCACGACGTTGTAGCTT // AAGCTACAACGTCGTGACTGG












Figure 3.3 Annealing, restriction enzyme, and ligation reactions for the preparation of the
fluorochrome-labelled restriction fragments. The cosmid DNA is shown as a Hindlll
restriction fragment for illustration purposes only; the fluorochrome-labelled oligonucleotide
is shown in bold type. In actuality, the reaction is initiated with uncut cosmid and the
restriction enzyme and ligase are added simultaneously. This diagram was adapted from
Carrano et al., 1988.
The cosmids were assembled into a contig of overlapping clones, based on the number of
shared fragments (of equal size) that each cosmid contained. The benefits of using this
technique included a single reaction mixture for the simultaneous restriction digest and
ligation reaction (only applicable if the double-stranded oligonucleotide linker destroyed the
restriction enzyme recognition site upon ligation to the restriction fragment being labelled).
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Advantages of using an automatic fluorescent sequencing machine included a fast through
put of samples with four different dyes run per lane (three fingerprinting reactions and one
internal size standard) and that an internal size standard in each lane allowed highly accurate
sizing of the restriction fragments. To confirm clone overlap inferred from the cosmid
fingerprinting, cosmid clones were PCR screened using novel STSs (Table 3.1) designed
from sequence at the ends of the genomic DNA cosmid clones's inserts. The primers used to
obtain these sequences were designed from the Supercosl™ vector sequence flanking the
multiple cloning site ("SC2": 5'-dTGGAAGTCAACAAAAAGCAGAGC-3' and "SC3":
5'-dGAGGCCCTTTCGTCTTCAA-3').
3.2.3 PAC contig assembly
To identify PAC clones located on chromosome 2p23, STSs and ESTs were used to PCR
screen the RCPI1 PAC library, constructed by P. de Jong -see Figure 3.4 below for strategy
used to screen the RCPI1 PAC library.
PCR screening of primary .. Secondary PAC pool Tertiary PCR screen
PAC pools (21 pools) ^ PCR screen(15 pools) (384 individual clones)







using T7 and SP6 primers
Grow 250 ml
PAC DNA extraction culture
(using modified alkaline lysis method)
PCR screen genomic clones
in physical contig to identify
over-lapping clones
Re-screen PAC library
Figure 3.4 Strategy for identifying PAC clones. STS or EST primer pairs were used to PCR
screen the PAC library RPCI1 (constructed by P. de Jong, Roswell Park Cancer Institute,
Buffalo). The RPCI1 library consists of approximately 120 000 clones.
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Table 3.1 Primer sequences for STSs generated from sequencing ends of cosmid and PAC
clones. STS nomenclature: '2 and '3 refer to STSs designed from cosmid sequence obtained
using SC2 and SC3 primers, respectively; T7 and SP6 refer to STSs designed from PAC
sequence obtained using T7 (5 '-dTAATACGACTCACTATAGGG-3') and SP6
(5 '-dTATTTAGGTGACACTATAG-3') primers respectively.
3.2.4 BAC clone identification
The recent availability ofBAC sequences produced as part of the Human Genome Project
facilitated the identification ofBACs located within the GCKR-KHK region by means of
searching the Genbank DNA sequence databases using EST sequences from within the
GCKR-KHK contig. This identified three partially sequenced BACs in the form of
unordered contigs. Further sequence analysis using gene identification programs based at
the HGMP resource centre, Hinxton, (submitted using the NIX interface), identified several
EST and gene sequences located on these BACs (Table 3.3). The gene sequences that were
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identified were used to place the BAC clones on to the GCKR-KHK interval physical contig
(see Figure 3.8).
3.2.5 Mapping of ESTs to GCKR-KHK region
ESTs mapped to the chromosome 2p23.3 region by radiation hybrid mapping according to
Genemap'99 were used to PCR screen genomic clones mapping to the GCKR-KHK region
(for list ofESTs, see http://www.ncbi.nlm.nih.gov/genemap). The sequencing of insert ends
from PAC and cosmid clones and comparison to the Genbank EST DNA database using the
BLAST program also identified several transcript sequences. A summary of all the genes
and ESTs that were identified to map within or near the GCKR-KHK genomic region can be
found in Table 3.4.
3.2.6 Identification of CpG islands
CpG islands are often associated with transcript sequences and can be identified by searching
for rare cutter restriction enzyme sites within genomic DNA sequences. As a preliminary
investigation into the presence ofCpG in the GCKR-KHK interval, a search for rare cutting
restriction enzyme sites was performed on genomic clones using the restriction enzyme Eagl
(cutting site: CGGCCG). The restriction analysis of the AT/A'-containing PI clone J0788
using the Eagl restriction enzyme had previously revealed five internal Eagl cutting sites
(Hayward & Bonthron, 1998). The largest Eagl fragment (-40 kb) was
radioactively-labelled with [a32P] dCTP by random priming and used to screen a colony
filter of the cosmid library described in Section 3.2.2 (performed by Dr B. Hayward). This
initial screening of the cosmid library using the PI clone J0788 Eagl fragment was
performed to increase the chances of identifying cosmids containing Eagl restriction enzyme
sites. Positive cosmids (cosmids: Al, A7, A10, B2, B8, BIO, C2, CI, C8, C12, D10, and
D11) were chosen for restriction analysis using Eagl. The resulting cosmid Eagl restriction
fragments were ligated into the pGEM vector and the inserts sequenced. Computer analysis
of the sequences was performed to ascertain the presence of a CpG island. The methods used




3.3.1.1 YAC clone contig assembly
A YAC physical contig was constructed that spanned both the GCKR-KHK and DFNB9
intervals on chromosome 2p23.3. This contig is shown in Figure 3.5 and consists of eleven
YAC clones identified by screening either the ICI YAC or CEPH mega-YAC libraries.
Figure 3.5 also displays the chromosomal markers and genes that were used to identify
overlapping YAC clones. The physical size for this genomic region, based on YAC sizes, is
estimated at <2 Mb.
3.3.1.2 Cosmid clone contig assembly
Cosmid fingerprinting produced a set of restriction fragment sizes for each cosmid clone
(overlapping cosmid clones share identical sized restriction fragments). Therefore, to
identify overlapping cosmid clones, the fingerprint data was transferred into a Microsoft
Excel spread sheet and cosmid clones put into order based on number of "common"
restriction fragments (data not shown). This alignment was carried out manually as there
were only 92 cosmid clones.
The analysis of cosmid fingerprinting data identified cosmid clones sharing common sized
restriction fragments, indicating that they were likely to be overlapping. To confirm cosmid
clone overlap, STSs designed from sequence at the ends of cosmid clones' inserts were used
to PCR screen the cosmid clone library (see Table 3.1 for STS details). By combining the
data from both the fingerprinting experiment and the STS library screening, a cosmid contig
was constructed (Figure 3.6 shows a selected number of cosmids shown to be overlapping by
both cosmid fingerprinting and STS screening).
Described later in this results section is the search for and mapping of ESTs/transcripts. One
EST that was mapped to cosmid B2 was WI-18702, designed from the human homologue of
the mouseMpvl 7 gene (a recessive kidney disease and deafness gene; this gene is discussed
in Chapter 5, Section 5.2). The human MPV17 gene consists of 8 exons (Karasawa et al.,















































Figure 3.5 YAC contig of chromosome 2p23.3. Polymorphic markers and genes mapping to
the YAC clones are indicated. The GCKR-KHK and DFNB9 intervals are shown on the
right hand side.
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exons 1-5 were present, but exons 6-8 were missing from YAC 26BA11. STS and EST
analysis of YAC 26BA11 (Hayward et al., 1996), had previously suggested the presence of
an internal deletion and that the deletion included the KHK gene. The absence ofMPV17
exons 6-8 suggests that the deletion in YAC 26BA11 starts within theMPV17 gene and
includes the KHK gene (see Figure 3.6). As no genomic clones had so far been identified
that span this deletion, other genomic clones would have to be identified for the construction





























Figure 3.6 Cosmid contig assembled by cosmid fingerprinting and STS/EST content. The
upper contig was assembled by analysis of cosmid fingerprinting data; the lower contig was
assembled by EST/STS content analysis ('2 and '3 refer to sequence at the ends of a
cosmid's insert, used to design the STS). The positions of the three genes KHK, MPV17 and
GCKR are shown (arrow indicates 5' to 3' orientation). All clones are cosmids except the
AT/K-containing PI clone J0788 (STS 5.3/5.4 was designed from one end of this clone). A
deletion was identified within cosmid B2; this cosmid, contains the 5' but not the 3' end of
theMPVI7 gene (deletion is shown by a dotted/dashed line).
3.3.1.3 PAC contig assembly
For the identification of other genomic clones within the GCKR-KHK interval, the RPCI1
PAC library was screened by PCR using STSs designed from the insert ends of cosmid
clones (see Table 3.1 for primer sequences and Figure 3.4 for PAC library screening
strategy). Once PAC clones were identified, their insert ends were sequenced and novel
STSs designed. These STSs were used to re-screen all the genomic clones used to construct
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the physical contig and thus allow the PAC clones to be accurately placed onto the
YAC/cosmid contig.
In total, 15 PAC clones were identified and placed onto the GCKR-KHK and DFNB9
interval physical contig - see Figure 3.7 and Table 3.2 for PAC clone names (Table 3.2
describes PAC clones identified that are not shown in Figure 3.7). STS analysis of the PAC
clones revealed that a complete contig spanning from KHK to GCKR could not be
constructed. Figure 3.7 shows the PAC clone contig (at the time of construction, it was not
known which genomic clone (J0788 or L1313) was closest to GCKR). Re-screening the
PAC library with a STS designed from sequence at the end ofPAC L1313 (STS L1313-SP6)
did not identify any new PAC clones. As one end of the PI clone J0788 insert is a repetitive
DNA sequence (the opposite insert end sequence was used to design STS 5.3/5.4), which
could not be used for STS design. Screening of the chromosome 2-specific PAC library
LL02NP04 filters by hybridisation of STS oligonucleotides again did not identify any new
PAC clones.
STS/EST PAC clone name
K1F3C (stSG4510) 14H17, 97K3
KCNK3 (see Section 5.5.2.1) 249B24
FOSL2 (STS 11971) 17F24
17F24-SP6 (Table 3.1) 190C22, 294C20
17F24-T7 (Table 3.1) 40P7, 159C16, 195F13
RBSK (stSG 15128) 22F16, 137K13
Table 3.2 PAC clones mapping to chromosome 2p23.3 (but not shown on physical contig in
Figures 3.7). All clones were identified by PCR screening the RPCI1 PAC library using the
ESTs/STSs indicated.
3.3.1.4 Completion of contig using BAC clones
Although screening of the RCPI1 PAC library had proved to be highly successful in
identifying clones mapping to chromosome 2p23, there was still a discontinuity in the
physical contig spanning the GCKR-KHK interval. However, the recent BAC clone
sequences that have been deposited into the Genbank sequence database by the Washington
University School ofMedicine as part of the Human Genome project, have allowed the
identification of genomic clones that complete the GCKR-KHK interval contig.
The searching of the Genbank sequence database using sequence from KHK, MPVI7, and
GCKR identified three partially sequenced BAC clones (NH0195B17, NH0538J11, and
45_M_3, respectively). A summary of the database sequence analysis for these three BAC
clones is described in Table 3.3. The analysis of the GCATTcontaining BAC clone 45_M_3
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confirmed the presence of GCKR and an EST already mapped to the physical contig by PCR.
However, sequence analysis of the KHK-containing BAC clone NH0195B17 and the
MPVI 7-containing BAC clone revealed them to contain two genes in common, SMVTand
CAD. Thus, by addition of these two BAC clones to the existing PAC contig, a complete
and contig was constructed, spanning from KHK to GCKR (Figure 3.7).
BAC clone Transcripts/ESTs revealed by sequence analysis
NH0195B17 KHK, SMVT, CAD, EMILIN, CGR11
NH0538J11 MPV17, SMVT, CAD, ZNT3, UCN, TFIIIC2
45_M_3 GCKR, leucine zipper transcription factor showing similarity to SREBP-2
Table 3.3 Sequence analysis of three partially sequenced BAC clones mapping to the
GCKR-KHK interval. Sequencing was performed by the Washington University School of
Medicine as part of the Human Genome Project. For full gene names and encoded protein



















Figure 3.7 PAC and BAC clone contig spanning the GCKR-KHK genomic region. The
contig was constructed by EST and STS content of the PAC clones, and sequence analysis of
the BAC clones. PAC clones are indicated by a solid line; BAC clones are indicated by
dashed/dotted line. STSs were designed from sequence at the ends of the PAC clones
(named SP6 and T7). The position of the genes KHK, SMVT, MPV17 and GCKR are
indicated (arrow direction indicates 5'-3' orientation of the gene).
3.3.2 Transcript and EST mapping
All the transcripts and ESTs that were mapped to the GCKR-KHK and DFNB9 interval
physical contig are summarised in Table 3.4. This Table describes 14 known genes and 15
ESTs (including THC contigs assembled by "The Institute ofGenome Research" (TIGR)).
Brief descriptions of the encoded protein function are given (if known), including a reference
(if the gene/EST is described elsewhere in this Thesis, a chapter/section number is given).
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The transcripts and ESTs shown in Table 3.4 were all identified by either sequence analysis
or EST PCR screening of the genomic clones used to construct the chromosome 2p23.3
physical contig. The construction of a highly detailed YAC, BAC, PAC and cosmid clone
contig of the GCKR-KHK interval allowed all transcripts and ESTs to be accurately mapped.
This detail allowed the relative order and orientation ofmany if the genes to ascertained. A







GCKR Glucokinase regulatory protein. Plays a role in sequestering
glucokinase in the nuclei of
hepatocytes.
See Chapter 1,Section 1.6.
KHK Ketohexokinase. KHK phosphorylates fructose to
fructose-1 -phosphate.
See Chapter 1, Section 1.7.
PPP1CB Protein phosphatase 1, catalytic
subunit, p isoform.
One of three catalytic subunits
of protein phosphatase 1 (PP1).
PP1 is one of 4 major
serine/threonine-specific protein
phosphatases involved in the
dephosphorylation of a variety of
proteins.
See Chapter 1, Section 1.9.
EIF2B4 Guanine nucleotide exchange
factor (delta subunit).
A subunit of the
heteropentameric guanine
nucleotide exchange factor.
The elF2B complex controls a key
regulatory step in initiation during
protein synthesis.
See Chapter 4, Section 4.2.
KIAA0064 Otherwise unknown. Sequence analysis reveals the
putative translation product to
contain a serine protease active site
motif and PX domain. Intimately
adjacent to the EIF2B4 gene.
See Chapter 4, Section 4.3.
RBSK Ribokinase.
Identified by its similarity to
bacterial and yeast ribokinases.
Role is to phosphorylate ribose to
ribose-5-phosphate.
See Chapter 4, Section 4.4.
KIF3C Kinesin-like gene. Forms a heterodimer with KIF3A.
Probable role in intracellular
transport.
See Chapter 7, Section 7.3.
Continued on next page.
Table 3.4 List of genes and ESTs mapping to the GCKR-KHK and DFNB9 physical contig







OTOF The DFNB9 gene.
Shows similarity to the C.
elegans spermatogenesis factor
FER-1 and human dysferlin.
Thought to be involved in vesicle
membrane fusion.
See Chapter 7, Section 7.6.
MPV17 Peroxisomal protein.
Recessive kidney and deafness
gene in mouse.
Involved in regulation of cellular
reactive oxygen species.
See Chapter 7, Section 7.2.
UCN Urocortin.




Plays a role in the mammalian stress
response and is related to fish
urotensin and corticotropin-releasing
factor (CRF).
See Chapter 7, Section 7.2.4.2.
KCNK3
(TASK)
A member of the mammalian
potassium ion channel family.
KCNK3 currents are very sensitive to
small changes in extracellular pH,
suggesting that TASK has a role in
cellular responses to changes in
extracellular pH.
See Chapter 7, Section 7.5.
EMILIN Sastin microfibril interface
/ocated protein.
An extracellular matrix glycoprotein.
FOSL2 FOS-like antigen 2.
Encodes a leucine zipper
protein that can dimerise with
proteins of the JUN family,
thereby forming the transcription
factor complex AP-1.
Genbank accession no. X16706.





Cell growth regulator 11.
Protein contains an EF-hand
domain.
Genbank accession no. U66468.
Has been shown to be





General transcription factor IIIC2
(GTF3C2).
GTF3C family proteins are essential
for RNA polymerase III to make a
number of small nuclear and
cytoplasmic RNAs, including 5S
RNA, tRNA, and adenovirus-
associated (VA) RNA of both cellular
and viral origin.
WI-19785 Xfin like/Zinc finger protein. Genbank accession no. T16385
StSG3685 Shows similarity to retinitis
pigmentosa 3 (RP3).
Genbank accession no. H03977
stSG 15582 Weakly similar to sodium iodide
symporter.
Genbank accession no. R69136
stSG3204 KIAA0764 Genbank accession no. T15764
SGC32173 Shows similarity to an
ATP(GTP) binding protein.
Genbank accession no. G25480
Continued on next page.
Table 3.4 (Continued from previous page). List of genes and ESTs mapping to the







ZNT3 Zinc transporter gene.







Encodes a trifunctional protein which
is associated with the enzymatic
activity of the first 3 enzymes in the





SMVT Sodium multi-vitamin transporter
Solute carrier family 5, member
6; SLC5A6.
This protein may be involved in the
entry of pantothenate, biotin, and
lipoate in all cell types
WI-14636 Anonymous EST Genbank accession no. G20997
WI-11296 Anonymous EST Genbank accession no. G24562
WI-18604 Anonymous EST Genbank accession no. H05599
StSG4391 Anonymous EST Genbank accession no. R37380
EST1 THC 291225 SREBP-like (sterol regulatory
element binding protein-2) leucine
zipper transcription factor.
EST2 THC 257039 Anonymous EST
Table 3.4 (Continued from previous page). List of genes and ESTs mapping to the
GCKR-KHK and DFNB9 physical contig (Figures 3.5 and 3.8). The putative function of the
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3.3.3 Cosmid EagI restriction fragment analysis
As a preliminary search for CpG islands (performed as part of the search for transcripts), 12
cosmids were chosen for Eagl restriction analysis (all positive for the PI clone J0788 large
Eagl restriction fragment - see methods). All were found to contain identical internal Eagl
restriction fragments (analysis of other randomly chosen cosmids revealed the presence of 2
out of 3 of these fragments). The Eagl restriction fragments produced from cosmid C2 (see
Figure 3.9) were cloned and sequenced. Sequence analysis revealed two of these fragments
(the smallest and largest) to be vector sequences. The third fragment was found to show
significant similarity to a partially sequenced BAC clone and a CpG island clone (Figure
3.10 and Table 3.5).
1Kb
ladder C2
Figure 3.9 Eagl restriction digestion of cosmid C2.
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C2 EagI frag. 4 gccgccgaccatcccaggtctaccgcacccaatcccccaggcttgcgagcgcttc 58
mill 1111111iiii11111ii11 iiiiiiiiiiiiiiiiiiiiiiiiiii
NH0503P10 120972 gccgcccaccatcccaggtctaccgcagggaatcccccaggcttgcgagcgcttc 121026
C2 EagI frag. 59 cgagggcaggaaagcctgtactgcagccccgccgccctctcc 100
I I II I II I I I II I I I I I I I I I I I I I I I I I I I I I I I I II I II I
NH0503P10 121027 cgagggcaggaaagcctgtactgcagccccgccgccctctcc 121068
I I I II I I I I I I I II I I I I I I II I I I I I II I I I I II II I
33H5 216 gggcaggaaagcctgtactacagcnccgccgccctctcc 178
Figure 3.10 Sequence alignment of cosmid B8 EagI fragment and sequences from BAC
NH0503P10 (nucleotides 120972-121068) and clone 33H5 (nucleotides 216-178). See






NH0503P10 AC013472 Homo sapiens chromosome 2 BAC clone
RP11 NH0503P10, working draft sequence,
19 unordered pieces. Sequence analysis
shows this clone to contain the STS
WI-14636 and sequence showing similarity
to dihydropyrmidase (Genbank accession
no. Q09296).
33H5 Z60767 Homo sapiens CpG island DNA genomic
Msel fragment (216 bp).
Table 3.5 Clone information for Figure 3.10
Sequence analysis of the database sequence for BAC clone NH0503P10 revealed the
presence of an EST sequence WI-14636, an EST already mapped by PCR screening to the
physical contig on chromosome 2p23.3. The discovery that one of the cosmid EagI
fragments was identical to the CpG island genomic clone 33H5 sequence suggested that a
transcript might reside nearby. To investigate whether a transcript could be associated with
this CpG island sequence, further sequence analysis of the surrounding genomic region to
the EagI fragment is required. PCR screening for ESTs had previously mapped the CGR11
gene to cosmid C2 therefore the CpG island sequence could be associated with the CGR11
sequence. Although the method of identifying CpG islands by rare cutter restriction analysis
of genomic clones had in this case identified a CpG island sequence, this experiment was not
continued due to the success of searching for transcripts by direct sequence analysis and
PCR screening using ESTs of genomic clones (described previously in this chapter).
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3.4 Discussion
3.4.1 Physical mapping on chromosome 2p23.3
3.4.1.1 Chromosome 2p23.3 physical contig
The construction of a physical contig spanning the GCKR-KHK genomic region and DFNB9
interval is a valuable resource for the detailed examination of transcripts within the GCKR-
KHK intergenic region and the identification of candidate deafness (DFNB9) genes. This
chapter describes the construction of a YAC contig that spans the GCKR-KHK genomic
region and DFNB9 interval, covering approximately 2 Mb on chromosome 2p23.3 (Figure
3.5). Also described is a more detailed physical contig that spans the GCKR-KHK region,
consisting ofYAC, BAC, PAC, and cosmid clones. The contigs were assembled using a
combination of STS and EST content analysis and cosmid fingerprinting (Figures 3.6 and
3.7).
Although GCKR and KHK had been estimated by FISH to be <500 kb apart on chromosome
2p23.3 (Hayward et al., 1996), EST content analysis ofYACs reveals none to contain both
GCKR and KHK. STS analysis ofYACs did allow GCKR and KHK to be physical linked,
but the analysis of STSs revealed this original YAC contig to be internally inconsistent (see
introduction, Section 3.1.2.1, Figure 3.1). The most likely explanation for this aberration
was a deletion within YAC 26BA11 at the KHK locus.
The physical proximity of GCKR and KHK, estimated to be -500 kb apart by FISH
(Hayward et ah, 1996),could not be refined from the YAC physical contig due to the deletion
within YAC 26BA11. Initially, the size of the deletion within YAC 26BA11 was unknown.
EST analysis of the YAC 26BA11 and the cosmid subclone library revealed that exons 1-5
of the MPV17 gene were present but exons 6-8 were absent. As KHK is also absent from
YAC 26BA11, the deletion in YAC 26BA11 is likely to span from within MPV17 to within
the AYftT-containing PI clone J0788 (see Figure 3.6).
For the identification of genomic clones that might span the gap within YAC 26BA11, the
RPCI1 PAC library was screened. In total, 4 PAC clones and 2 PI clones were identified to
map at the GCKR-KHK interval. These included the clones 13L13 and J0788 that contain
the genes MPV17 and KHK respectively. Although contig construction suggests these two
clones to partly contain some of the genomic DNA deleted in YAC 26BA11, STS and EST
66
content analysis of clones 13L13 and J0788 reveals these PAC clones to be non-overlapping.
Further screening ofPAC libraries did not identify any other PAC clones able to span the
YAC 26BA11 deletion.
3.4.1.2 Identification of chromosome 2p23.3 BAC clones
As part of the Fluman Genome Project, partially sequenced BAC clone sequences have been
released into the Genbank database. EST and STS screening of the Genbank database using
sequences fromMPVI7 and KHK, identified the BAC clones NH0195B17 and NH0538J11.
Computer analysis of the database sequences for BACs NH0195B17 and NH0538J11 reveals
them to contain KHK and MPV17 respectively (KHK and MPV17 are located on opposite
sides of the YAC 26BA11 deletion). Further sequence analysis of the database sequences
for these two BAC clones using the BLAST program reveals both BACs to contain the genes
SMVT and CAD, thus indicating that these two BACs are overlapping and span the YAC
26BA11 deletion (see Figures 3.7 and 3.8). The complete YAC, BAC, PAC and cosmid
contig confirms the physical proximity of GCKR and KHK that was first shown by FISH
(Hayward et al., 1996). The physical distance between GCKR and KHK is estimated by
FISH to be -500 kb and the physical contig confirms this to be a good estimate of the
GCKR-KHK interval size.
Further database searching using sequence from GCKR identified the chromosome 2 BAC
clone 45_M_3. Although the genomic region surrounding GCKR had already been cloned in
the form ofYAC, PAC and cosmid clones (Figure 3.8), further analysis of the 45_M_3 BAC
database sequence confirms the presence of an EST (similar to a sterol regulatory binding
protein transcription factor SREBP-2). This EST had previously been identified by direct
sequence analysis of the cosmid clones within the chromosome 2p23.3 physical contig
(Table 3.4).
3.4.1.3 Orientation of GCKR-KHK contig to DFNB9 interval
The physical linkage between the GCKR-KHK locus and the DFNB9 interval was
established by YAC 964D8, a CEPH mega-YAC originally known to contain the STSs
D2S2350 and D2S1979 (Figure 3.5). However, initially it was unclear as to the correct
orientation of GCKR and KHKwith respect to the DFNB9 interval. This was due to a lack
ofmarkers mapping to YAC 964D8, and radiation hybrid mapping ofboth KHK and GCKR
that was inconclusive as to the correct positional orientation of these two genes. Further STS
analysis of the YAC 964D8 reveals it to also contain STSs D2S174, D2S165, D2S366,
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D2S365, D2S1424, D2S2629, and AFM115YB6 but not D2S2247 (Figure 3.5). EST
content analysis ofYAC 964D8 reveals it to contain OTOF, CENPA, KCNK3, FOSL2,
RBSK, and GCKR but not ZNT3, CGR11 or KHK (Figure 3.5). This mapping data strongly
suggests that the correct orientation ofKHK and GCKR with respect to the centromere and
the DFNB9 interval is centromere//W/A7G:CA7?/DFNB9. As a note of caution, examination
of other YAC contigs on chromosome 2p23.3 such as the Whitehead 3.2 contig, reveal high
frequencies of internal deletions in the chromosome 2p23.3 region. This phenomenon may
be responsible for the lack ofYACs that contain both GCKR and KHK. Therefore, as the
orientation of the GCKR and KHK is based upon the STS and EST content ofYAC 964D8,
the existence of a deletion in this YAC might alter the GCKR-KHK orientation with respect
to the DFNB9 interval. Although it is has been previously noticed that large scale YAC
contig projects contain high frequencies of region specific internal deletions (Collins et al.,
1995), an explanation for this phenomenon has yet to be found.
3.4.2 Transcript mapping in chromosome 2p23.3
3.4.2.1 Transcript mapping
The chromosome 2p23.3 physical contig is an ideal tool for transcript searching by PCR
screening for ESTs and direct sequencing of clones combined with computer analysis of
sequences. In total, 14 known gene sequences and a further 15 ESTs were mapped to
chromosome 2p23.3 (see Table 3.4). Within the GCKR-KHK interval (see Figure 3.8), 7
genes and 5 ESTs map to the physical contig. The transcript sequences that have been
mapped to the cosmid contig are in their correct order relative to GCKR and KHK.
However, the correct positional order of CAD and SMVT relative to GCKR and KHK is
unknown and will require further sequencing ofBAC clones NH0195B17 and NH0538J11
for its elucidation. Gene orientation is indicated on Figure 3.8 if known.
3.4.2.2 CpG Island mapping
To identify other transcripts at the GCKR-KHK locus, a preliminary search for CpG islands
located within the chromosome 2p23.3 physical contig was performed by searching for rare
cutter restriction enzyme sites. This experiment involved the cloning and sequencing of
Eagl restriction fragments from cosmid clones within the chromosome 2p23.3 physical
contig. As a preliminary experiment, cosmids positive for the PI clone J0788 Eagl large
fragment were chosen for Eagl restriction analysis. This was carried out to increase the
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chances of identifying cosmids containing Eagl restriction sites (and would also aid cosmid
contig construction).
Cosmids positive for the PI clone J0788 Eagl large fragment, were all found to contain three
Eagl restriction fragments. The cloning and sequencing of these three Eagl restriction
fragments from the cosmid C2 revealed that two of the fragments were vector sequence. The
third fragment showed significant similarity to a genomic CpG island clone 33H5 (Figure
3.10 and Table 3.5). This might indicate the presence of a CpG island on cosmid C2 and the
presence of a transcript. Further sequencing of the surrounding region to the cloned Eagl
fragment is required to investigate whether the CpG island sequence is associated with a
transcript sequence. As cosmid C2 is known to contain CGR11 (Figure 3.8), this CpG island
sequence might be associated with this gene.
BLAST analysis of the C2 Eagl fragment also revealed significant similarity to sequence
from the chromosome 2 BAC clone NH0503P10 (Figure 3.10 and Table 3.5). As the
database sequence for BAC NH0503P10 is partial and made up of unordered contigs, it is
difficult to accurately place this BAC clone onto the chromosome 2p23.3 physical contigs
shown in Figures 3.5 and 3.8. However, further analysis of the BAC clone sequence using
BLAST program reveals it to contain the chromosome 2 STS WI-14636, which also maps to
YACs 18AG7 and 26BA11, and PAC J0788 (see Figure 3.8). This data places the BAC
NH0503P10 close to KHK on the physical contig. Further analysis of the BAC NH0503P10
database sequence reveals it to also contain a sequence highly similar to the gene encoding
dihydropyrmidase (Table 3.5). Further work is required to place this BAC accurately onto
the GCKR-KHK physical contig and to identify other transcripts that it may contain.
Although the search for CpG island-like sequences had proven successful, this experimental
approach was not continued due to the success of transcript identification by direct
sequencing and PCR screening of genomic clones.
3.4.2.3 Examination of transcripts
Characterised genes and ESTs that were identified to reside on chromosome 2p23.3 are
described in Table 3.4. Initial inspection of the putative protein functions encoded by
transcripts on chromosome 2p23.3 reveals a variety ofprotein functions with no obvious
common theme. In addition to the candidate type 2 diabetes genes encoding the glucokinase
regulator protein and ketohexokinase (discussed in Chapter 1), examples of other known
genes residing on chromosome 2p23.3 include: the MPV17 gene, ofwhich the mouse
homologue is a recessive kidney and deafness gene (see Chapter 5, Section 5.2); the
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urocortin gene, which encodes a neuropeptide; EMILIN, which encodes a extracellular
matrix protein; TFIIIC2, which encodes a RNA polymerase III general transcription factor;
and KCNK3, a potassium ion channel gene.
The aim of the following chapters is to 1) identify and characterise transcripts encoding
proteins that might be functionally related to GKRP and KHK or involved in biochemical
pathways related to carbohydrate metabolism with a possible involvement in type 2 diabetes
(see Chapter 4), and 2) identify candidate non-syndromic recessive sensorineural deafness
DFNB9 genes (see Chapter 5). Examination of the encoded protein functions of known
genes residing on Chromosome 2p23.3 reveals none to encode proteins that are obviously
related to GKRP, KHK, or carbohydrate metabolism. However, many anonymous ESTs also
map to this genomic region. Therefore, to search for genes that might have related functions
to GKRP, KHK, or carbohydrate metabolism, the ESTs were examined and several chosen
for investigation (see Chapter 4).
In the case of candidate DFNB9 genes, MPV17 is an obvious candidate deafness gene due to
the mouse knock-out phenotype (see Chapter 5, Section 5.2). KCNK3 is also a potential
candidate deafness gene due to the important role of potassium ions within the inner ear (see
Chapter 5, Section 5.5). These two genes plus a kinesin-like gene (KIF3C, see Chapter 5,
section 5.3) that was also identified as a candidate deafness gene, are all discussed in Chapter
5.
The transcript map shown in Figure 3.8 does indicate this genomic region to be gene rich
with the transcripts packed closely together. This suggests that promoter and possible
enhancer sequences for some of these transcripts may be located within or near other
transcripts. Added to the finding that the this relatively small GCKR-KHK genomic region
on chromosome 2p23.3 shows conserved synteny with a small region ofmouse chromosome
5 (see Chapter 2), this may provide circumstantial evidence that genes at the GCKR-KHK
locus are evolutionary linked and that a common cw-acting regulatory element acting on
transcripts at the GCKR-KHK genomic region might exist.
The physical contig spanning the GCKR-KHK genomic region and DFNB9 interval provides
an ideal framework for transcript mapping, transcript characterisation, and for the
investigation of genomic organisation on chromosome 2p23.3. The location of genes and
ESTs is very important when considering their candidacy for involvement in human diseases
especially if the disease gene maps to a specific genomic interval. The physical contig
shown in Figure 3.5 defines the genomic region containing GCKR, KHK, and the DFNB9
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interval on chromosome 2p23.3. Only genes and ESTs mapping to this genomic region were
considered for further investigation in the following chapters (see Chapters 4 and 5).
Apart from EST mapping and gene investigation, the chromosome 2p23.3 physical contig
and transcript map gives an interesting insight into genomic organisation and helps to define
the size of the region of conserved synteny with mouse chromosome 5 (see Chapter 2).
Furthermore, a gene for familial syndromic esophageal atresia has been recently mapped to
chromosome 2p23-24 (Celli et al., 2000). The physical contig and transcript map at
chromosome 2p23.3 described in this chapter will be a useful tool for the identification of




4 Characterisation of transcripts within the
GCKR-KHKgenomic region
4.1 Introduction
As part of a detailed examination of the GCKR-KHK genomic region on chromosome
2p23.3, this chapter describes the identification and investigation of transcripts encoding
proteins with 1) possible functions related to the glucokinase regulatory protein (GKRP -is
encoded by GCKR) and ketohexokinase (KHK), or 2) a role in biochemical pathways
relating to carbohydrate metabolism. The investigation of transcripts that map to the
GCKR-KHK genomic region will use the candidate gene approach to identify transcripts for
further scrutiny.
The candidate gene approach is exemplified by both GCKR and KHK as good candidate type
2 diabetes genes. Their candidacy is based upon biochemical evidence that reveals an
important inhibitory interaction ofGKRP with glucokinase (GCK), and a modulation of
GKRP inhibition on GCK by fructose-1-phosphate, a product ofKHK (see Chapter 1, Figure
1.2). The intimate co-localisation ofGCKR and KHK to a 500 kb region of chromosome
2p23.3 raises an intriguing possibility that other transcripts encoding proteins that are
metabolically related to GCKR and KHK may also be located on this region of chromosome
2p23.3. To investigate this hypothesis, transcripts were mapped to a physical contig that
spans the GCKR-KHK intergenic region (see Chapter 3, Figure 3.8), and as described in this
chapter, several transcripts were chosen for further investigation.
The mapping of transcripts to the physical contig spanning the GCKR-KHK genomic region
(described in Chapter 3), reveals this genomic region to be gene dense, with at least 7 genes
and 5 ESTs mapping to the -500 kb genomic region between GCKR and KHK. These
transcripts are used in this chapter as the basis for an investigation into genes located at the
GCKR-KHK genomic locus that encode proteins with possible functions related to GKRP,
KHK, or carbohydrate metabolism. Further examination of the genes that map to the
GCKR-KHK region shows only one gene, EIF2B4, to fit this criterion (see Section 4.2).
However, a number ofESTs designed from anonymous cDNA clones also map to this
genomic region (Chapter 3, Table 3.4). Therefore, the ESTs mapping to this genomic region
were investigated. To prioritise the ESTs for investigation, sequence analysis was performed
on the Genbank database cDNA clone sequences from which the ESTs were designed. The
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cDNA clone sequence analysis may reveal a putative function of the encoded protein and
provide useful information that can be used to decide which ESTs to choose for further
investigation.
This chapter describes the investigation of three transcripts at the GCKR-KHK locus: 1)
EIF2B4, encoding the delta subunit of initiation factor eIF2B - a protein complex that plays
a key role in the regulation ofprotein synthesis; 2) KIAA0064, a putative gene arranged in an
intimate "head to head" arrangement to EIF2B4; and 3) RBSK, encoding ribokinase - a
member of the same kinase family as KHK. Ultimately, the aim of this research was to
gather evidence for the possible involvement of the GCKR-KHK genomic region on
chromosome 2p23.3 in the pathogenesis of type 2 diabetes.
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4.2 The guanine nucleotide exchange factor delta subunit
(EIF2B4)
4.2.1 Introduction
4.2.1.1 Identification of EIF2B4
The first putative transcript to be identified for further investigation was a sequence showing
significant similarity to the Saccharomyces cerevisiae "general control" GCD2 gene. This
was identified by the sequencing of insert ends from cosmid subclones ofYACs 29IH8 and
26BA11, two G'CAT'-containing YACs (see Chapter 3, Figure 3.8). Further analysis of the
GCD2-like sequence reveals it to encode the delta subunit (eIF2B8) of the human guanine
nucleotide exchange factor eIF2B, an initiation factor complex known to play a key role in
protein synthesis initiation.
The EIF2B4 transcript was chosen for further investigation because of previous research
showing eIF2B activity to be stimulated by insulin , glucose, and sugar phosphates (Gilligan
et al., 1996; Singh & Wahba, 1995; Welsh et al., 1997b). This suggested that eIF2B plays a
major role in regulating protein synthesis in relation to cellular levels of both insulin and
metabolites. Therefore, defective eIF2B function might contribute to the pathogenesis of
type 2 diabetes. As the initial aim of this investigation was to identify and characterise
transcripts on chromosome 2p23.3 that co-localise with the candidate type 2 diabetes genes
GCKR and KHK, and which themselves might encode proteins that play a role in the
pathogenesis of type 2 diabetes, EIF2B4 represented such a candidate gene and warranted
further investigation.
4.2.1.2 Eukaryotic protein synthesis
The translation ofmRNA into protein is a complex multi-step process mediated by proteins
termed translation factors. It can be divided into three phases: initiation, elongation and
termination (reveiwed in Hershey, 1991). During initiation, the methionyl-tRNA and several
initiation factors associate with the 40S ribosomal unit to form the 43S pre-initiation
complex; this complex binds to mRNA and migrates to the correct AUG initiation codon,
after which the addition of the 60S ribosomal subunit occurs. This is followed by
elongation, during which amino acids from amino acyl-tRNAs are added to the growing
peptide in the order dictated by the mRNA bound to the ribosome. The termination phase
allows the completed protein to be released from the ribosome.
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4.2.1.3 Identification of initiation factor genes
Initiation factor genes were first identified by gene expression studies in starving yeast,
although at the time their regulatory function in translation was not realised. Yeast initiation
factors are encoded by GCN and GCD genes, names derived from the role of these proteins
in "general amino acid control". In both yeast and mammals, starvation and stress result in a
reduction in the rate ofprotein synthesis. Down-regulation of protein synthesis conserves
cell resources and limits cell division under adverse growth conditions. The starvation of
Saccharomyces cerevisiae, for example by growth of the yeast in media lacking an amino
acid, results in de-repression of transcription of at least 40 different genes encoding amino
acid biosynthetic enzymes in many unrelated metabolic pathways and this enables the cell to
alleviate the nutrient starvation conditions. This response (called "general amino acid
control") is mediated by an increase in levels of the transcriptional activator protein GCN4.
In yeast, "general control" is mediated by both positive (GCN) and negative (GCD)
regulatory factors (Greenberg et al., 1986; Harashima & Hinnebusch, 1986; Hinnebusch,
1986).
The genes that encode GCN and GCD factors were identified by examining the effect of
mutations in yeast genes on general control. The effect ofmutations in yeast GCN and GCD
genes could be measured by using reporter genes such as GCN4:\lacZ fusion or lacZ fusions
with biosynthetic enzyme genes such as HIS4C (HIS4C encodes histidinol dehydrogenase,
which converts histidinol to histidine in the last step of histidine biosynthesis). Positive
regulatory genes were identified by the effect ofmutations that block de-repression of the
reporter gene (gen mutations e.g. GCN2), negative regulatory genes were identified by the
effect ofmutations which result in constitutive de-repression of the reporter gene (gcd
mutations e.g. GCD1 ,GCD22, GCD6 and GCD7).
Various combinations ofmutations in the GCN and GCD genes, used to explore interactions
among the GCN and GCD factors, provide genetic evidence that some factors interact more
closely. For example, deletion of GCN3 is normally non-lethal and the double mutant
gcd6-l and gcd7-201 is non-lethal, but deletion of GCN3 in the presence ofgcd6-l and
gcd7-201 is lethal (Bushman et al., 1993). These genetic experiments suggests that
subgroups of the GCN and GCD genes may code for subunits of larger protein complexes.
Biochemical proof that these protein complexes exist was provided later by co-purification
ofprotein complexes through biochemical fractionation steps and co-immunoprecipitation
using antibodies against the proteins of interest. For example, GCD1, GCD2 and GCN3 were
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shown to be integral components of a high-molecular-weight complex of approximately 600
kDa (Cigan et al., 1991).
The role ofGCD and GCN factors in translation regulation was realised when research into
mammalian protein synthesis using biochemical techniques identified several proteins
involved in protein synthesis regulation that showed homology to the GCD and GCN factors.
The study of translation in yeast using yeast mutants such as the temperature-sensitive lethal
gcdl-101 mutation (EIF2B3) confirmed the role ofGCD and GCN factors in translation
regulation. Following a shift to the non-permissive temperature, yeast with the gcdl-101
mutation show reduced amounts of incorporation of radio-labelled amino acids into proteins
and reduced amounts of a translation initiation intermediate containing charged initiator
tRNA (Bushman et al., 1993).
Research into regulation of eukaryotic protein synthesis using genetic and biochemical
techniques has identified many initiation factors with important functions (see next section).
Sequence analysis reveals many of the mammalian and yeast initiation factors are similar at
both the amino acid and DNA level. Therefore, the cloning ofGCN and GCD genes in yeast
can be used to identify mammalian homologues by sequence comparison. The importance
of studying translation regulation in yeast is also demonstrated by the many genetic
experiments that have been performed to reveal the interaction ofGCD and GCN factors.
Although the exact interaction between initiation factors and the mechanisms by which
translation is regulated have still to be fully elucidated, it is clear that this will require further
research using both yeast and mammalian systems.
4.2.1.4 Translation initiation
In eukaryotic initiation, 12 initiation factors have been identified so far that are involved in
the translation initiation process (elFIA, eIF2, eIF2B, eIF2C, eIF3, eIF4A, eIF4B, eIF4E,
eIF4F, eIF4G, eIF5 and eIF6). All perform important functions during translation initiation
but one factor in particular, eIF2B, plays a key role in recycling of translation initiation
factor 2 (eIF2) for translation initiation (Hershey, 1994; Proud, 1992; Samuel, 1993; Webb
& Proud, 1997). A simplified overview of the role of eIF2B in translation initiation is shown
in Figure 4.1.
The translation initiation process begins with the formation of a ternary complex comprising
eIF2, GTP, and charged initiator tRNAMet and subsequent binding of this complex to the 40S
ribosomal subunit. Binding ofmRNA and recognition of the start codon (AUG) by initiator
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tRNAMet leads to GTP hydrolysis and release of the functionally inactive eIF2-GDP binary
complex. The exchange ofGDP bound to eIF2 for GTP by eIF2B allows eIF2 to be recycled
for further rounds of initiation (Figure 4.1). Regulation of translation initiation may occur at









Figure 4.1 Role of eIF2B in translation initiation. eIF2B catalyses the exchange ofGDP for
GTP which re-activates eIF2, allowing further rounds of initiation.
4.2.1.5 The elF2B complex
In mammals, analysis of the protein complex eIF2B reveals it to comprise five subunits: a,
P, y, 8, and e (now known as subunits 1 to 5, respectively), and these subunits are the
mammalian homologues of the yeast general control factors GCN3, GCD7, GCD1, GCD2
and GCD6, respectively. The yeast subunits all show considerable amino acid sequence
similarity to their mammalian counterparts (a:40-42%, (1:35-36%, y: 19%, 5:31%, e:30%);
(Kimball et al., 1996; Price & Proud, 1994). The fact that all five subunits of yeast eIF2B
were first identified as translational regulators ofGCN4 strongly suggests that regulation of
guanine nucleotide exchange on eIF2 is a key control point for translation in yeast cells just
as in mammalian cells.
While other guanine nucleotide-exchange factors are generally monomeric, eIF2B is a much
more complex protein, comprising five subunits. The reasons for this extra complexity may
reflect the key role that eIF2B plays in regulation of general protein synthesis in which
eIF2B interacts with its substrate eIF2 - itself a three subunit protein. It is now becoming
clear that eIF2B activity is itself regulated by many different cellular factors. Therefore to
fully understand eIF2B subunit function, the regulatory mechanisms acting on eIF2B must

















regulated by phosphorylation (Ser51)
elF2B binding?
rFtNA binding?
Figure 4.2 eIF2 and eIF2B - possible subunit functions and phosphorylation sites. The sizes
of the subunits are roughly proportional to their actual molecular masses. It should be noted
that the inter- and intra- subunit interactions are, as yet, not fully understood.
4.2.1.6 Regulatory mechanisms of elF2B
4.2.1.6.1 Phosphorylation of elF2a subunit
Regulatory mechanisms known to alter eIF2B activity include phosphorylation of residues in
subunits of both eIF2B or eIF2 (see Figure 4.2). The best characterised of these is
phosphorylation of the eIF2a subunit on Ser51, blocking eIF2 recycling by competitively
inhibiting eIF2B (Dholakia et al., 1989; Gaspar et al., 1994). In yeast, reduction in general
protein synthesis during general control (which is coupled to an increase in expression of
GCN4) is due to phosphorylation of eukaryotic initiation factor 2 (eIF2) by the eIF2a
subunit kinase GCN2 (Cigan et al., 1993). In mammals, the mechanism of eEF2a
phosphorylation is used to reduce protein synthesis in response to haem-deficiency, viral
infection, amino acid deficiency and certain stress conditions such as heat shock - see Figure
4.3. There are two kinases in mammalian cells (the haem-controlled repressor and the
double-stranded RNA-activated inhibitor) that have eIF2a phosphorylation capabilities
(Proud et al., 1991). However, inhibition of peptide-chain initiation in skeletal (but not
cardiac) muscle of diabetic rats which correlates with a reduction of eIF2B activity, shows
no change in the level of eIF2a phosphorylation (Karinch et al., 1993). This suggested the
existence of other regulatory mechanisms.
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Figure 4.3 Possible mechanisms by which mitogens and growth factors may activate eIF2B,
and by which cell stresses may inhibit this protein - (+) activation; (-) inhibition. Arrows
only imply connections between the components shown, not the nature of the connection or
whether it is direct. Abbreviations: GSK-3, glycogen synthase kinase-3; PKR,
RNA-activated kinase; HRI, haemin-regulated inhibitor; GCN2, Saccharomyces cerevisiae
eIF2a protein kinase ; eIF2a(P) phosphorylation of eIF2a subunit.
4.2.1.6.2 Phosphorylation of elF2Be subunit
Research into direct regulation of eIF2B activity reveals that phosphorylation of the eIF2Bs
subunit (at the Ser540 residue) by glycogen synthase kinase-3 (GSK-3) which is an insulin
sensitive protein kinase, results in inhibition of eIF2B GDP/GTP exchange activity, giving a
regulatory role for this subunit (Singh et ah, 1996b). The likely mechanism by which insulin
















Figure 4.4 Overview of the signalling pathway likely to be involved in the regulation of
eIF2B by insulin - adapted from Proud et al, 1997. Briefly, the binding of insulin to its
receptor activates the intrinsic tyrosine kinase activity of the receptor, leading to binding and
subsequent phosphorylation of the insulin receptor substrates (IRS-1/2). The resulting
phosphotyrosine residues of the insulin receptor substrate include docking sites for the SH2
domains (regions of Src homology) of phosphatidylinositol 3-kinase (PI 3-kinase) and
binding leads to activation of this enzyme. PI-3-kinase phosphorylates PtdIns(4,5)P2
(phosphotidylinositol(4,5)diphosphate) to PtdIns(3,4,5)P3
(phosphotidylinositol(3,4,5)triphosphate), and this molecule can either act directly or
indirectly (by stimulation of other protein kinases) to activate protein kinase B (PKB). PKB
in turn phosphorylates GSK-3 (glycogen synthase kinase-3) leading to its inactivation.
Inactivation ofGSK-3 leads to dephosphorylation of the eIF2B£ subunit and activation of
eIB2B resulting in increased activation ofpeptide chain initiation by insulin. This cascade
ofphosphorylation/dephosphorylation of factors suggests a complex mechanism in which
insulin regulates eIF2B activity.
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4.2.1.6.3 Allosteric effectors
There is evidence for regulation of eIF2B by allosteric effectors. Both sugar phosphates and
inositol phosphates have been shown to directly stimulate eIF2B by allosteric activation
(Singh & Wahba, 1995). Other studies have shown the activity of purified mammalian
eIF2B to be inhibited by NAD+ and NADP ! while NADH and NADPH stimulate activity
(reviewed in Price & Proud, 1994). This might be explained by sequences in the y and e
eIF2B subunits that show features also found in nucleotide binding enzymes, suggesting
possible binding to adenine and guanine nucleotides and NADH/NADPH. In diabetic rats,
eIF2B activity is reduced in skeletal muscle but not in cardiac muscle and this correlates with
an increase in the ratio ofNADPH/NADP" in heart but not in the skeletal muscle (Karinch et
al., 1993). This may indicate that NADPH plays an important role in maintaining eIF2B
activity in the heart of diabetic patients and that in this case, phosphorylation of eIF2B
subunits and other initiation factors like eIF2 is not involved. Also, photo-affinity labelling
studies using 8-azidopurine nucleotides suggests that regions of the 5 and y subunits may
constitute an ATP-binding domain (Rowlands et al., 1988) and that the (3 subunit is involved
in GTP binding (Dholakia et al., 1989).
4.2.1.6.4 Other regulatory mechanisms
In isolated rat islets of Langerhans, exposure to elevated glucose concentrations activates
eIF2B (Gilligan et al., 1996) with no change in eIF2a phosphorylation (eIF2a
phosphorylation inactivates eIF2B activity) and no inactivation ofGSK-3 activity (GSK-3
phosphorylates eIF2Be causing eIF2B inactivation). Whether eIF2B stimulation by glucose
is by direct allosteric activation or by a novel mechanism has still to be elucidated.
4.2.1.7 Medical implications
The stimulation of eIF2B activity by glucose and insulin (Karinch et al., 1993; Proud &
Denton, 1997; Welsh & Proud, 1993) provides evidence that eIF2B is likely to play an
important role in the cellular response to both insulin and glucose. The enhancement of
eIF2B activity in response to high glucose levels may contribute to the activation of
preproinsulin mRNA translation in the pancreatic islet. Therefore, insufficient eIF2B
activity may lead to decreased insulin production by the pancreas and contribute to the
pathogenesis of type 2 diabetes. As eIF2B activity is stimulated by insulin, defective eIF2B
function may also contribute to the pathogenesis of type 2 diabetes in terms of insulin action,
for example if hepatocytes are unable to produce adequate amounts of proteins and enzymes
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involved in glucose storage. Furthermore, the signalling pathways that mediate eIF2B
activity, for example the regulatory mechanism shown in Figure 4.4 in which insulin
stimulates eIF2B activity, represent potential drug targets for disease states like diabetes.
4.2.1.8 Experimental aims
As part of the characterisation of the genomic region on chromosome 2p23.3, this section
describes the identification and cloning of the EIF2B4 gene that is located within the
GCKR-KHK intergenic region. Sequence analysis ofEIF2B4, characterisation of genomic
structure and investigation into transcript expression is performed. These results have
provided new information concerning the generation of different eIF2B8 isoforms. The
potential role ofEIF2B4 in the pathogenesis of type 2 diabetes and the significance of the




4.2.2.1 Isolation of genomic and cDNA Clones
The EIF2B4 transcript was first identified by analysis of sequences produced by the
sequencing of cosmid insert ends from the cosmid subclone library created from YAC
29IH8, a YAC known to contain GCKR (see Chapter 3). Sequencing using the SC2 primer
(5'-dTGGAAGTCAACAAAAAGCAGAGC-3') on cosmid "G4" reveals a sequence
showing significant similarity to the S. cerevisiae GCD2 gene. Further analysis shows this
cosmid sequence to be identical to several human cDNA clones containing parts of the
human E1F2B4 gene, including EST H45644 (see Figure 4.5 for alignment between G4-SC2
cosmid sequence and EST H45644 - sequences are anti-sense). The GAP alignment shown
in Figure 4.5 reveals that the G4-SC2 cosmid sequence from nucleotides 1 to 121 is almost
identical to the cDNA sequence from H45644. This suggests that the G4-SC2 sequence
starts within an exon and extends into intronic sequence. Indeed examination of the
boundary between matching and non-matching sequence reveals an exon-intron boundary















I I I I I I I I I I I I I I I II I I II II I I I I II I II
1 CACAAGCTCTGGGGGAGTCACATCATAGACTA 32
151 GATTCAACAACCGTAGGAGTGCGTGGTTCTGCCAGTTAGCCAGCGCAACA 200
II I I I I II I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I
33 GATTCAACAACCGTAGGGATGCGTGGTTCTGCCACTTAGCCAGCTCAACA 82.
201 TGTTCTCCCCGCTTACATTGCAGATCATCAGGGTCAT





I II II I I I II I I : II I
124 AATGGAAGGCGTACCCATTATGTTCTTTCAGAAAAGAAGTTCTAGTTTAT 173
301 CAAACCAGACACTGGTACATTATGGGGCTCGAGCCACCAGGGGCTAACTG 350
I I I II II I I I
174 CCGCCCCTCTCCCTCCCTCTCAAGTCTTCACAGGTAGCTGGAGGCTTCTC 223
351 TGCTGTCCCTACCCGTGACATCACAGACCCATTGGGCCAAGAGTGCATGA 400




G4-SC2 274 GCT 276
Figure 4.5 GAP alignment ofEST H45644 (upper sequence) with cosmid sequence G4-SC2
(lower sequence) - sequences are shown as anti-sense. An exon-intron boundary is shown at
nucleotides 119-120 (cosmid sequence).
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Cloning of the EIF2B4 transcript (see following sections) reveals it to include the EST
WI-12589. To obtain other genomic clones that contain EIF2B4, PCR screening using
WI-12589 (WI-12589A: 5'-dAGGGAGTATGGCATTTATTAACC-3');WI-12589B:
5'-dTAGTCTATGATGTGACTCCCCC-3') was performed on the YACs that map to the
GCKR-KHK genomic region (3AG3, 18AG7, 26BA11, and 29IH8 - see Chapter 3, Figure
3.8) and the cosmid subclone libraries created from YACs 29IH8 and 26BA11.
4.2.2.2 Sequencing of cDNA clones
To clone EIF2B4, overlapping cDNA clones containing parts of the EIF2B4 sequence were
identified by BLAST searching using the cosmid G4-SC2 sequence. The human cDNA
clones giving significant similarity scores to the G4-SC2 sequence were obtained from the
IMAGE consortium (IMAGE clone numbers 176330, 632738, 357973, and 173249) and
sequenced on both DNA strands. Sequence analysis reveals these cDNA clones to all
overlap and contain poly(A) tails. The longest cDNA sequence was 573 bp from clone
H45644 and this included the poly(A) tail. The poly(A) tail indicates that the sequence
obtained is from the 3' end of the gene and that clones containing the 5' end were still to be
identified.
To identify cDNA clones containing the 5' end ofEIF2B4, searching of "The Institute of
Genomic Research" (TIGR) human gene index (HGI) database of overlapping cDNA clones
(THC contigs) using the cDNA clone 176330 sequence was performed. This reveals the
176330 sequence to be part of a larger cDNA clone contig corresponding to THC 180051.
This contig spans 1639 bp ofDNA and consists of 25 cDNA clones. To complete the
EIF2B4 gene sequence, cDNA clones were chosen from THC 180051 that would span the
whole 1639 bp (Figure 4.6).
The overlapping EIF2B4 cDNA clones (IMAGE clone numbers 512237, 365427, 274777,
and 380606) were obtained from the IMAGE consortium. The cDNA clones were
"mini-prepped" using the alkaline lysis technique and the clone inserts sequenced on both
strands using the Thermosequenase cycle sequencing kit (Amersham). Primers used for
sequencing were the universal primers M13F (5'-dGTTTTCCCAGTCACGAC-3') and
M13R (5'-dCAGGAAACAGCrfATGAC-3') and internal insert primers designed from








Figure 4.6 cDNA clone contig for EIF2B4 (see Table 4.1 for clone identification).








Left (nt) Right (nt)
1 176330 20 434
Adult brain N2b5HB55Y,
Soares
2 512237 394 871 Corneal stroma, Stratagene
3 365427 821 1109 Fetal heart NbHH19W, Soares
4 274777 1214 1639 Retina N2b4HR, Soares
5 380606 1097 1639 Retina N2b4HR, Soares
Table 4.1 cDNA clone IMAGE clone numbers for Figure 4.6
4.2.2.3 Structural analysis
To determine the EIF2B4 genomic structure, oligonucleotides were designed from the cDNA
sequence and used to obtain sequence data across the exon/intron boundaries from the
genomic cosmid clones G4 and A4, both of which contained the EIF2B4 gene. Sizes of
introns were determined by amplification across each intron using cosmid genomic DNA as
template and primers within adjacent exons. The fragments were analysed on a 1 -5 %
agarose gel and sized against a Gibco BRL 1 kb ladder. As most introns were found to be
small, their exact sizes were determined by sequencing across the whole intron.
4.2.2.4 Alternative EIF2B4 splice forms
The presence of alternative EIF2B4 splice forms was investigated by RT-PCR (see Methods
in Chapter 6). RT-PCR was performed using human total RNA as template from brain,
heart, and muscle. PCR was also performed on a HepG2 cDNA (created from hepatocyte
RNA). The primers used were designed from the EIF2B4 cDNA sequence and are described
in the Results section (see Section 4.2.3.5, Table 4.2). PCR products were excised from




4.2.3.1 Physical mapping of EIF2B4
Sequencing of cosmid G4 using primer SC2 reveals it to contain EIF2B4. This cosmid is a
subclone produced from the GCA7?-containing YAC 29IH8. YAC 29IH8 has previously
been mapped by FISH to chromosome 2p23.3 (Warner et al., 1995). Therefore, the mapping
ofEIF2B4 to YAC 29IH8 indicates EIF2B4 also to map to chromosome 2p23.3. Analysis of
the EIF2B4 sequence reveals it also to contain the EST WI-12589. PCR screening ofYACs
mapping to 2p23.3 using WI-12589 reveals that both YACs 29IH8 and 26BA11 contain
EIF2B4. PCR screening of the cosmid subclone libraries created from both YACs 29IH8
and 26BA11 using WI-12589 reveals several positive cosmid clones (A4, A8, Bl, D3, F3,
G6, G7 and H6). Cosmid fingerprinting and STS content analysis had previously been used
to assemble the cosmid subclone libraries into a cosmid contig and this indicates cosmid A4
to map between GCKR and KHK approximately 150 kb from GCKR (Figure 4.7).
YAC 29IH8
YAC 26BA11






Figure 4.7 Co-localisation ofEIF2B4 with GCKR and KHK. The arrows represent genes,
gene orientation (5'to 3') is indicated by the arrow direction. Genomic clones containing
EIF2B4 are indicated above the EIF2B4 arrow. This diagram is a simplified version of
Figure 3.8 shown in Chapter 3.
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4.2.3.2 EIF2B4 cDNA sequence
Once the cDNA clones 176330, 512237, 365427, 274777, and 380606 (see Figure 4.6) had
been sequenced, their sequences were aligned and assembled into an overlapping contig.
Initially, alignment of the cDNA clone sequences did not reveal an open reading frame.
However, comparison of the cDNA sequences from clones 380606 and 274777 with
homologous mouse, rat, and rabbit EIF2B4 cDNAs reveals a 4 bp deletion in the human
cDNA (Figure 4.8A; see also Figure 4.9iii, the 4 bp deletion corresponds to nucleotides
45-48), which later proved to be situated at the position of the second splice junction


























Figure 4.8 Comparison of human cDNA clone sequences 274777 and 380606 with the
corresponding regions ofEIF2B4 sequences from mouse, rat and rabbit (Genbank accession
numbers M98036, Z48225, and X75451 respectively). A) a 4 bp deletion is found in cDNA
clone 274777; B) a 26 bp deletion is found in cDNA clones 274777 and 380606. The red
vertical bars represent the positions of splice junctions, as subsequently determined.
To obtain a complete cDNA sequence, an RT-PCR product spanning the region in the cDNA
clone sequence containing the 4 bp deletion was generated from human fetal kidney RNA.
Its sequence includes the missing 4 bp, thus aligning perfectly with other species' sequences.
Examination of the cosmid genomic sequence at the IVS2 acceptor site reveals a cryptic
GCAG acceptor site as the first 4 nucleotides of exon 3 (Figure 4.12, nucleotides 1074-1077;
see also Figure 4.13).
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Similarly, comparison of the cDNA clone 274777 sequence to the corresponding EIF2B4
cDNA sequences for mouse, rat and rabbit revealed clone 274777 to contain a 26 bp deletion
(Figure 4.8B; see also Figure 4.9iii, the 26 bp deletion corresponds to nucleotides 557-582).
This deletion later proved to be situated at the IVS6 acceptor site (Figure 4.12, the 26 bp
deletion corresponds to nucleotides 2484-2509), and examination of the genomic sequence
reveals a cryptic CCAG acceptor site within exon 7 positioned exactly before the deletion
splice site (Figure 4.12, nucleotides 2506-2509).
The complete composite cDNA sequence for the cDNA clones described in Figure 4.6
(TIGR cDNA clone contig THC180051) is shown in Figures 4.9i and 4.9iii. It is 1643 bp
long, consisting of an open reading frame of 1569 bp, 19 bp of 5' non-coding sequence and
75 bp of 3' non-coding sequence, with a consensus poly(A) addition signal (Figure 4.9iii,
nucleotides 1557 to 1562). The 522 amino acid predicted translation product (Figures 4.9i
and 4.9iii) has a molecular weight of 57478 Da.
It is known that the mouse eIF2B8 exists as 2 different isoforms (Henderson et al., 1994) -
the "short" isoform (Genbank accession number M98036) and the "long" isoform (Genbank
accession numberM98035). Both mouse isoforms share 1577 bp of identical sequence
toward the 3' end and only differ in their 5' ends. The TIGR contig THC 180051 (Figure 4.6)
contains the human equivalent to the mouse short isoform and none of the cDNA clones in
the contig contain the human equivalent of the long isoform. Searching the human EMBL
sequence databases with the mouse long isoform 5' end did not reveal any cDNA clones
showing homology to the alternative 5' end.
However, the comparison of the mouse EIF2B4 long isoform with the human genomic
EIF2B4 sequence reveals that the human alternative 5' exon sequence did indeed exist and is
situated in the first intron, adjacent to the second exon (Figure 4.12, nucleotides 572-704).
Although none of the human cDNA clones that were sequenced contain this alternative 5'
exon, RT-PCR performed on heart and brain mRNA using a primer designed from sequence
within the alternative first exon and another primer within exon 12 (primers DL5 and D2
respectively, see Section 4.2.3.5, Table 4.2), produces a RT-PCR product of the correct
theoretical size (Figure 4.14). Sequencing of this RT-PCR product proved that the human
alternative 5' exon (the "long" isoform) was transcribed in both heart and brain. The
complete human cDNA sequence for the "long" isoform by comparison with the mouse long
isoform is 1708 bp long, consisting of an open reading frame of 1632 bp, 39 bp of 5' non-
coding sequence with the 3' end (exons 2-13) identical to that of the short isoform. The 543
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amino acid predicted translation product has a molecular weight of 59622 Da (Figure 4.9ii
and 4.9iii). The short and long isoform cDNA sequences have been submitted to the EMBL
sequence database and assigned accession numbers AJ011305 and AJ011306 respectively.

































Continued on next page.
Figure 4.9 Human EIF2B4 cDNA sequence and putative translation product, i) short 5'
exon 1A, start codon located at nt 20-22, ii) long 5' exon IB, start codon located at nt 38 to
40 and iii) 3' end - the 4 bp deletion in cDNA clone 274777 corresponds to nucleotides
45-48. The 26 bp deletion in cDNA clones 274777 and 380606 corresponds to nucleotides
557-582.
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iii) 3' end (exons 2-13) - continued from previous page
630 TCCAATGCCCGGTGTATTGCCCTGCTTCGTGCCTTGCAGCAGGTGATTCAGGATTACACA 689
210 SNARC IALLR L Q Q V Q D
690 ACACCGCCTAATGAAGAACTCTCCAGGGATCTAGTGAATAAACTAAAACCCTACATGAGC 749
230 T N V N K K M
750 TTCCTGACTCAGTGCCGTCCCCTGTCAGCGAGCATGCACAACGCCATCAAGTTCCTTAAC 809
250 F L M H N K N
810 AAGGAAATCACCAGTGTGGGCAGTTCCAAGCGGGAAGAGGAGGCCAAGTCAGAACTTCGA 869




310 F K I N G V V
990 GTATCACGAATTCTTCAGGAGGCTTGGACAGAGGGCCGGCGGTTTCGGGTGGTAGTGGTG 1049
330 V W V V V V
1050 GACAGCCGGCCATGGCTGGAAGGAAGGCACACACTACGTTCTCTAGTCCATGCTGGTGTC 1109
350 D R W H V H G V
1110 CCAGCCTCCTACCTGCTGATTCCTGCAGCCTCCTATGTGCTCCCAGAGGTTTCCAAGGTG 1169
370 P A V V K V
1170 CTATTGGGAGCTCATGCACTCTTGGCCAATGGGTCTGTGATGTCACGGGTAGGGACAGCA 1229
390 L L H N V M V
1230 CAGTTAGCCCTGGTGGCTCGAGCCCATAATGTACCAGTGCTGGTTTGCTGTGAAACATAC 1289
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1590 aaaa
Figure 4.9 (Continued from previous page). 3' end ofEIF2B4 cDNA sequence and putative
translation product. The stop codon is located at nucleotides 1536-1538, poly(A) addition
signal sequence is underlined (nucleotides 1557-1562) with the poly(A) at nucleotides
1576-1594.
4.2.3.3 Comparison of human elF2BS to other mammalian elF2B8 subunits
The human eIF2B8 amino acid sequence (short isoform) was compared to the sequence of
other mammalian eIF2BS subunits from which a consensus sequence was produced (Figure
4.10). This reveals the eIF2B8 subunit to be highly conserved in mammals, with 82% of































































Human Mouse Rat Rabbit Consensus
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ConsensusL--A-DRYVQEKIVLA-QAI-RFA--KIS-GDVILVYGCSSLVSRILQE-EG -FRWW P-L GRH-L V-GVP-SYLLIPAASYVLPEV Humankehanh
toMousekdqashp Ratkdqtnns Rabbitedhshp ConsensusKVLLGAHALLANGSVMSRVGTAQLALVARAH VP CCEYKFCERVQTDAFVSNELDDPDDLQC-RG--V-LANWQ—S RLLNLVYVTPP L Human Mouse Rat Rabbit ConsensusVITELGMIPCSSVPWLRVKSDQ Figure4.10Comparisonfhu aneIF2B8am nocidseque cewithothera maliaIprot ins (mouse,rat,andabbitGenb nkaccessionumbersM98036Z4 225X75451respectiv ly).
4.2.3.4 Structural organisation of the human EIF2B4
The genomic organisation ofEIF2B4 was determined by sequencing across exon-intron
boundaries using cosmids G4 and A4 as template and primers designed from the EIF2B4
cDNA sequence. The gene was completely sequenced except for intron 11 and the results
are summarised in Figures 4.10, 4.11 and4.12. The human EIF2B4 gene spans
approximately 5.9 kb of genomic DNA and consists of 14 exons (1A, IB, 2-13) and 12
introns (there are 2 alternative first exons, with exon IB located directly in front of exon 2) -
see Figure 4.11. The exons range in size from 44 bp to 246 bp and introns from 118 bp to
1.8 kb (Figures 4.10 and 4.11). The first methionine codon of the open reading frame for the
short isoform is located in exon la and for the long isoform in exon lb. Both long and short
isoforms share the stop codon and poly(A) addition signal (Gil et al., 1987) which are
located in the last exon, exon 13. An Alu repeat region is found in intron 11, located 187 bp
upstream from exon 12 (Figure 4.12). All introns show the consensus sequence
(C/T/A)AG-exon-GT(G/A) at their boundaries (Figure 4.13). The present gene structure is
the first described for any EIF2B subunit. The EIF2B4 genomic sequence was submitted to
the EMBL sequence database and assigned accession numbers AJ011307 (exons 1-11) and
AJ011308 (exons 12-13).
50 133 44 136 204 80 92 115 77 103 128 178 181 237
J9 \m m a a el a a n ds qd jl oa i 131
224 328 204 272 190 232 202 186 255 136 1.8 kb 118
Figure 4.11 Genomic organisation ofEIF2B4. Exons are shown as boxes. The diagram is













































R Q Q 165
aggtgatgggtgcaaagtgagaaggataggtgcttgggtcagagtagtcttactgttcacttcctttcca 2100
gctttatcccatcctttttaaactctgggccattggtcctgttcccttgttttgtcaagGTTCCTACACG 2170












Q Q 234 Continued on next page.
Figure 4.12 The complete EIF2B4 genomic sequence and its putative translation product.
Exon lb (the "long" alternative first exon) is immediately adjacent to exon 2, corresponding
to nucleotides 572-704 (shaded yellow). The 4 bp deletion in cDNA clone 274777
corresponds to nucleotides 1074-1077. The 26 bp deletion in cDNA clones 274777 and
380606 corresponds to nucleotides 2484-2509. The cDNA deletions are shaded green.
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V L P E 396
cataatctcaccttcccaaagttacagttttgtttttgttttgagataaggatgg 3975























Figure 4.12 (Continued from previous page). The complete EIF2B4 genomic sequence and
its putative translation product. The translation termination signal is marked with an asterisk








Exon6-TCTCTGACCCAGTTTATGAGgtaggat cc ta tgaaat tgt 232


















Figure 4.13 Exon-intron splice junction sequences. Intron sequences at the 5'- and 3'-end of
the exons are in lower case letters. Exon sequences are in capital letters.
4.2.3.5 Alternative EIF2B4 splice forms
As described previously, the human EIF2B4 gene is expressed as both long and short
isoforms that only differ by their 5' first exon. To investigate the tissue expression of these
two isoforms, RT-PCR was performed using primers designed from within either of the two
EIF2B4 alternative first exons (primer G7R from exon 1A and primer DL5 from exon IB),
in conjunction with a primer in exon 12 (primer G2) - see Table 4.2.




Table 4.2 Oligonucleotide sequences for RT-PCR. The primers G7R and DL5 were
designed from the EIF2B4 alternative short and long first exon, respectively. Primer G2 was
designed from EIF2B4 exon 12 sequence.
Therefore, RT-PCR primer pair G7R/G2 amplifies EIF2B4 exons 1A-12 (theoretical size of
PCR product = 1230 bp) and primer pair DL5/G2 amplifies EIF2B4 long exons 1B-12
(theoretical size ofPCR product = 1237 bp). RT-PCR was performed using total human
RNA from brain, heart, and muscle. Also, PCR was performed on a human HepG2 cDNA
library.
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The results reveal that both long and short isoforms are expressed in brain, heart, muscle and
liver. However, while heart, muscle and liver yielded one single PCR product of the correct
theoretical size, RT-PCR from brain RNA yielded multiple products (see Figure 4.14 for
comparison ofRT-PCR products from heart and brain). This suggests that multiple EIF2B4














Figure 4.14 RT-PCR products for both short and long EIF2B4 isoforms amplified from
heart and brain RNA. PCR products were run on a 1% agarose gel and stained with
ethidium bromide.
To investigate the RT-PCR products from heart and brain (shown in Figure 4.14), the
individual PCR products were excised from the agarose gel, purified and sequenced. The
purified RT-PCR fragments are shown in Figure 4.15 and the results of sequencing are
summarised in Table 4.3.
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A1 B1 B2 B3C1 D1 D2 D3
1.6 kb ► ( m< 1.6 kb
1.0 kb > |^||||^ fffftfc m < 1.0 kb
0.5 kb ► m
^ gif < 0.5 kb
0.3 kb ^m 0.3 kb
Figure 4.15 Purified RT-PCR products. Lane labels refer to RT-PCR shown in Figure 4.14





5'- exon Exons Missing Comment
Al Heart la None Full length
B1 Brain la - Artefact RT-PCR product
B2 Brain la Exons 2 and 3 Removes 180 nucleotides
B3 Brain la None Full length
CI Heart lb None Full length
D1 Brain lb Exons 7 and 8 Removes 192 nucleotides
D2 Brain lb Exon 10 Removes 128 nucleotides
D3 Brain lb None Full length
Table 4.3 Results of sequencing RT-PCR products ofEIF2B4 from heart and brain mRNA.
RT-PCR products relate to that shown in Figures 4.14 and 4.15.
The sequencing of the RT-PCR products from heart and brain (summarised in table 4.3)
shows that in the heart, the long and short isoforms are both expressed in their full length
forms (Table 4.3, RT-PCR products "Al" and "CI"). However, sequencing of the multiple
EIF2B4 brain RT-PCR products reveals that apart from the full length long and short
isoforms (Table 4.3, RT-PCR products "B3" and "D3"), other shorter splice forms exist in
the brain (Table 4.3, RT-PCR products B2, D1 and D2).
Sequencing of these shorter RT-PCR products reveals they are due to the removal of one or
two exons. The exon 1A isoform "B2" (see Table 4.3), contains exon 1A but not exons 2
and 3, resulting in the loss of 180 nucleotides (60 amino acids). The removal of exons 2 and
3 however, does preserve the original open reading frame and therefore would produce a
protein of 462 amino acids (full length short isoform is 522 amino acids long).
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The exon IB isoform "Dl"(see Table 4.3), contains exon IB but not exons 7 and 8, resulting
in the loss of 192 nucleotides (64 amino acids). The removal of exons 7 and 8, like the B2
splice form, preserves the original open reading frame and would therefore produce a protein
of 479 amino acids (full length long isoform is 543 amino acids). In contrast, the exon IB
isoform "D2" contains exon IB but not exon 10, resulting in the loss of 128 nucleotides.
This does not preserve the original open reading frame, and if translated would result in a
truncated protein of 405 amino acids. It should be noted that the although the removal of
exon 10 does not preserve the original open reading frame, a new open reading frame coding
for 92 amino acids that spans from exon 11 to within exon 12 is produced.
4.2.3.6 Genomic arrangement of mouse alternative first exons
A search of the EMBL mouse cDNA database using the long alternative 5' end EIF2B4
sequence revealed several clones with significant similarity including the IMAGE clone
556389 (see Figure 4.16 and Table 4.4). BLAST sequence analysis of the clone 556389
database sequence (Genbank accession number AA103972) reveals that it contains both the
short and long alternative first exons in a similar organisation to that found in human
genomic DNA (exon 1A (short)-exonlB (long)-exons2-13).
cDNA clone 556389 (582 bp)
«4
■H
Figure 4.16 Pictorial representation of a BLAST search using mouse cDNA clone 556389.
See Table 4.4 below for sequence identification.
Sequence Genbank ace. no. Sequence description
1 M98035
Mus musculus guanine nucleotide exchange factor delta
subunit (long isoform) mRNA, nucleotides 6-144.
2 M98036
Mus musculus guanine nucleotide exchange factor delta
subunit (short isoform) mRNA, nucleotides 8-100.
3 Z66245
Homo sapiens CpG island DNA genomic Mse 1 fragment,
clone 84b2, reverse read cpg84b2.rtla, nucleotides 274-305.
4 D31764 Homo sapiens mRNA for KIAA0064 gene, nucleotides 1-29.
Table 4.4 Clone identification for Figure 4.16.
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Closer inspection of the BLAST analysis of EST AA103972 reveals that there is a 13 bp gap
between the regions of identity for sequences M98035 and M98036 (corresponding to
nucleotides 427-439, Figure 4.17). The analysis ofEST AA103972 also reveals homology
to a CpG island clone (Genbank accession number Z66245) and a human putative transcript
called KIAA0064 (Genbank accession number D31764) - see Figure 4.16. As this mouse
clone contains both long and short 5' end alternative Eif2b4 exons plus 13 bp of sequence
between them, and a region of sequence showing similarity to the human putative transcript
KIAA0064, it is assumed that this clone is in fact derived from genomic mouse DNA and not
a cDNA clone. To investigate whether the same features existed in the human genome,
further sequencing was performed in the 5' flanking region of the human EIF2B4 gene. A
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Figure 4.17 Comparison ofmouse EST AA103972 sequence (nucleotides 319-582) and the
mouse Eif2b4 short (M98036) and long (M98035) isoforms. The AA103972 sequence is the
upper sequence.
The sequence comparison shown in Figure 4.18 reveals that the putative transcript
KIAA0064 is present in both human and mouse genomes in the same "head to head"
orientation to the EIF2B4 gene. Other noticeable features is a high degree of sequence
similarity between the human and mouse K1AA0064-EIF2B4 intergenic regions, even in the
non-coding sequences. This can partly be explained by conservation of the human and
mouse EIF2B4 and KIAA0064 genes' 5TJTRs. The major difference revealed in Figure 4.18
is that while in human, there is 263 bp between the end ofEIF2B4 exon la and the start
codon of exon lb, there is only 13 bp between the end ofmouse Eif2b4 exons la and the
start codon of exon lb. Further sequence analysis shows that both the human and mouse
EIF2B4-KIAA0064 intergenic regions are CpG islands (Figure 4.18 - human: nucleotides
61-801; mouse: nucleotides 51-535). The human CpG island (740 bp) is larger than in the
mouse (484 bp) due the extra sequence found between human EIF2B4 exons la and lb.
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KIAA0064
P I S F H M
human GAATGGAAAAGTGCATGTTCCCTACGGCAGCGCACGGCCGGGCTCCGGACTGTGAGGGCC 6 0
mouse GAATGGAAAAGTGCATGTTCCCTAAGGCA GAGCTCCGTACTACCAGGTTC 50
P I S F H M
human GCAGCGGCTCTGCACGCTCCCCCTCCGCTGCTCAGCGAGTCCCCGCAGCCTCACTCGCCA 120




mous e TTTTGGTGGGCCTGAACTCCGAGGTGGGAAGGCTGTAGGATGACGGCTCTGCGA-GCAGC 168
human CGCCTGGGCATGCTGGGAACTGTAGTCTAAAGGGCAAGAGCCACCTGTCCGGATAGGGAG 239
mouse AACCTCGGCATGCTGGGAGCTGTAGTCG--AGCGCCGGAGACGC- - -TCCTAATTGGGAA 223
human CCCAAAGTGGAGTTGGCCCTCATTGCAACCCGTAGTGCGGGGCGGC-CTCGGGGCCCGTC 298
mouse CCCAACATCCT-TTGGTCCTCACCGCGACCCGTAGTCCTGGGCGGGACCCAGTGCACGCC 282
human GGAAATTGTAGTCCGATTGGGGCTGCC GGTTCGCTTCTGCGGCTCAGCCTCCAGC 353
mouse GGAAGTTGTAGTCCGCTGGGGACTGACTCCGCGGGAGGCATCAGGGG-- -AGCCAGCAGC 339
human CCAGGTGGCGCTGTGGACCCTGCAGCCGCGGAGCGAGGCAGCGGGGCGGCTCCGTGACCA 413
llllllllllllll II I I llllll
mouse CCAGGTGGCGCTGT AGTGTG AGTGACCT 367














EIF2B4 exon 1 b ►
MPTQQPAAPSTRA
human GCCTGCCGGCGGATCCGTGGTCATGCCAACCCAGCAGCCGGCTGCGCCGAGTACTCGTGC 780
mouse GCCGGGCAGCCGAGCTGTGGTCATGCCAACCCAGCAGCCAGCTGCGCCGACGAGTCT-- - 514
MPTQQPAAPTSL
pkpsrslsgslcalfsdad





Figure 4.18 Comparison of the 5'end of the human EIF2B4 gene and the mouse EST
AA103972 sequence. The coding regions ofEIF2B4 exons la and lb, and KIAA0064 are
indicated (putative translation products are shown). The blue shaded region indicates the




4.2.4.5 EIF2B4 chromosomal localisation
Section 4.2 describes the cloning and investigation of the human EIF2B4 gene. EIF2B4
encodes the delta subunit of the guanine nucleotide exchange factor eIF2B, a protein
complex that plays a key role in the regulation of protein synthesis in yeast and mammals.
This transcript was chosen for investigation primarily because it co-localises with the genes
glucokinase regulator (GCKR) and ketohexokinase (KHK) on chromosome 2p23.3, and also
because previous studies have shown eIF2B activity to be stimulated by glucose (Gilligan et
al., 1996), sugar phosphates (Singh & Wahba, 1995) and insulin (Welsh et al., 1997b). This
suggests that like the candidate type 2 diabetes genes GCKR and KHK, EIF2B4 can also be
considered a candidate type 2 diabetes gene.
The assembly of a physical contig using YAC, BAC, PAC and cosmid clones spanning this
genomic region has shown EIF2B4 to reside between these two genes approximately 150 kb
from GCKR and 350 kb from KHK (Figure 4.7; see also Chapter 3, Figure 3.8). The
physical contig also reveals that the EIF2B4, KHK and GCKR genes are all arranged in the
same 5'-3' orientation with respect to the centromere. The mapping of Gckr and Khk to
mouse chromosome 5 (as described in Chapter 2) reveals a new region of conserved synteny
between human chromosome 2p23 and mouse chromosome 5 (Wightman et al., 1997). The
mapping ofEIF2B4 to between GCKR and KHK, suggests that the mouse Eif2b4 gene also
probably maps to mouse chromosome 5.
4.2.4.6 EIF2B4 cDNA sequence and genomic structure
As in the mouse, the human EIF2B4 gene is expressed as two different isoforms. The
"short" isoformmRNA is 1643 nucleotides in length and consists of an open reading frame
of 1569 bp, 19 bp of 5' non-coding sequence and 75 bp of 3' non-coding sequence, with a
consensus poly(A) addition signal. The predicted short isoform protein is of 522 amino
acids (Figures 4.9i and 4.9iii) and a molecular weight of 57478 Da. The "long" isoform
mRNA is 1708 nucleotides in length and has an open reading frame of 1632 bp, 39 bp of 5'
non-coding sequence and 75 bp of 3' non-coding sequence, with a consensus poly(A)
addition signal. The predicted long isoform protein has 543 amino acids (Figure 4.9ii and
4.9iii) and a molecular weight of 59622 Da. Comparison of the short and long isoforms
reveals that they only differ at their 5' ends and the analysis of the EIF2B4 genomic structure
shows that this is due to the existence of two alternative first exons.
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The structural analysis of the human EIF2B4 gene shows it to consist of 14 exons (la, lb,
and 2-13) that are expressed as two isoforms, both consisting of 13 exons but differing by
their 5' first exons. The short isoform is highly conserved between human, mouse
(Henderson et al., 1994), rat (Price et al., 1996) and rabbit (Price et al., 1994), and
significant homology is found with the yeast GCD2 gene (overall DNA sequence identity is
87%, 87%, 86%, and 43% respectively). The long isoform which has previously only been
described in the mouse, shares 87% identity at the nucleotide level to the human long
isoform. Although it is not known why there are two alternative first exons, examination of
the encoded amino acids shows that the short 5' exon generally encodes hydrophobic
residues and the long 5' exon encodes more hydrophilic residues. This may indicate a
difference in protein interactions either between the eIF2B8 subunit and the other eIF2B
subunits and/or the eIF2B substrate, eIF2.
The comparison ofmammalian eIF2B8 at the amino acid level between human, mouse, rat
and rabbit reveals a very high degree of sequence conservation, with 82% of residues
conserved between all four mammals. Closer inspection shows that sequence similarity
increases towards the C-terminus where two long stretches of conserved amino acid
sequences can be found between residues 385 to 466 and 482 to 524 (Figure 4.10). It is
notable that the peptide sequence encoded by exon 12 is completely conserved between
human, mouse, rat and rabbit, and that this region shows very high homology to the yeast
GCD2 peptide (56% identical). It is also very striking that the residues that vary between
human, mouse, rat, and rabbit are not randomaly distributed throughout the eIF2B8 peptide
sequence but are grouped together. The sequence conservation between species indicates
eIF2B8 to also have a highly conserved function. The peptide regions that show complete
identity between human, mouse, rat, and rabbit are therefore likely to be either the functional
regions of eIF2B8 and/or the regions that interact with the other eIF2B subunits or the eIF2B
substrate, eIF2.
4.2.4.7 Cryptic splice sites
During the cloning ofEIF2B4, two cDNA clones were sequenced that were shown to contain
deletions (Figure 4.8), later shown to be caused by the presence of cryptic splice sites within
the EIF2B4 cDNA sequence. The EIF2B4 cDNA clones 380606 and 274777 were both
found to have a 4 bp deletion at the start of exon 3 due to a cryptic GCAG acceptor site (see
Figures 4.9 and 4.12). Similarly, the cDNA clone 274777 also contained a 26 bp deletion
located at the start of exon 7, due to the presence of a cryptic CCAG acceptor site (see
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Figures 4.9 and 4.12). The translation ofmRNA containing the 4 bp and 26 bp deletions
would create truncated proteins of 29 and 214 amino acids respectively (size of short isoform
is 522 amino acids). These truncated proteins would most likely be non-functional.
4.2.4.8 Tissue expression of EIF2B4
The investigation oiEIF2B4 tissue expression by RT-PCR shows that both the short and
long isoforms are expressed in heart, brain, muscle and liver. Database searching for
EIF2B4 sequences also shows the existence of short isoform EIF2B4-containing cDNA
clones, produced from a variety of tissues. This evidence suggests EIF2B4 to be
ubiquitously expressed. Interestingly, database searching does not identify any human
EIF2B4 long isoform cDNA clones. Whether this is due to lower expression levels of the
EIF2B4 long isoform is not known. Although RT-PCR shows the eIF2BS long isoform to be
expressed in various tissues, this method is non-quantitative and therefore RNase protection
would be a better method to investigate the comparative expression levels of the EIF2B4
short and long isoforms.
4.2.4.9 Alternative EIF2B4 splice forms
Although RT-PCR shows that full length short and long EIF2B4 isoforms are expressed in
heart, brain, muscle and lung, it was discovered that shorter alternative EIF2B4 splice forms
exist in the brain (but not heart, muscle or lung). The brain EIF2B4 splice forms are
summarised below in Figure 4.19.
Figure 4.19 Schematic representation of the brain EIF2B4 alternative splice forms. B2, Dl,
and D2 refer to alternative splice forms described in Table 4.3.
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The EIF2B4 splice form B2 has exons 2 and 3 missing, splice form D1 has exons 7 and 8
missing and splice form D2 has exon 10 missing. While the missing exons in splice forms
B2 and D1 preserves the original open reading frame, the removal of exon 10 in splice form
D2 does not preserve the original open reading frame, and if translated would create an
alternative 3' end (but also a truncated eIF2B8 protein). It is conceivable that as these
alternative splice forms encode most of the eIF2B8 protein, that they do have some
functionality. As the alternative splice forms are not present in heart, muscle, or liver, the
alternative splice forms might have a brain specific function. This function is as yet
unknown.
4.2.4.10 EIF2B4 promoter region
Analysis of the 5' flanking region ofEIF2B4 reveals that the putative transcript KIAA0064 is
located upstream (Figure 4.16). The two genes are orientated in opposite directions with 466
bp separating the two start codons ofKIAA0064 and EIF2B4 (short isoform). This intimate
"head to head" orientation suggests that these two genes may share promoter elements.
Sequence analysis of the intergenic region in both the human and mouse genome reveals a
high degree of sequence conservation, including the presence of a CpG island (Figure 4.18).
CpG islands are stretches of non-methylated DNA rich in CpG dinucleotides (in which C
occurs immediately 5' to G) and are found at the promoters of a large proportion of genes
(Bird, 1993). It has recently been shown that CpG islands are coincident with DNA
replication origins in mammalian chromosomes (Delgado et al., 1998). The intimate
location of the KIAA0064 transcript in a "head to head" orientation to EIF2B4, suggests that
this CpG island could be associated with the promoter sequences for both EIF2B4 and
KIAA0064. This genomic organisation ofEIF2B4 and KIAA0064 probably reflects the high
gene density of chromosome 2p23.3 described in Chapter 3. Due to the intimate location of
KIAA0064 to EIF2B4, the KIAA0064 transcript was further investigated (see Section 4.3).
4.2.4.11 EIF2B4 mutations and subunit interactions
There is considerable evidence that the phosphorylation of the eIF2B substrate, eIF2, on its
alpha subunit (eIF2a), is an important regulatory mechanism used by eukaryotic systems to
inhibit guanine nucleotide exchange by eIF2B and thereby decrease protein synthesis in
response to certain cellular factors. This protective measure may occur in response to
haem-deficiency, viral infection, nutrient deficiency and other stress conditions like heat
shock (Scheper et al., 1997; Scheper et al., 1998). Yeast genetic experiments and rat
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biochemical data implicate the eIF2BS subunit in the "sensing" of eEF2a phosphorylation
and have identified mutations in the yeast and rat gene sequence that can cause eIF2B
insensitivity to its substrate's phosphorylation (Pavitt et al., 1997).
The double point mutations that change the eIF2B8 residues Leu377—>Lys and Glu381->Gln
lead to insensitivity to eIF2aP in both yeast (Vazquez de Aldana & Hinnebusch, 1994) and
rat (Kimball et al., 1998). This would indicate that this region of the peptide plays an
important role in "sensing" the phosphorylation state of eIF2aP. As the human eIF2B8
peptide sequence also contains Leu377 and Glu381, it is possible that mutations in the EIF2B4
gene sequence that change these two amino acids could also lead to eIF2aP insensitivity.
Therefore, the presence ofEIF2B4 mutations in the natural human population that alters the
residues Leu377 and Glu381, might make eIF2B unresponsive to eIF2aP. This may have
health implications by making a system unable to respond effectively (by decreasing protein
synthesis) to certain cellular conditions such as viral infection and nutrient deficiency.
The complex eIF2B structure appears to relate to the many regulatory mechanisms that can
affect eIF2B activity. Although the exact function of the eIF2B8 subunit is unknown, it is
intriguing that the eIF2Ba, eIF2B(3, and eIF2B8 subunits share mutual sequence similarities
at their C-termini (Price et al., 1996) and that these three subunits can actually form a
complex in yeast (which however, does not possess guanine nucleotide exchange activity
(Yang & Flinnebusch, 1996)). This suggests a close interaction between these subunits and a
role for the three subunits (a, (3, and 8) in "sensing" eIF2aP. Other mechanisms that alter
eIF2B activity include the dephosphorylation of eIF2Be subunit by GSK-3 (Welsh et al.,
1997a) for example in response to insulin (see Figure 4.4). Sugar phosphates are thought to
allosterically stimulate eIF2B activity but the mechanism by which glucose stimulates eIF2B
activity is unknown. It is clear that understanding of all the regulatory pathways that act on
eEF2B will undoubtedly help to understand the eIF2B subunit functions.
4.2.4.12 Further research
The cloning of short and long isoforms ofEIF2B4 that is described in this section adds to the
already complex eIF2B structure. Further investigation into the eIF2B8 subunit function
should therefore take into account the existence of the two eIF2B8 isoforms. Added to
eIF2B structure complexity is the expression of alternative EIF2B4 splice forms (for both
short and long isoforms) in the brain. It would be interesting to further investigate these
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EIF2B4 splice forms, to see if they are translated and functional, and whether they possess a
brain specific function.
The identification ofpoint mutations in the EIF2B4 subunit by yeast studies yeast (Vazquez
de Aldana & Hinnebusch, 1994) and rat biochemical experiments (Kimball et al., 1998) that
can make the eIF2B complex insensitive to substrate phosphorylation, thereby preventing
inhibition of eIF2B activity and the regulation ofprotein synthesis in response to viral
infection and stress conditions, suggests that eIF2B8 plays an important role in the eIF2B
complex. It also suggests that mutations in the EIF2B4 gene could play an important role in
some disease processes by affecting the cell's ability to respond to viral infection.
The EIF2B4 gene was originally investigated because of its co-localisation with the
candidate type 2 diabetes genes GCKR and KHK on chromosome 2p23.3, and because of its
candidacy as a type 2 diabetes gene. Although defective eIF2B function could be involved
in the pathogenesis of type 2 diabetes, more knowledge of eIF2B subunit function is
required before the EIF2B4 gene can be called a legitimate type 2 diabetes gene. However if
EIF2B4 is linked to a disease process in the future, the characterisation of the EIF2B4
genomic structure that is described in this section will allow mutation screening to be
performed.
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4.3 The putative KIAA0064 gene
4.3.1 Introduction
4.3.1.1 Mapping of KIAA0064
In Section 4.2, the investigation of the 5' flanking region to the EIF2B4 gene revealed the
presence of part of the putative KIAA0064 gene (see Figure 4.18). Sequencing of the
EIF2B4-KIAA0064 intergenic region showed there to be 424 nucleotides between the
KIAA0064 start codon and the EIF2B4 exon la start codon. Due to the intimate "head to
head" arrangement ofEIF2B4 and K1AA0064, the putative KIAA0064 gene was further
investigated.
KIAA0064 was first mapped to the GCKR-KHK genomic region using the EST named
stSG149, designed from a cDNA clone sequence (Genbank accession number G43097).
This EST had been previously mapped, using radiation hybrid panels, to the genetic interval
D2S165-D2S352 (Genemap99: http://www.ncbi.nlm.nih.gov/genemap/). In the present
project, as described in Chapter 3, PCR screening of genomic clones located to the
GCKR-KHK genomic region was used to map stSG149 to the YACs 26BA11 and 29IH8,
and to PACs 13L13 and 119A8. Therefore, even before the identification ofKIAA0064
upstream ofEIF2B4 by sequencing (described in Section 4.2), the EST stSG149 (originally
designed from KIAA0064) was known to map to the GCKR-KHK intergenic region.
4.3.1.2 The KIAA0064 transcript
The putative KIAA0064 cDNA sequence was deduced during a study to predict coding
sequences of unidentified human genes by analysis of clones from a cDNA library of the
human immature myeloid cell line KG-1 (Nomura et al., 1994). In that study, cDNA clones
were only chosen for further characterisation if they fitted the following criteria: 1)
sequencing of the 5'-terminal ends of the cDNA clone inserts revealed no significant
similarity to known gene sequences, and 2) the cDNA clone inserts were >2 kb in size, and
corresponded to at least 90% of the transcript sizes shown by Northern hybridisation. The
KlAA0064-coni&mmg cDNA clone fitted these criteria and was completely sequenced
(Genbank accession number D31764). This strategy was utilised in order to increase the
chances of sequencing only cDNA clones that contained a complete coding region from a
novel gene.
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The 2043 bp KIAA0064 cDNA sequence contains an open reading frame encoding 470
amino acids. Gene expression analysis by Northern hybridisation revealed that KIAA0064 is
ubiquitously expressed (Nomura et al., 1994). At the time of its original description, the
KIAA0064 sequence showed no similarities to any sequence in the Genbank/EMBL
databases. However, as described in this chapter, database comparisons now show the
protein encoded by K1AA0064 to be highly similar to three other hypothetical proteins (two
from D. melanogaster and one from C. elegans). Although the function ofKIAA0064
remains unknown, amino acid sequence analysis shows KIAA0064 to contain two protein
motifs: 1) a motif found at the active site of serine proteases (the trypsin family), and 2) a
motif known as the phox homology (PX) domain. This latter motif is a novel domain that
has so far been identified in the NADPH oxidase subunits, sorting nexins, and
phosphatidylinositol 3-kinases (Ponting, 1996). Although there is no experimental evidence
for the function of the PX domain, a short amino acid motif within the PX domain
(proline-X-X-proline, where X is any amino acid), may act as a binding partner for Src
homology (SH) 3 domains of other proteins (Kay et al., 2000; Mayer & Eck, 1995; Pawson
& Gish, 1992). SH3 domains are 50-70 amino acids long and are often present in eukaryotic
signal transduction and cytoskeletal proteins. The ligand specificity of SH3 domains was
revealed by investigating the peptide binding properties of SH3 domain-containing proteins,
for example Src and phosphatidyl inositol 3-kinase regulatory subunit (Rickles et al., 1994).
By displaying peptide libraries on beads or phage, the optimal ligand preference for SH3
domains was found to be for a proline rich peptide sequence based around a
proline-X-X-proline core (where X is any amino acid).
This section describes the elucidation of the genomic structure and precise location of
KIAA0064, further examines the protein motifs present in KIAA0064, and assesses any
possible functional relationship between KIAA0064 and the adjacent EIF2B4 gene.
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4.3.2 Methods
4.3.2.1 Isolation of genomic clones
The primer pair for stSG149 (a: 5'-dGGATTGCCCCTTCTCTTTTC-3' and b:
5'-dAACACAGACCTCTGCCCATC-3'), which amplifies a PCR product of size 180 bp
(corresponding to the KIAA0064 3'UTR nucleotides 1817 to 1996, Genbank accession
number D31764), was used to screen the KHK-GCKR YAC and PAC contig.
The cosmid clone 'A4', which had been previously been shown to contain the whole of the
EIF2B4 gene (see Section 4.2), was also found to contain the 5' end ofKIAA0064 by direct
sequencing upstream from EIF2B4, using a primer designed in EIF2B4 intron 1 called
G12int (5'-dAGGCCCGGCTCTTCACTC-3').
4.3.2.2 KIAA0064 structure analysis
Oligonucleotides were designed from the KIAA0064 cDNA sequence (Genbank accession
number D31764) and used to obtain sequence data across the exon-intron boundaries by
direct sequencing on the cosmid clone A4. Intron sizes were determined either by
sequencing across the whole intron or by PCR amplification across the intron using cosmid
genomic DNA as template and primers within adjacent exons. The PCR products were
analysed on a 1-5 % agarose gel and sized against a Gibco BRL 1 kb ladder.
4.3.2.3 Sequence analysis
The cDNA and protein sequence analysis was performed using the BLAST program
(Altschul et al., 1990), based at NCBI. Protein alignments were produced using the GCG




Fine STS content mapping of stSG149 to clones in the GCKR-KHK physical contig shows
KIAA0064 to map approximately 150 kb from GCKR and 350 kb fromKHK (Figure 4.20 is a
simplified version ofFigure 3.8 shown in Chapter 3). The genomic clones shown to contain
KIAA0064 by PCR screening were YACs 29IH8 and 26BA11, PACs 13L13 and 119A8, and
cosmid subclone A4 (refer to Figure 4.20).
YAC 29IH8
YAC 26BA11
YAC18AG7 , 150 kb i
KHK KIAA0064 EIF2B4 GCKR
centromere
Figure 4.20 Co-localisation ofKIAA0064 with EIF2B4, GCKR and KHK. The arrows
represent genes, gene orientation (5'to 3') is indicated by the arrow direction. YAC genomic
clones are indicated. This diagram is a simplified version ofFigure 3.8 in Chapter 3.
4.3.3.2 KIAA0064 genomic structure
The DNA sequencing and inter-exon PCR analysis of cosmid A4 reveals the human
KIAA0064 gene to span approximately 6.2 kb of genomic DNA, consisting of 15 exons and
14 introns. The complete KIAA0064 genomic sequence (except intron 2) was obtained by
sequence analysis of cosmid A4 (Figure 4.21). The sequences were deposited in the EMBL
sequence database and assigned the accession numbers as follows: KIAA0064 exons 1-2,
AJ404855; and KIAA0064 exons 3-15, AJ404856. The first methionine codon of the open
reading frame is located in exon 1 at nucleotides 457^159, the stop codon at nucleotides
5413-5415 (Figure 4.21). The exons range in size from 42 bp to 522 bp and the introns from
85 bp to 1.1 kb. The KIAA0064 genomic structure and its intimate positional relationship to
EIF2B4 are shown in Figure 4.22. The genomic sequence of the KIAA0064 coding regions
from cosmid A4 agreed with the published cDNA sequence (accession number D31764).


































































Continued on next page.































































Figure 4.21 The complete KIAA0064 genomic sequence and its putative translation product.
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4.3.3.3 cDNA analysis
A BLASTN search of the Genbank database using the KIAA0064 cDNA sequence revealed
two significant hits, the Homo sapiens Eph-like receptor kinase EPHB1B gene (accession
number AF037332) and a Homo sapiens CpG island DNA genomic Msel fragment, clone
84gl 1 (accession number Z63465). The KIAA0064 and EPHB1B sequences were 97.5%
identical (1840 out of 1887 nucleotides were identical) over a region ofKIAA0064 from
nucleotides 142-2028 (the KIAA0064 cDNA sequence is 2043 nucleotides in length;
accession number D31764) and of the EPHB1B 3'UTR from nucleotides 5330-7221 - see
Figure 4.23. Examination of the two sequences shows small deletions and additions of
nucleotides in the KIAA0064-\ike sequence of the EPHB1B 3'UTR compared to KIAA0064.
There are more deletions than additions, resulting in the KIAA0064-\ike sequence of the
EPHB1B 3'UTR being 5 nucleotides shorter than the region of similarity with KIAA0064.
Although the putative start codon ofKIAA0064 is retained in the KIAA0064-like sequence of
the EPHB1B 3'UTR, there is no corresponding long open reading frame, due to a single C
nucleotide deletion in the EPHB1B 3'UTR (corresponding to nucleotides 1038, Figure 4.21),
which results in a stop codon (corresponding to nucleotides 1393-1395, Figure 4.21).
Therefore, although the KIAA0064-like sequence of the EPHB1B 3'UTR is transcribed as
part of the EPHB1B transcript, it appears not to be a protein coding sequence. This suggests




Figure 4.23 Location of a KIAA0064 pseudogene in the 3'UTR of the EPHB1B gene. The
diagram represents the EPHB1B cDNA (nucleotides 1-7261). The EPHB1B coding region
(nucleotides 1718-4639) is represented by blue, and the EPHB1B 5'UTR and 3'UTR are
shown as grey boxes. The KIAA0064 pseudogene is represented by a green box (nucleotides
5330-7221).
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Closer examination of the similarity between KIAA0064 and the Homo sapiens CpG island
DNA genomic MseI fragment, clone 84gl 1, reveals that the region of similarity
encompasses the whole ofKIAA0064 exon 2. Comparison of the KIAA0064 exon 2 and
intronic sequences (IVS1 and IVS2) with the clone 84gl 1 database sequence shows that the
clone 84gl 1 database sequence corresponds to nucleotides 940-1155, Figure 4.21. This
suggests that it is highly likely that the 84gl 1 clone originated from chromosome 2p23.3.
Analysis of the KIAA0064 genomic sequence obtained in the present study, using the
GRAIL/CpG island program (Roberts, 1991) predicts nucleotides 1-777 to be a CpG island,
Figure 4.21. This CpG island extends into the KIAA0064-EIF2B4 intergenic region
(described in Section 4.2).
4.3.3.4 Predicted KIAA0064 protein analysis
A BLASTP search ofEMBL databases using the KIAA0064 amino acid sequence reveals
that this protein shows greatest similarity to three hypothetical proteins: the two D.
melanogaster hypothetical proteins, accession numbers AAF52870 and AAF46070 (40%
and 26% identity, respectively), and the C. elegans hypothetical 54.2 kDa protein F17H10.3
in chromosome X, accession number CAA93650 (29% identity). There was also similarity
to a lesser extent to another C. elegans hypothetical protein (accession number CAB02091),
and to two hypothetical open reading frames in S. cerevisiae and S. pombe (accession
numbers CAB02091 and CAA88260, respectively). No functional information is known
about these hypothetical proteins, so that no predictions can be made concerning KIAA0064
function. However, two amino acid sequence motifs are recognisable within the KIAA0064
sequence.
The first motif is found at the active site of serine proteases and spans from amino acids 10
to 21 in KIAA0064 (Figure 4.24). The active site of an enzyme is the region that binds
substrates and contains the residues that directly participate in the making and breaking of
bonds. In the case of serine proteases, a highly reactive serine residue plays a critical role in
catalysis that results in the hydrolysis of a peptide substrate. It is the nucleophilicity of the
serine -OH at the serine protease active site that gives the serine residue the name of "active
serine". The structure and mechanism of a serine protease enzyme was first defined in
bovine chymotrypsin (Birktoft & Blow, 1972; Kraut, 1977) and has subsequently been
defined in many other active serine enzymes.
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The KIAA0064 serine protease active sitemotif is encoded entirely within KIAA0064 exon
1. Although the sequence comparison shown in Figure 4.24 suggests there to be a serine
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Figure 4.24 Comparison of the putative KIAA0064 serine protease active site to similar
motifs found in various other serine proteases. The putative active serine residue is starred
(that is, the highly reactive serine residue that acts as a nucleophile during catalysis). The
putative KIAA0064 active serine was assigned by similarity of the KIAA0064 active site
motif to known serine protease active site sequences. The symbol A indicates the location
of a splice junction in the amino acid sequence. Abbreviations: UPA, urokinase
plasminogen activator, TLP, trypsin-like protease.
BLAST analysis of the KIAA0064 peptide sequence also reveals similarity of amino acids
1-105 ofKLAA0064 to a protein motif called the PX domain. The PX domain is found in a
large group of eukaryotic proteins including NADPH oxidase subunits, sorting nexins
(proteins that are thought to be involved in targeting cell surface receptors to the lysosome
(Haft et al., 1998), and phosphatidylinositol 3-kinases (Ponting, 1996). Figure 4.25 shows a
consensus PX domain compared to the putative KIAA0064 PX domain. This shows that the
KIAA0064 PX domain spans from amino acid residues 1-105, and contains several highly
conserved residues including a two prolines (amino acids 57-60) that might represent a
binding domain (proline-X-X-proline, where X is any amino acid) for the SH3 domain of
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Figure 4.25 Comparison of a consensus PX domain (Ponting, 1996) to the putative PX
domain contained in KIAA0064 (amino acid residues 1-105). Matching residues are shown




4.3.4.1 Characterisation of KIAA0064
Section 4.3 describes the determination and analysis of the structure of the putative gene
KIAA0064. This gene was identified to lie in the GCKR-KHK intergenic region by
sequencing upstream of the EIF2B4 gene (a gene characterised in Section 4.2) and also by
mapping of the EST stSG149 (see Chapter 3, Figure 3.8). EIF2B4 had been investigated due
to its possible regulation by glycaemic status. The intimate "head to head" arrangement of
KIAA0064 with EIF2B4 (see Section 4.3, Figure 4.22) inevitably raises questions about
possible regulatory interactions between the two genes. There is less than 200 bp ofDNA
between the putative transcriptional start sites ofKIAA0064 and EIF2B4, suggesting that
KIAA0064 and EIF2B4 may share promoter and/or regulatory elements. This makes it
logical to have included an investigation ofKIAA0064 along with EIF2B4, which was
selected for study because of evidence that it is glucose-regulated.
The KIAA0064 cDNA had previously been cloned and shown to be 2043 nucleotides in size,
containing an open reading frame encoding 470 amino acids (Nomura et al., 1994). The
characterisation of the KIAA0064 genomic structure described in this chapter reveals
KIAA0064 to span approximately 6.2 kb of genomic DNA, consisting of 15 exons and 14
introns with the exons ranging in size from 42 bp to 522 bp and introns from 85 bp to 1.1 kb
(Figure 4.21). The KIAA0064 genomic sequence was found to be 100% identical to the CpG
island clone 84gl 1 (accession number Z63465) in the region ofKIAA0064 exon 2, indicating
the presence of a CpG island. Computer analysis of the KIAA0064 genomic sequence
confirms this, and shows that this CpG island spans the EIF2B4-KIAA0064 intergenic
region, indicating that the 5' regions of both KIAA0064 and EIF2B4 are CG-rich. As CpG
islands are often associated with promoters of genes (Bird, 1993; Delgado et al., 1998), the
location of this CpG island at the KIAA0064 EIF2B4 intergenic region suggests that it is
associated with the promoter sequences of both genes. As described in Chapter 3 (see Figure
3.8), a further 4 ESTs were mapped close to the KIAA0064 and EIF2B4 genes (stSG9174,
WI-19785, EST1, and EST2, - refer to Table 3.4 in Chapter 3 for further EST information).
Due to the high density of genes residing at the GCKR-KHK interval, it is likely that other
CpG islands will reside at this genomic region.
119
4.3.4.2 Homology between KIAA0064 and EPHB1B
At the cDNA level, KIAA0064 is almost identical to a region of the EPHB1B 3UTR, a
human EPH-related receptor protein-tyrosine kinase gene (accession number AF037332).
EPHB1B is the "long" isoform ofEPHB1 (accession number AF037331) (Tang et al., 1995).
Both EPEIB1gene isoforms share identical coding regions but differ at their 5TJTRs and
3'UTRs. The striking difference between EPHB1 and EPHB1B is the presence of a much
longer 3'UTR in EPHB1B (2622 nucleotides compared to 695 nucleotides). Examination of
the EPHB1B sequence reveals that the region of similarity with KIAA0064 occurs only in the
EPHB1B 3TJTR. Detailed examination of the region of similarity between KIAA0064 and
the KIAA0064-\ike region in the EPHB1B 3TJTR reveals, however, that they are not 100%
identical. The EPHB1B sequence lacks a region of identity with the first 141 nucleotides of
KIAA0064 (part of the 5TJTR), but it does contain an equivalent to the KIAA0064 start codon
(EPHB1B nucleotides 5410 to 5412, Figure 4.23). However, comparison of the sequence
downstream of this equivalent methionine residue to the KIAA0064 sequence, reveals that
there are a number of differences including single and multiple bp deletions/additions and
substitutions that produce a shortened open reading frame that if translated would result in a
68 amino acid truncated protein. The absence of any corresponding KIAA0064 full length
open reading frame within the EPHB1B gene sequence, added to the fact that the similarity
between KIAA0064 and EPHB1B occurs only in the EPHB1B 3TJTR, strongly suggests that
the EPHB1B 3'UTR contains a processed KIAA0064 pseudogene.
4.3.4.3 Chromosomal mapping of EPHBIb and KIAA0064
The radiation hybrid mapping ofKIAA0064 to chromosome 2 (Nomura et al., 1994) was
confirmed by two methods. The screening of a human-rodent mono-chromosomal cell
hybrid panel using stSG149 (designed from an EST within the KIAA0064 sequence)
confirmed that this STS mapped only to chromosome 2. The sequencing of the KIAA0064
gene from a cosmid subclone ofYAC 26BA11, a YAC mapped by FISH to chromosome
2p23.3 by FISH (Warner et al., 1995) provided evidence for the co-localisation ofKIAA0064
with EIF2B4, GCKR, and KHK. Indeed, mapping ofKIAA0064 to the GCKR-KHK physical
contig described in Chapter 3, shows KIAA0064 to reside -150 kb from GCKR and -350 kb
from KHK (Figure 4.20).
The EPHB1 gene, which contains the KIAA0064 pseudogene, was known to map to human
chromosome 3 (EPHB1 and EPHBIB are encoded by the same gene and only differ at their
120
5' termini; EPHB1B has a much longer 3UTR which contains the KIAA0064 pseudogene).
This had been shown by both PCR screening of a human-rodent somatic cell hybrid panel
and by FISH using a EPHB1 -containing PI clone (Tang et al., 1995). The primers used to
map the EPHB1gene were designed from the EPHB1 3UTR sequence shared by both
EPHB1 isoforms, out-with the KIAA0064 pseudogene, therefore mapping both isoforms to
chromosome 3. It was intriguing to find that the sequence for primer stSG149a (stSG149
maps KIAA0064 to chromosome 2) can be found within the EPHBIB 3TJTR and the
stSG149b primer sequence also exists except that there is one cytosine nucleotide missing
within the primer sequence. The screening of a human-rodent mono-chromosomal cell
hybrid panel using stSG149 confirmed that it mapped only to chromosome 2. This proved
that the one base deletion within the EPHBIB 3TJTR on chromosome 3 within the stSG149b
primer sequence was enough to prevent any amplification of a PCR product from the
EPHBIB gene.
Although the KIAA0064 mouse homologue has not been mapped, examination of the
Jackson map ofmouse chromosome 5 in the region of conserved synteny corresponding to
human chromosome 2p23 (Wightman et al., 1997), reveals that an EST called D5Ertd260e
(Ko et al., 2000) co-localises with Gckr and Khk. This EST, an anonymous cDNA J0071F09
from a 3.5-dpc mouse blastocyst cDNA library, shows significant similarity to the human
KIAA0064 gene and is likely to be the KIAA0064 mouse homologue. This suggests the
co-localisation of GCKR, KHK, and K1AA0064 to be evolutionarily conserved in human and
mouse genomes and allows for the possibility of common cA-acting regulatory elements for
these genes.
4.3.4.4 Protein motifs in KIAA0064
The analysis of the KIAA0064 peptide sequence reveals that the N-terminus shows
homology to the active site of serine proteases (amino acids 10-21, see Figure 4.24) and a
more extended region of homology to a PX domain (amino acids 1-105, see Figure 4.25).
There are several residues well conserved between species within both these domains,
possibly indicating that they have been conserved to carry out an important function.
However, without investigation using biochemical techniques, it is impossible to say whether
these motifs possess any functional significance.
The protein similarity search reveals that the closest known human protein to KIAA0064
was a PX domain-containing protein called sorting nexin 1 (SNX1). The SNX1 protein was
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first identified using a yeast two-hybrid experiment to identify proteins that bound to the
cytoplasmic domain of the epidermal growth factor (EGF) receptor (Kurten et al., 1996).
Homology between SNX1 and the yeast proteinMvplp which is known to be involved in
targeting hydrolases to the vacuole, led to the hypothesis that SNX1 may be involved in EGF
receptor degradation in lysosomes (Ekena & Stevens, 1995). The identification and cloning
of a further three novel proteins that contain a PX domain and show homology to SNX1 led
to the formation of a family of sorting nexin proteins (Haft et al., 1998). To date, 14 sorting
nexin proteins have been cloned and a search of sequence databases suggests the existence of
orthologues in yeast and C. elegans.
Studies ofPX domain-containing proteins in yeast have revealed that they are often
associated with processes involving the actin cytoskeleton, membranes and/or GTP binding
proteins. For example, the S. cerevisiae protein Beml appears to co-ordinate rearrangement
of the cortical cytoskeleton during cell polarisation in response to mating factors (Chenevert
et al., 1992; Peterson et al., 1994). It is impossible to predict what other proteins the protein
encoded by KIAA0064 would interact without biochemical experimentation, for example by
utilising the yeast two hybrid system.
It is also unclear without further experimentation whether genetic interactions between
KIAA0064 and the adjacent EIF2B4 gene might occur. However, the evolutionary
conservation of the intimate genomic location between KIAA0064 with EIF2B4 in human
and mouse does suggest the possibility of interactions at the transcriptional level, as a result




4.4.1.1 Identification of a ribokinase-like EST
During the search for transcripts that map to GCKR-KHK genomic region that might have a
related function to the GKRP (glucokinase regulatory protein) or KHK (ketohexokinase), an
EST (Genbank accession number T69020) was identified that showed significant similarity
(45% at the nucleotide level) to the E. coli ribokinase gene. A comparison of this
ribokinase-like EST to the corresponding region of the E. coli ribokinase gene is shown in
Figure 4.26. As ribokinase (RBSK) and KHK are both members of the same sugar kinase
family (Bork et al., 1993), this human ribokinase-like EST was investigated to examine a
possible evolutionary link to KHK.
T69020 GTAAAAGAACTAATATTTGCAAAGAAAGGGG—ACGAGGACATTTTCTAATAAG C 53
I I I III I II I III II I I I I MINI I
E. coli GAATCACCACTCGAAAGTGTGATGGCAGCGGCGAAAATCGCCCATCAAAATAAGACTATC 4613
T6 9 0 2 0 ATTA-GCAGGAGCAGCCACCCCCAAGTACATTTTATTCCCAGGNATATTTATTTTGGGAC 112
E. coli GTTGCGCTTAACCCGGCTCCGGCTCGCGAACTTCCTGACGAA-CTGCTGGCGCTGGTGGA 4672
T6 9 0 2 0 TAATAGCAATCAAAACAGA—GTAAGCGGAAGGTCTTTTTTGTAAGGGT AAGATGA 166
E. coli CATTATTACGCCAAACGAAACGGAAGCAGAAAAGCTCACCGGTATTCGTGTTGAAAATGA 4732
T6902 0 CTGTGTTCCTGCAGCCTGGACACTGACTGCTGCAATGAAATTGGATCTGTTGAGCA-TGT 225
E. coli TGAAGATGCAGCGAAGGCGGCGCAGG-TACTGCATGAAAAAGGTATCCGTACTGTACTGA 4791
T6 9 0 2 0 CTTCCAAGGACAGATTTGGATAGTAAGCCAGGTAGAAGGCCAGAGCTCCCACAAAGCTNT 285
E. coli TTACTTTAGGAAGTCGTGGTGTATGGGCTAGCGTGAATGGTGAAGGTC A--GCGCG 4845
T6 9 02 0 CACCAGCACCCGTGGTATCCACAGCCTTGACTTTCTCTGTGGGAATGTGCTTTGGCTCAG 345
E. coli TTCCTGGATTCCGGGTGCAGGCTGTCGATACCATTGCTGCCGGAGATACCTTTAAC G 4902
T6 9 0 2 0 GTTCTGTCTGTGACAGCACCAC ACATCCTTCAGCCCCTAAGGNTAATGATTACCAC 401
E. coli GTGC-GTTAATCACGGCATTGCTGGAAGAAAAACCATTGCCAGAGGCGATTCGTTTTGCC 4961
T6 9 02 0 CTGGGCAGCCCCTTTTCAAGGAGCACTAN-TGCAGCCTNCCCAGCATC—TTNCAG 454
E. coli CATG-CTGCCGCTGCGATTGCCGTAACACGTAAAGGCGCACAACCTTCCGTACCGT 5016
Figure 4.26 Sequence comparison of human EST T69020 sequence with the E. coli
ribokinase gene (part of a large genomic sequence assigned Genbank accession number
M13169). Numbering refers to database entry numbering.
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The ribokinase-like EST was first identified by examination of the Genemap99 at NCBI
(http:/www.ncbi.nlm.nih.gov/genemap/map.cgi?CHR=2), revealing that SHGC15128, an
EST showing significant similarity to E. coli ribokinase, Genbank accession number
T69020, was located between the markers D2S171 andD2S165 on chromosome 2p23. This
places SHGC15128 within the same genomic region as GCKR and KHK (based upon
radiation hybrid mapping data at NCBI). PCR screening of genomic clones located at the
GCKR-KHK genomic region using SHGC15128 revealed that this EST maps to the YAC
29IH8, already known to contain GCKR (see Chapter 3, Figure 3.5). As ribokinase belongs
to the same sugar kinase family as KHK, -500 kb from GCKR (shown by FISE1 studies
(Hayward et al., 1996) and the GCKR-KHK physical contig described in Chapter 3, Figure
3.8), the ribokinase-like EST was chosen for further investigation.
4.4.1.2 Sugar kinases
The main source of carbon and energy used by cells is the metabolism of sugars. After
transport into a cell, the first step ofmetabolism is to phosphorylate the sugar, preparing it
for further chemical reactions, either catabolic or anabolic. The main catabolic pathway is
glycolysis, a sequence of reactions that converts glucose into pyruvate with the concomitant
production ofATP. For glucose to enter the glycolytic pathway, it is first phosphorylated by
a hexokinase (see Chapter 1). Other abundant sugars, for example fructose and galactose,
can be "funnelled" into the glycolytic pathway, but again the first step of their metabolism is
the phosphorylation by their own specific kinase (fructokinase (KHK) and galactokinase
respectively). Some sugars are so rare in the natural environment, for example ribulose,
xylulose, or fucose, that they can only be processed by specialised micro-organisms.
Glucose, fructose, and galactose, all contain six carbon atoms in their structure and are
processed as energy sources by entering the glycolytic pathway. Ribose is another abundant
sugar. It however contains five carbon atoms in its structure and once phosphorylated, enters
the pentose phosphate pathway, or is used in the biosynthesis of nucleotides, histidine, and
tryptophan. The first step of ribose metabolism is the ATP-dependent phosphorylation of
ribose to ribose-5-phosphate by ribokinase (see Figure 4.27).
Many cells have a greater requirement forNADPH for reductive biosynthesis than for
ribose-5-phosphate for incorporation into nucleotides and nucleic acids. In this situation,
ribose-5-phosphate is converted into the glycolytic intermediates glyceraldehyde
3-phosphate and fructose-6-phosphate by two enzymes called transketolase and transaldolase
(Katz & Rognstad, 1967). These enzymes constitute a reversible link between the pentose
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phosphate pathway and glycolysis. Therefore, excess ribose-5-phosphate formed by the
pentose phosphate pathway can be completely converted into glycolytic intermediates.
4.4.1.3 Sugar kinase families
The examination of sugar kinase primary structures in combination with biochemical data
reveals at least three distinct non-homologous sugar kinase families: hexokinases,
ribokinases and galactokinases (Bork et al., 1993). Each family appears to have strikingly
different conserved sequences, suggesting each family to possess its own distinct
three-dimensional structural motifs. As kinases catalyse chemically equivalent reactions on
similar or identical substrates, this has been interpreted to suggest that the enzymatic
function of sugar phosphorylation has evolved independently on three distinct structural
frameworks by convergent evolution.
4.4.1.4 The ribokinase family
The ribokinase family of sugar kinases is a structurally distinct group of both prokaryotic
and eukaryotic sequences including several fructokinases, the minor 6-phosphofructokinase
from E. coli, 1-phosphofructokinases, and 6-phosphotagatokinases. The primary structure of
every family member contains at least one of three conserved regions, identifying it as a
member of the ribokinase family (Bork et al., 1993). The creation of an evolutionary tree by
multiple sequence alignment reveals that substrate specificity is the major organising
principle. This suggests that in this family, divergence of substrate specificity occurred
before species divergence, ie. that fructokinases branched off from ribokinases before the
divergence of yeast and E. coli (Bork et al., 1993).
Ribokinase (RBSK) and ketokexokinase (KHK) are part of the same ribokinase family of
kinase proteins because they both contain at least one of the three conserved amino acid
sequence motifs. Although RBSK and KHK are part of the same family, they phosphorylate
different substrate sugars (ribose and fructose, respectively). Figure 4.27 shows the
phosphorylation of ribose to ribose-5-phosphate and fructose to fructose-1-phosphate by
ribokinase and ketohexokinase respectively. Comparison of the sugar and sugar-phosphate
chemical structures shown in Figure 4.27 reveal that RBSK and KHK carry out similar
functions by adding one phosphate group to a carbon atom outwith the carbon ring of each
sugar (carbon atom "5" and "1" respectively). Although ribose and fructose are five and six
carbon sugars respectively, both sugars contain a five carbon furanose ring (Figure 4.27).
Therefore, RBSK and KHK phosphorylate structurally similar substrates. As ribokinases
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and fructokinases contain conserved amino acid motifs, these motifs might be involved in
kinase function and substrate specificity for furanose sugars. Non-conserved regions of
amino acid sequence in ribokinase and fructokinase proteins might be involved in substrate
















Figure 4.27 Role of ribokinase and ketohexokinase. A) Phosphorylation of ribose to
ribose-5-phosphate by ribokinase. B) Phosphorylation of fructose to fructose-1-phosphate by




Ketohexokinase (KHK) is a member of the ribokinase family of proteins (Bork et al., 1993).
The identification of a ribokinase-like EST near to the KHK gene on chromosome 2p23.3,
raises the possibility that the ribokinase-like EST and KHK gene originate from a common
ancestral gene. However, based on the known evolutionary relationships between the
ribokinase family members, this would be surprising, since as mentioned above, it is
believed that divergence of substrate specificities within the family predates the prokaryotic-
eukaryotic divergence. This section describes the cloning and characterisation of the novel
ribokinase-like gene. To investigate the possibility that KHK and the ribokinase-like gene
have evolved by divergent evolution from a common ancestral gene, their amino acid
sequences and genomic structures were compared. Similar sequence motifs and similar
genomic structural features, might suggest that these two genes have indeed originated from




4.4.2.1 cDNA cloning and sequencing
The EST SHGC15128 (designed from the cDNA clone Genbank accession number T69020)
was used in a BLAST search ofEMBL and Genbank EST databases. Overlapping cDNA
clones were identified and a cDNA contig was thereby constructed that spanned 1196
nucleotides (Figure 4.28). These cDNA clones were obtained from the IMAGE consortium







Figure 4.28 Ribokinase EST clone contig. See Table 4.6 for cDNA clone identification.







1 220049 1.1 Retina N2b4HR, Soares
2 484872 0.68 Pregnant uterus NbHPU, Soares
3 246380 0.8 Fetal liver and spleen 1NFLS, Soares
4 82322 1.1 Liver, Stratagene.
5 484876 0.6 Pregnant uterus NbHPU, Soares
Table 4.6 cDNA clone identification for Figure 4.28.
4.4.2.2 Isolation of genomic clones
The SHGC15128 primer pair (5'-dAAGAAAGGGGACGAGGACAT-3' and
S'-dCTTACCCTTACAAAAAAGACCG'; corresponding to nucleotides 940-960 and
1062-1081 respectively, Figure 4.29) was used to screen the PAC human genomic library
RPCI1 by PCR (obtained from the HGMP Resource Centre, Hinxton, U.K.). Standard PCR
conditions were used (1.5 mM MgCl2) with the "hot start" PCR program 94°C, 5 min; 40 x
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(94°C, 45s; 58°C, 45s; 72°C, lmin). Two positive PAC clones containing the
ribokinase-like gene were obtained: F1622 and K13137.
During the investigation of the ribokinase-like gene genomic structure, sequencing problems
were experienced at the 5' end of the gene when using PAC DNA as template. To obtain
alternative genomic clones for sequencing, cosmid clones were isolated for the
ribokinase-like gene 5' end by screening a chromosome 2 cosmid library (LL02NC02). This
was carried out by radioactively labelling the oligonucleotide R15
(5'-dACCTTTGAGCGATGGCGG-3'; corresponding to RBSK nucleotides 1-18, Figure
4.29) and screening the cosmid filters by hybridisation (Filters AE1, AE2, and AE3, supplied
from the HGMP Resource Centre, Flinxton, U.K.). Four positive R15 cosmid clones were
obtained: 43K21, 46P3, 8307, and 99K11.
4.4.2.3 Structural analysis
Oligonucleotides were designed from the cDNA sequence and used to identify exon-intron
boundaries using as template DNA from the PAC clones F1622 and K13137, both ofwhich
contain SHSG15128 (designed from the RBSK 3'UTR). Sequencing using the PAC DNA as
template proved troublesome, however, especially at the 5' end of the RBSK gene.
Therefore, the cosmid clone 43K21 was also used as template. Sizes of introns were
determined by PCR amplification across each intron using PAC DNA as template and
primers within adjacent exons. The fragments were analysed on a 1-5% agarose gel and sized
against a Gibco BRL 1 kb ladder.
Although all exon-intron boundaries were identified in the ribokinase-like gene by
sequencing using genomic PAC and cosmid clones, not all the intron sizes could be
determined, due to unspecific PCR amplification. Alteration of the PCR conditions by
raising the annealing temperature and addition of betaine or DMSO (to reduce template
DNA secondary structure) did not improve the specificity of the PCR. A long-range PCR kit
(Stratagene) was also used, in case the introns were large, but again no specific PCR product
was obtained. Use of different primers and different genomic clones for template DNA did
not improve the results.
4.4.2.4 Sequence analysis
Sequence analysis was performed using the MAGI sequence alignment program (ClustalW),
based at the HGMP resource centre.
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4.4.3 Results
4.4.3.1 The ribokinase-like cDNA and putative translation product
The sequencing of overlapping cDNA clones showing significant homology to a
ribokinase-like gene revealed a 1196 bp cDNA sequence with a single 969 bp long open
reading frame (corresponding to nucleotides 12-980; Figure 4.29), encoding a putative
translation product of 322 amino acids with a molecular weight of 34.15 kDa. This
ribokinase cDNA sequence was deposited in the EMBL sequence database and assigned the
accession number AJ404857. The putative translation product possesses two conserved
regions, characteristic of the ribokinase family, corresponding to amino acids 51-78 and
258-279 (underlined in Figure 4.29).
The putative translation product of the human ribokinase gene shown in Figure 4.29 was
compared to ribokinase proteins from other species (Figure 4.30). This shows that
homologous ribokinase proteins are highly conserved between D. melanogaster, H.
influenzae, E. coli, B. subtilis, and S. cerevisiae, and display identity to the human RBSK of
44%, 37%, 35%, 35%, and 28% respectively. The significant similarity of the human
ribokinase-like gene described in this section strongly supports the notion that this gene is
the human ribokinase gene (RBSK). Figure 4.30 also reveals there to be several regions of
highly conserved amino acid residues throughout all six ribokinase proteins examined. The
two amino acid sequences highlighted in Figure 4.30 are indicative of ribokinase family
members (Bork et al., 1993).
4.4.3.2 Structural organisation of the human RBSK gene
To determine the genomic structure of the RBSK gene, primers that were designed from the
RBSK cDNA sequence were used to sequence across the exon-intron boundaries, using
ZTSSAl-containing PAC clones as template DNA (isolated from PAC libraries using
SHSG15128). The sequencing using the PAC DNA as template proved troublesome,
especially at the 5' end of the RBSK gene (probable secondary structure due to high G+C
nucleotide content). Therefore the cosmid clone 43K21 was also used as sequencing
template. The results of sequence analysis ofPAC and cosmid clones are summarised in
Figure 4.31. The RBSK gene consists of 8 exons and 7 introns. The exons vary in size from
63 bp to 390 bp. As shown in Figure 4.29, the first methionine codon of the open reading
frame is located in exon 1 (nucleotides 12-14), whereas the stop codon is located in the last
exon, exon 8 (nucleotides 978-980). Exon 8 contains 216 bp of 3TJTR sequence.
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1 ACCTTTGAGCGATGGCGGCGTCTGGGGAACCCCAGAGGCAGTGGCAAGAGGAGGTGGCGG 6 0
MAASGEPQRQWQEEVAA17
61 CGGTGGTAGTGGTGGGCTCCTGCATGACCGACCTGGTCAGTCTTACTTCTCGTTTGCCAA 12 0
VVVVGSCMTDLVSLTSRLPK37
121 AAACTGGAGAAACCATCCATGGACATAAGTTTTTTATTGGCTTTGGAGGGAAAGGTGCCA 180
TGETIHGHKFFIG F G G K G A N 57
181 ACCAGTGTGTCCAAGCTGCTCGGCTTGGAGCAATGACGTCCATGGTGTGTAAGGTTGGCA 240
QCVQAARLGAMTSMVCKVGK 77
241 AAGATTCTTTTGGCAATGATTATATAGAAAACTTAAAACAGAATGATATTTCTACAGAAT 3 00
D S F GNDYIENLKQNDISTEF97
301 TTACATATCAGACTAAAGATGCTGCTACAGGAACTGCTTCTATAATTGTCAATAATGAAG 360
TY QTKDAATGTAS I IVNNEG 117
361 GCCAGAATATCATTGTCATAGTGGCTGGAGCAAATTTACTTTTGAATACGGAGGATCTGA 420
















Y L A YYPNLSLEDMLNRSNFI 297
901 TTGCAGCAGTCAGTGTCCAGGCTGCAGGAACACAGTCATCTTACCCTTACAAAAAAGACC 960
AAVSVQAAGTQSSYPYKKDL 317
961 TTCCGCTTACTCTGTTTTGATTGCTATTAGTCCCAAAATAAATATACCTGGGAATAAAAT 102 0




Figure 4.29 cDNA sequence of human ribokinase (RBSK) gene; the start codon is located at
nucleotides 12-14 and the stop codon at nucleotides 978-980. The underlined amino acid
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The intron sizes were investigated by using primers designed from within the exons and
using PCR to try and amplify across the intronic sequence. For introns 1, 2, 3, 4, and 7, PCR
amplification proved successful. However, PCR was unable to amplify a clean PCR product
for introns 5 and 6. This could have been due to the large size of the introns or due to
miss-priming by the oligonucleotides. The use of long range PCR, addition ofDMSO or
betaine to the PCR reaction (to help destroy secondary structure of the template DNA),
alternative primers and template DNA, did not resolve this problem.
RBSK
100 bp 133 bp 64 bp 63 bp 165 bp 92 bp 189 bn 390 bp
2.0 kb 0.7 kb 0.9 kb 3.5 kb ? kb ? kb 1.6 kb
Figure 4.31 Genomic structure of ribokinase gene. Exons (1-8) are shown as shaded boxes,
coding regions darker than untranslated regions. The diagram is not to scale; exact exon sizes
(bp) and approximate intron sizes (kb) are indicated where known.
4.4.3.3 Amino acid sequence analysis
The human ribokinase gene (RBSK) is the third member of the ribokinase family to be
cloned (the other two are ketohexokinase (KHK) (Bonthron et al., 1994)and adenosine
kinase (ADK) (Singh et al., 1996a). Comparison of the encoded proteins ofRBSK to KHK
and ADK reveals 17% and 20% identity respectively. All three kinase amino acid sequences
contain two conserved domains that are characteristic of ribokinase proteins (Figure 4.32),
providing evidence that all three proteins belong to the same ribokinase family.
51 FGGKGANQCVQAARLGA MTSMVCKVGKD 78
39 RGGNASNSCTVLSLLGA PCAFMGSMAPG 66
78 AGGSTQNSOKVAQWMIQQPHKAATFFGCIGID 109
•k -k -k . ...
258 KVKAVDTTGAGDSFVGALAFYL 279
247 PPRWDTLGAGDTFNASVIFSL 2 68
246 QKEIIDTNGAGDAFVGGFLSQL 267
.•k'kk'k-k'k.k "k
Figure 4.32 Comparison of conserved ribokinase family domains in the human ribokinase
(RBSK), ketohexokinase (KHK), and adenosine kinase (ADK) proteins. Numbering
corresponds to amino acid number. Clustal alignment program nomenclature: indicates
fully conserved residue, ":" indicates a "strongly similar" residue is fully conserved, and
"." indicates a "weakly similar" residue is fully conserved. Genbank accession numbers for








The co-localisation ofRBSK and KHK to chromosome 2p23.3 suggested the possibility these
two genes might have originated from a common ancestral gene. Although comparison of
amino acid sequences show these proteins to be related by sequence, gene structure can be
more revealing than sequence similarity for the investigation of gene evolutionary linkage.
To investigate the hypothesis of an evolutionary link between RBSK and KHK, the genomic
structures ofRBSK and KHK were compared. Figure 4.33 shows a comparison ofRBSK to
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Figure 4.33 Comparison of ribokinase and ketohexokinase proteins. Numbering corresponds
to amino acid number. Clustal alignment program nomenclature: indicates fully
conserved residue, ":" indicates a "strongly similar" residue is fully conserved, and "."
indicates a "weakly similar" residue is fully conserved. Red and green triangles indicate
positions of exon-intron boundaries in the amino acid sequence for ribokinase and
ketohexokinase,respectively. Blue highlighted sequences represent conserved amino acid
motifs of the ribokinase family. Genbank accession numbers for RBSK and KHK (3A form)
are AJ404857 and CAA55347, respectively.
Although comparison of the RBSK and KHK amino acid sequences reveals 17% identity,
comparison of the positions of their exon-intron boundaries show RBSK and KHK to possess
completely distinct genomic structures (Figure 4.33). This is further discussed below.
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4.4.4 Discussion
4.4.4.1 Cloning of the human ribokinase gene
This section describes the cloning, structural analysis, and chromosomal localisation of the
human ribokinase (RBSK) gene. The cDNA sequence contains a 969 bp open reading frame
encoding a predicted protein of 322 amino acids (34.15 kDa) - see Figure 4.29. For
sequence comparison, there are presently only two other related human sugar kinase genes
that have been cloned, ketohexokinase (KHK) and adenosine kinase (ADK). Comparison of
RBSK to KHK and ADK at the amino acid level reveals 17% and 20% identity, respectively.
Inspection of the RBSK, KHK, and ADH sequences reveal that all three possess two
conserved amino acid motifs that are characteristic of ribokinase family members (Bork et
al., 1993).
The putative protein encoded by RBSK shows significant homology to other prokaryotic and
eukaryotic ribokinases but similarity is also seen to other ffuctokinases and adenosine
kinases. The overall homology of human RBSK with ribokinase proteins from D.
Melanogaster, H. influenzae, E.coli, B. subtilis, and S. cerevisiae is 44%, 37%, 35%, 35%,
and 28% respectively (Figure 4.30). The conservation of sequence between ribokinase
proteins suggest that many of the conserved residues are essential for the three dimensional
structure and ribose phosphorylation function. It is interesting that the S. cerevisiae
ribokinase protein displays relatively low identity to the human ribokinase protein.
Examination ofFigure 4.30 reveals that this is mainly due to the insertion of several
stretches of amino acids that are not present in any of the other homologous ribokinase
proteins. This results in the S. cerevisiae ribokinase protein being 11 residues longer than
the human ribokinase protein (333 amino acids compared to 322 amino acids, respectively).
The function of these extra amino acids is unknown.
Mapping ofRBSK to the same YAC (29IH8) as the GCKR gene (GCKR is located -500 kb
from KHK) reveals RBSK and KHK to be -800 kb apart (estimated from the physical YAC
contig of the GCKR-KHK genomic region described in Chapter 3,). Although the mouse
homologue ofRBSK has not been completely characterised, mouse ESTs exist in the
databases that show significant homology to the human RBSK gene (for example,Genbank
accession numbers AA560831 and AA260331). The physical mapping of human RBSK to
between the GCKR and KCNK3 genes on the 2p23.3 physical contig (gene order
KHK/GCKR/RBSK/KCNK3), suggests that like KHK, GCKR and KCNK3, the RBSK gene
will also prove to map to the region of conserved synteny on mouse chromosome 5.
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The mapping ofboth RBSK and KHK to human chromosome 2p23.3 suggests that these two
genes might have originated from a common ancestral gene. The comparison ofRBSK to
KHK at the amino acid level reveals 17% identity (no significant homology is seen at the
nucleotide level). This amino acid sequence similarity places both RBSK and KHK within
the same ribokinase family. However, such a low level of sequence similarity alone does not
provide enough information to conclude that RBSK and KHK have originated from a
common ancestral gene.
Comparison of the RBSK and KHK genomic structures reveals that they consist of 8 and 9
exons, respectively. However, KHK has two alternative exons (3a and 3c) that show enough
similarity to each other to suggest that they arose through an intragenic duplication event
within the KHK gene (Bonthron et al., 1994; Hayward & Bonthron, 1998). Therefore, it is
possible that before this intragenic exon duplication event within KHK, both RBSK and KHK
would have consisted of 8 exons. However, comparison of the intron-exon boundary
positions relative to the amino acid sequence alignment reveals that in fact both genes have
very different genomic structures (Figure 4.33). This suggests that although both RBSK and
KHK belong to the ribokinase family and both carry out the enzymatic function of furanose
sugar phosphorylation (see Figure 4.27), their exon-intron structures have evolved
independently. Indeed, none of the splice junctions can be perfectly aligned between the two
genes. This would suggest that although the RBSK and KHK genes show amino acid
sequence similarity, their divergence is an ancient one (predating the introduction of introns
into these genes). Their chromosomal co-localization is therefore presumably coincidental,
rather than reflecting genomic evolutionary history.
The RBSK gene was investigated because like KHK, it resides on chromosome 2p23.3 and
both encoded proteins belong to the ribokinase family. The work described in previous
sections in this chapter, though, was motivated by the metabolic relatedness ofKHK and
GKRP, and the idea that other candidate type 2 diabetes genes with metabolically linked
functions might, also reside on chromosome 2p23.3. Although RBSK itself is an unlikely
candidate type 2 diabetes gene, it is interesting to note that in times of excess
ribose-5-phosphate (the product of ribose phosphorylation by RBSK), ribose-5-phosphate
can be converted into the glycolytic pathway intermediates glyceraldehyde 3-phosphate and
fructose-6-phosphate by the action of transketolase and transaldolase. As discussed in
Chapter 1 (Section 1.5.4, Figure 1.2), fructose-6-phosphate has been shown to increase
glucokinase inhibition by glucokinase regulatory protein (GKRP). In other words, the
generation of excess ribose-5-phosphate could affect glucokinase activity through the
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fructose phosphate effect on GKRP. This could act as a subtle mechanism for reducing
glucose phosphorylation in times of excess ribose, therefore conserving glucose. This
illustrates that a very detailed understanding of the relevant biochemical pathways and the
complex interactions between them will be required to fully understand subtle disease




5 Candidate neurosensory non-syndromic
recessive deafness 9 (DFNB9) genes
5.1 Introduction
5.1.1 Mapping of the DFNB9 gene to chromosome 2p22-23
The DFNB9 gene was first localised to 2p22-23 by genetic analysis of prelingual and fully
penetrant deafness in a Sunnite consanguineous family living in an isolated village ofNorth
Lebanon (Chaib et al., 1996) - this locus was first described as DFNB6 but this designation
had already been assigned to the DFNB locus 3pl4-p21 (Fukushima et al., 1995). At this
stage the DFNB9 gene was defined to a 2 cM interval delimited by the markers D2S2303
and D2S174 at 2p23.1 (see Chapter 3, Figure 3.5). The identification of a second Middle
Eastern kindred with autosomal recessive non-syndromic hearing loss segregating to the
DFNB9 locus (Leal et al., 1998) presented further evidence of a DFNB gene at the 2p22-23
locus. This second linkage study suggests that the locus containing the DFNB9 gene is less
than 1.08 cM, 95 % confidence interval (0-2.59 cM).
The study of genetic maps covering the DFNB9 region reveals that the genomic interval in
which the causative gene is determined to reside, maps close to the GCKR-KHK genomic
region (see Chapter 3, Figure 3.5). As much of this genomic region has already been cloned,
the aim of this research is to identify and characterise candidate DFNB9 genes and examine
their role in the pathogenesis of sensorineural deafness.
5.1.2 Syndromic and non-syndromic deafness
Significant hearing impairment affects 1 in 1000 children, and of these cases, approximately
60% are genetically determined (Marazita et al., 1993). Inherited hearing impairment can be
classified as syndromic or non-syndromic, reflecting the presence or absence of inherited
physical abnormalities, respectively. Approximately 30% of patients with prelingual
deafness show syndromic hearing impairment, that is they have additional anomalies.
Within the prelingual non-syndromic hearing impairment category, inheritance is most
commonly autosomal recessive (75%-80%), followed by dominant (20%-25%) and X-linked
(1%-1.5%) (Van Camp et al., 1997). Numbered sequentially on the basis of time of
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discovery, dominant loci carry the prefix DFNA, recessive loci the prefix DFNB, and
X-linked loci the prefix DFN. Mitochondrial mutations are designated by the site of the
mutation (for example, A1555G, T7445C). To date, 31 dominant, 28 recessive, 8 X-linked,
and 4 mitochondrial loci for non-syndromic hearing loss have been identified. The genes
that have been found to underlie syndromic and non-syndromic deafness have been shown to
encode a large diversity ofmolecules, including extracellular matrix components, enzymes,
transcriptional complex factors, cytoskeletal components and membrane components, as well
as four different mitochondrial encoded proteins, three tRNA molecules and one rRNA
molecule. The genetic locations of deafness loci and descriptions of genes cloned so far can
be found at the Hereditary Hearing Loss Home Page (see
http://dnalab-www.uia.ac.be/dnalab/hhh/).
The many different cell types in the inner ear and diverse range of genes shown to be
expressed in the inner ear demonstrate the heterogeneity underlying the genetic basis of
sensorineural deafness with estimates of over 100 genes involved in non-syndromic deafness
with an autosomal recessive mode of inheritance (Morton, 1991). Localisation of the genes
underlying NSHI initially proved difficult because in addition to the genetic heterogeneity of
deafness, many cases of prelingual NSHI show an autosomal recessive mode of inheritance
and assortative mating in the deaf community (where several deafness genes are introduced
into the one pedigree) and this genetic heterogeneity precludes pooling of families for
linkage studies.
The cloning ofNSHI genes was made possible mainly due to gene localisation studies that
were performed in large multigenerational inbred families from ethnically isolated regions.
The high degree of consanguinity in these families meant that the families were large enough
to generate significant LOD scores for linkage within a single pedigree. Ethnically isolated
families also lacked assortitive mating. A recent advance was the homozygosity mapping of
autosomal recessive deafness genes using small consanguineous multiplex families with >3
affected patients (Fukushima et al., 1995).
5.1.3 Cloning genes for non-syndromic deafness
Once a gene for non-syndromic hearing loss has been localised to a genomic region, several
strategies can be utilised to clone the relevant gene. It is advantageous to define the region
of interest by fine mapping so that the search for candidate genes can be focused and any
ESTs/genes mapping out with the defined interval rejected for further investigation. The
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construction of a physical map covering the genomic region of interest using genomic clones
such as YACs, BACs and PACs, allows sequence-tagged sites (STSs) including
microsatellite repeat polymorphisms and expressed sequenced tags (ESTs) to be located
conveniently by PCR screening. If the gene or EST content of the candidate region is
unknown, it is necessary to identify novel open reading frames and this can be carried out by
techniques such as cDNA selection, exon trapping or direct sequencing (see Chapter 3,
Section 3.1.3).
Genes and ESTs known to be in the candidate region must be prioritised for further
investigation. In the search for candidate non-syndromic deafness genes, it is useful to check
that the gene or EST is expressed in a cochlear cDNA library. It should be noted however
that the PAX3 gene, which encodes a transcription factor that underlies a syndromic form of
hearing loss called Waardenburg type 1/3 is not actually expressed in the ear at all, but in
adjacent structures such as the developing neural tube (Baldwin et al., 1995). Therefore one
should be cautious about discarding genes as candidates because they are not expressed in
the ear. Genes with functions similar to other genes that are known to play a role in the
pathogenesis of deafness are also good candidates for further investigation.
Identifying good candidate sensorineural deafness genes requires the knowledge of the
molecular interactions in the development and function of the inner ear. It is a highly
intricate structure (Figure 5.1) and many of the molecular mechanisms involved in hearing
are unknown or are just beginning to be understood (Steel & Brown, 1994). Briefly,
endolymph- and perilymph-filled channels course around the cochlea, the auditory sense
organ, and around the sacculus, utriculus and the three semicircular canals, which together
form the vestibular part of the inner ear that detects head position and movement and hence
aids balance. Several types of sensory epithelia form the auditory transduction apparatus of
the cochlear duct: the organ ofCorti; the maculae of the utricle and saccule; and the cristae
ampullae of the semicircular canals. These structures consist of a highly organised array of
supporting and sensory cells, the latter carrying a distinct bundle of actin-filled stiff
microvilli, called stereocilia, on their apical surface. The neuroepithelia are covered in an
acellular gelatinous membrane that can be displaced relative to the neuroepithelia by sound
or head movement. This displacement provokes a deflection of the sensory hair cell
stereociliary bundles, which in turn opens up the mechanotransduction channels located at
the tip of the stereocilia. It has been proposed that the tip link, a filamentous connection
attaching the tip of a stereocilium to the nearest taller stereocilium, is the gating spring for
opening transduction channels. The resultant influx of potassium, from the potassium rich
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endolymph through the mechanotransduction channels, alters the membrane potential, which
results in the release of a synaptic transmitter from the hair cell. On neurotransmitter release,
an afferent nerve fibre at the base of the hair cell transmits to the brain a patter ofaction
potentials encoding certain characteristics of the stimulus, such as intensity, frequency and
time course. This knowledge of the intricate structure of the inner ear and complex
molecular mechanisms that underlie hearing allow the ESTs/genes within the genomic
interval for which a non-syndromic hearing loss gene has been localised, to be prioritised for
further investigation. The next step is to clone and characterise the gene from which the EST
originated.
The full length cDNA sequence can be derived by searching DNA sequence databases such
as Genbank and constructing a cDNA contig covering the full length of the gene. If the
cDNA contig is incomplete, techniques such as 3' and 5' RACE (rapid amplification of
cDNA ends) can be used to produce the full length cDNA sequence. Once the full length
cDNA sequence for the candidate deafness gene has been ascertained, mutation screening of
the deafness patients with linkage to the correct genomic region can proceed in two ways.
Directly, by cDNA screening if the gene is illegitimately transcribed in lymphoblastoids cell
lines, or indirectly, by determining the genomic structure of the gene (see Section 5.3.2.3)
and making PCR primers from the DNA sequence flanking the exons in order to amplify the
individual exons. The search for mutations can be carried out using techniques such as
heteroduplex analysis (Cotton, 1993; Grompe, 1993) and/or single strand conformational
polymorphism analysis (Orita et al., 1989), complemented by direct sequencing. This allows
comparison of the gene sequence from deafness patients to that of the control population.
Once a nucleotide change has been identified, it must be studied to establish whether it
represents a benign polymorphism or a disease-causing mutation. Critical factors to consider
include the frequency of this change in the general population, its impact at the amino acid
level, the importance of the involved amino acid in the protein, especially cross-species, and,


















Outer ear canal Eustachian tube
Spiral ganglion
(a) The human outer, middle and inner ear. The outer ear canal leads to the tympanic
membrane (ear drum), and sound vibrations are transmitted from there to the inner
ear via the three middle ear ossicles, the malleus, incus and stapes. The stapes
inserts into the oval window at the base of the cochlea.
(b) One turn of the cochlear duct. During sound stimulation, the organ of Corti vibrates
and the sensory hair cells are stimulated by a shearing movement between the top
surface of the organ ofCorti and the tectorial membrane. Most afferent neurons
innervate inner hair cells (shown here on the left of the black pillar cells) and their
cell bodies form the main part of the spiral ganglion, which in turn leads to the
cochlear nerve. The three or more rows ofouter hair cells (to the right of the pillar
cells) receive primarily efferent innervation, and are believed to act as motor cells,
enhancing the response of the cochlea. The stria vascularis on the lateral wall of the
cochlea duct has a key role in generating the high resting endocochlear potential in
the endlymph that fills the scala media, and also controls the high K+ and low Na+
concentation in the endolymph. Scala vestibuli and scala tympani both contain
perilymph, a fluid that is much more like a normal extracellular fluid, with low K+
and high Na+ levels and no resting high resting potential. The stippled area
represents bone.
(c) A typical sensory hair cell. The actin-filled stereocilia are arranged in rows of
graded heights at the top of the hair cell. Tip links connect the shorter stereocilia to
the adjacent taller stereocilia, and it is the tip links that is thought to activate
transduction channels of the hair cell, leading to depolarization and initiation of
synaptic activity at the base of the cell.
Tectorial membrane
SlereoOlium
Figure 5.1 The structure of the ear. Figure adapted from Steel and Brown, 1994.
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5.1.4 Potential mouse homologues for non-syndromic hearing
impairment
An alternative method to identify potential human deafness loci is to identify genes
responsible for hearing loss in the mouse. The structure and development of the inner ear,
and the pathology leading to hearing impairment is very similar between mice and humans
(Steel & Brown, 1994) therefore the mouse is a good model animal for the study of deafness.
In fact it was the genetic analysis of both Snell's waltzer and shaker-1 mice that identified
the role of unconventional myosin genes found to underlie deafness in mice and humans
(Hasson, 1997); see Section 5.3.1.2. With over 60 mouse mutations having been mapped in
the mouse genome that cause abnormalities in the inner ear, the identification and analysis of
these genes should provide an extremely useful insight into the pathology leading to
deafness. Further more, the identification of human homologues to these mouse genes will
provide new candidate genes for the study of human hearing impairment.
5.1.5 Aim
This chapter describes the search for candidate DFNB9 genes. During this search, three
genes were identified as candidate DFNB9 genes: MPV17, KIF3C, and KCNK3. These
genes all map close to, or within the DFNB9 interval on human chromosome 2p23 and
encode proteins with potentially important functions within the inner ear. One other gene
called CRMP1 was identified as a potential deafness gene although mapping data ruled out
this gene as a candidate DFNB9 gene. Briefly, investigation of these genes involved
mutational analysis ofMPV17, cloning and characterisation of K1F3C, and mapping of
KCNK3 and CRMP1.
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5.2 The MPV17 gene
5.2.1 Introduction
5.2.1.1 Mpv17- a candidate kidney disease and deafness gene
TheMpvl7 gene was first identified during an experiment to produce transgenic mouse
strains by defective retrovirus insertion into the germline (Weiher et al., 1990). Mice
homozygous for one of the integrations were found to develop a phenotype of
glomerulosclerosis at age of three months or older and die later as a consequence of renal
failure. TheMpvl 7 gene was identified at the integration site and its expression was found
to be completely abolished in the homozygous mice (Weiher et al., 1990) thus implying
Mpvl 7 to be a recessive kidney disease gene.
Further study of theMpvl 7 (-/-) mice was performed by examining the inner ear. This work
was carried out because the kidney and the inner ear are known to both have specialised
epithelia involved in active ion transport (Mizuta et al., 1995). Other links between the
kidney and inner ear are suggested by numerous drugs that have both nephrotoxic and
ototoxic side effects (Begg & Barclay, 1995), and congenital anomalies exist that can cause
lesions in both organs (Bergstrom et al., 1979). Electron microscopic investigations
performed on the inner ears ofMpvl 7 (-/-) mice revealed degeneration of the stria vascularis
and spiral ligament, loss of cochlear neurons and degeneration of the organ ofCorti (Meyer
zum Gottesberge et al., 1996). These alterations observed were similar to those described for
Alport's syndrome, which is a hereditary kidney disorder associated with deafness (Alport,
1927). In Alport's syndrome, it is mutations in the basement membrane collagen genes
COL4A3, COL4A4 and COL4A5 which are mainly found in the basilar membrane, parts of
the spiral ligament, and stria vascularis that underlie the sensorineural hearing loss (Barker et
al., 1990; Mochizuki et al., 1994). Although the mechanism ofhearing loss is unknown, in
the glomerulus there is focal thinning of the basement membrane. The observation of similar
abnormalities in the inner ear of theMpvl 7 (-/-) mouse means that this mutant mouse was a
valuable genetic model for both renal disorders and deafness.
In contrast to transgenic mouse or rat models where the disorder phenotype is induced by
expression of a foreign transgene (Dressier et al., 1993; Kopp et al., 1992), theMpvl7 (-/-)
mouse defines an endogenous gene whose loss of function correlates with the phenotype. At
first it could not be excluded that a second gene distinct from theMpvl 7 gene was also
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affected by the retrovirus insertion and that the non-function of the second gene was causing
theMpvl 7 homozygous phenotype. However in a later experiment, the functional rescue of
the glomerulosclerosis phenotype in the Mpvl 7 (-/-) mice by transgenesis with the human
MPV17 homologue (Schenkel et al., 1995) proved definitively that mutation of the Mpvl 7
gene led to kidney disease. However, there was inconclusive evidence for the rescue of the
deafness phenotype (Schenkel, personal communication).
Mapping ofMpvl 7 andMPVI7 added further circumstantial support to the evidence for
MPV17 as a candidate deafness gene. The Mpvl 7 gene mapped in mice to chromosome 5
and in humans to the region of conserved synteny on chromosome 2p21-23 (Karasawa et al.,
1993). The studies described in Chapter 2 further showed thatMPV17 in fact maps within
the KHK-GCKR contig. The mapping of a sensorineural non-syndromic recessive deafness
gene (DFNB9) to the same region on chromosome 2p22-23 (Chaib et al., 1996) made
MPV17 an excellent candidate DFNB9 gene and thus warranted further investigation.
5.2.1.2 The MPV17gene
Both humanMPVI7 and mouseMpvl 7 encode a 176 amino acid protein. Comparison of the
two amino acid sequences reveals 92% identity, corresponding to 14 amino acid differences
(Karasawa et al., 1993; Weiher et al., 1990). One feature of the mouseMpvl 7 gene is the
presence of a B1 and B2 repetitive element located in the 3'UTR (no repeat elements are
found in the humanMPVI7 gene 3'UTR). The determination of theMPV17 genomic
structure reveals it to contain 8 exons and 7 introns with the exon sizes varying in size from
24 bp to 484 bp and the introns varying in size from 0.09 kb to 5.3 kb. The start codon was
found to be located within exon 2 and the termination codon within exon 8.
With the establishment of the intron-exon junction sequences, primers were designed within
the intron sequences (Karasawa et al., 1993), allowing PCR amplification of the protein
coding regions from human genomic DNA from blood samples or biopsy material. This
would enable the screening of the MPV17 gene in patients with renal disorders and/or
deafness by PCR and subsequent analysis by sequencing or SSCP analysis.
Several cases of familial glomerulosclerosis have been screened for mutations inMPVI7,
including patients suffering from congenital nephrotic syndrome of the Finnish type (CNF),
a recessive disorder present in the Finnish population. Mutation screening ofMPV17 in
individuals with CNF revealed no alterations within the MPV17 gene (Schenkel et al., 1995)
At around the same time, analysis ofCNF families (CNF is now called Nephrosis-1,
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NPHS1), mapped the gene underlying NPHS1 to chromosome 19ql3.1 (Kestila et al., 1994).
This gene was later cloned and named "nephrin" (Kestila et al., 1998). TheMPV17 gene
remains a good candidate gene for renal disorders. Furthermore, screening of deafness
patients for alterations within theMPVI7 gene has not been reported, thereforeMPV17
cannot be ruled out as a candidate gene for deafness.
5.2.1.3 Function of MPV17
When theMpvl 7 gene was first cloned in the mouse, it was noticed that two hydrophobic
regions were present that suggested that the protein may be membrane associated although
both regions did not constitute a typical transmembrane domain (Weiher et al., 1990). At this
point there was no information concerning the Mpvl7 function but an EMBL database
search revealed significant similarity to the peroxisomal membrane protein Pmp22 (Kaldi et
al., 1993). The rat Pmp22 protein was found to be identical to Mpvl7 in >25% of all
positions and although Pmp22 andMpvl 7 are not orthologues, the amino acid sequence
similarity hinted thatMpvl7 might also be a peroxisomal protein.
The investigation ofMpvl 7 subcellular localisation was performed by raising antibodies to
bacterially producedMpvl 7 proteins, followed by the use of immunofluorescence
techniques (Zwacka et al., 1994). This study showedMpvl7 to co-localise with catalase, a
marker for peroxisomal localisation. Thus, Mpvl7 is indeed a peroxisomal protein.
The peroxisomes are small, membrane limited cytoplasmic organelles that contain enzymes
that degrade fatty acids and amino acids, generating ATP and heat by catabolism. A
by-product of these reactions is hydrogen peroxide, a corrosive substance that oxidises many
amino acid side-chains. To counter the potentially harmful effects of the hydrogen peroxide,
peroxisomes also contain copious amounts of the enzyme catalase, which degrades hydrogen
peroxide to water and oxygen. The localisation ofMpvl 7 to the peroxisomes represents a
novel link between the peroxisome and glomerular disease.
Examination of the peroxisomes inMpvl 7 (-/-) mice revealed that there was no structural
abnormality, no deficiency in enzymic activity and no change in membrane permeability
(Zwacka et al., 1994). As the peroxisomes are a site of detoxification of 02" radicals and
peroxides, the intermediates of these pathways were investigated in mutant and normal cells.
The production of 02~ radicals and other reactive oxygen species (ROS) was measured in
primary skin fibroblasts from mutant and non-mutant mice by loading the cells with
hydroethidine which reacts with the ROS to form the fluorescent dye ethidium. The
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intracellular ROS was measured by FACS (fluorescent activated cell sorting) analysis and
this revealed that loss ofMpvl7 protein led to a reduced ability to produce ROS. The
evidence suggests a beneficial effect ofROS production on glomerular function.
To test whetherMpvl7 has a direct involvement in ROS production, overproduction of the
Mpvl7 transcript in transfected 3T3 murine fibroblast cells was investigated (Zwacka et al.,
1994). This resulted in dramatically enhanced levels of intracellular ROS and indicated that
Mpvl7 is either directly involved in cellular ROS production or at least accomplishes a
rate-limiting step in the process. Widespread expression of theMpvl7 gene (Weiher et al.,
1990) contrasts with the apparent specific kidney and inner ear phenotype, and suggests that
lack ofMpvl 7 expression might alter the regulation of other genes leading to theMpvl 7 (-/-)
phenotype. As both the kidney and inner ear show morphological defects in the basement
membrane, the Mpvl7 protein might play an important role in a regulatory mechanism of
enzymes involved in basement membrane metabolism.
The matrix metalloproteinase 2 (MMP-2) protein plays a critical role in the basement
membrane turnover within the glomerulus and this led to the study of this protein inMpvl 7
(-/-) mice. A direct relationship betweenMpvl7 and MMP-2 was found in theMpvl 7 (-/-)
mice in which there was over-expression ofMMP-2 at both mRNA and protein level (Reuter
et al., 1998). Moreover, when the humanMPV17 gene was introduced into Mpvl 7-negative
cells, MMP-2 expression was repressed. This suggests that MMP-2 is likely to be a common
mediator ofboth glomerulosclerosis and deafness. However, the molecular mechanism by
whichMpvl 7 expression controls MMP-2 is unknown. This mechanism maybe complex as it
was also found that the transcription factor c-jun expression paralleled theMMP-2
expression and that there was stronger expression of the tissue-specific inhibitor of
metalloproteinase 2 (TIMP-2) in thqMpvl 7 negative tissue culture cells (Reuter et al., 1998).
5.2.1.4 Aim
The MPV17 gene is an excellent candidate gene for kidney disease and deafness. This
section describes the screening for mutations/polymorphisms in the MPV17 gene from two
patients with both glomerulosclerosis and deafness, and a further glomerulosclerosis patient.
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5.2.2 Methods
5.2.2.1 Mapping of MPV17
The gene encoding MPV17 was localised to the GCKR-KHK genomic region by PCR
screening the YAC, PAC and cosmid contig (see Chapter 3, Figure 3.8) using the primers
designed to amplify exons 4-5 (Table 5.1).
5.2.2.2 PCR amplification of MPV17 coding region
Six primer pairs (see Table 5.1) designed from theMPV17 intronic sequence (Karasawa et
al., 1993) were used for exon amplification from patient DNA using standard PCR
conditions and a hot start PCR program: 5 min 94°C; 40x(94°C, 1 min; X°C, 1 min; 72°C, 2
min). The PCR products ranged in size from 160 to 448 nucleotides and were sequenced on








1 dGGGTCTCTCACAGAGTGGGTG 55 233
dGTGGGCACTCATGGCTTCGAC
2 dCTTATCGTGGAGAGGGACGGT 55 206
dAGGAAGTGAGGGCGGCGCAG
3 dTGTCCCTCCCTCCTTGAATGG 55 240
dGAACTAAGACCACTGTTGAGC
4-5 dGATACTTGGGGCAGGGAGCTT 58 426
dAGCCCGCCAGCCAGAGACATT
6-7 dCGCAAGTGTTAATTTGTTCCT 55 402
dTTTGTCTCCAACTGTTGGTAA
8 dATCTCCAGCCCTTGCTCACTG 58 160
dAAACGATGGAGTGAGGCAGG
Table 5.1 Primers and annealing temperatures for MPV17 exon amplification. Expected
size for each PCR product is indicated. The second exon 8 primer was designed within the
3'UTR so that only the protein coding region of exon 8 was amplified.
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5.2.3 Results
5.2.3.1 Isolation of genomic clones
PCR screening and sequence analysis of genomic clones map MPV17 to YACs 26BA11 and
29IH8, BAC NH0538J11, the PAC 13L13, and cosmid B2 (see Figure 5.2, and Chapter 3,
Figure 3.8). More detailed PCR analysis of the YAC 26BA11 and the YAC 26BA11 cosmid
subclone B2 using the primer pairs shown in Table 5.1, reveal that MPVI7 exons 1 to 5 are
present and exons 6-8 are missing. Although a YAC contig spanning this genomic region
using YACs 26BA11, 29IH8, 3AG3, and 18AG7, had previously been constructed by
Hayward et al, 1996, STS content analysis revealed that it was not possible to assemble an
internally consistent contig (Chapter 3, Figure 3.1, discussed in Section 3.1.2.1).
The identification ofPAC 13L13 and BAC NH0538J11, that both contain MPV17, and the
construction of a complete physical contig at the GCKR-KHK interval (Chapter 3, Figure
3.8), shows that the inconsistency in the original YAC contig was due to a deletion in YAC
26BA11. This deletion starts from nearMPV17 exon five and includes the KHK gene. A
simplified contig of the GCKR-KHK interval is shown in Figure 5.2. Mapping ofMPV17
places this gene within the GCKR-KHK interval, -300 kb from GCKR. The construction of
a detailed cosmid contig (described in Chapter 3), added to the discovery thatMPV17 exons
6 to 8 are absent from YAC 26BA11 and cosmid B2, reveals that the MPV17 gene is in the
opposite orientation to GCKR and MPV17.
5.2.3.2 Mutation screening
The 8 exons fromMPVI7 were PCR amplified from genomic DNA from two patients with
both glomerulosclerosis and deafness, and a further glomerulosclerosis patient.. Each PCR
product was sequenced in both directions and the exon sequences generated compared to the
publishedMPV17 sequence. No differences were found within the coding region of the
patient MPV17 gene to that of the published sequence. This suggests that mutations in the












Figure 5.2 Co-localisation ofMPV17 with GCKR and KHK. The arrows represent genes,
gene orientation (5'to 3') is indicated by the arrow direction. Genomic clones containing
MPV17 are indicated above the EIF2B4 arrow. This diagram is a simplified version of
Figure 3.8 shown in Chapter 3.
151
5.2.4 Discussion
5.2.4.1 The role of MPV17 in glomerulosclerosis and deafness
Screening the coding region ofMPVI7 and the 5TJTR (exon 1) from patients with
glomerulosclerosis and/or deafness revealed no mutations or polymorphisms. This suggests
that in these patients, MPV17 is unlikely to play a causal role in glomerulosclerosis or
deafness. Further screening of patients with kidney disease and/or deafness who show
linkage to chromosome 2p21-23 region should be carried out before this gene can be fully
ruled out from involvement in the pathogenesis of glomerulosclerosis and deafness in
humans. Even if further screening reveals no mutations, theMPV17 gene will remain an
interesting candidate gene for glomerulosclerosis and deafness. Further study ofMPV17
function will provide an important insight into the molecular interactions in the kidney and
inner ear, and may help in understanding the mechanisms underlying the development of
both glumerulosclerosis and deafness.
5.2.4.2 Another gene located upstream of MPV17
The cloning of the mouse and human urocortin genes (Ucn and UCN) and characterisation of
their genomic locations led to the discovery that the Mpvl 7 gene is located adjacent to both
mouse and human urocortin genes in the 5' upstream region (Donaldson et al., 1996; Zhao et
al., 1998). The identification of theMpvl7 gene approximately 2.1 and 1.3 kb upstream of
exon 1 of the Ucn and UCN genes respectively, and transcription in the same orientation
raises the possibility that expression of Ucn is also disrupted in theMpvl 7 (-/-) mice. If the
retroviral insertion affected bothMpvl 7 and Ucn, it is possible that disruption of Ucn
contributes to theMpvl 7 (-/-) mouse phenotype.
Although the glomerulosclerosis and deafness phenotype in Mpvl 7 (-/-) mice was rescued by
transgenesis with the humanMpvl 7 homologue (Schenkel et al., 1995), it is unknown
whether the other accompanying aspects of the phenotype were rescued. Other aspects of
theMpvl 7 (-/-) phenotype include hypertension, and visible symptoms such as inactivity,
weight loss and pallor.
The neuroregulator function ofurocortin lends itself to an intriguing role in the other aspects
of theMpvl 7 (-/-) mouse phenotype. The urocortin is a member of the
corticotropin-releasing hormone family that plays a role in the mammalian stress response
and is related to fish urotensin and corticotropin-releasing factor (CRF) (Vaughan et al.,
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1995). The actions ofCRF and related peptides are mediated by seven transmembrane
domain G-protein-coupled receptors (CRF-Rs). Synthetic urocortin has been shown to have
potent biological actions on biological events mediated by both CRF-R1 (stimulation of
pituitary ACTH release, increase in arousal and anxiety) and CRF-R2 (vasodilation
(Vaughan et al., 1995), cardiac ionotropism (Parkes et al., 1997), reduction of vascular
permeability (Turnbull et al., 1996) and suppression of appetite (Spina et al., 1996)). The
specific involvement ofurocortin in these biological processes suggests possible links to the
hypertension, weight loss and inactivity ofMpv (-/-) mice, perhaps as a result of diminished
Ucn expression. For the elucidation of any urocortin role in theMpvl 7 (-/-) mouse
phenotype, extensive study of the Ucn expression in the Mpvl 7 (-/-) mouse must be carried
out.
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5.3 The KIF3C gene
5.3.1 Introduction
5.3.1.1 Identification of an EST showing similarity to KIF3B
The examination ofESTs that map to the DFNB9 interval on chromosome 2p23 revealed the
presence of an EST (stSG4510, designed from the cDNA clone Genbank accession number
R43988) that shows similarity to the KIF3B gene, a member of the kinesin family. Sequence
comparison of this EST with KIF3B reveals 52% identity at the nucleotide level (see Figure
5.3). Kinesins are microtubule-based motor proteins and share a similar function to the
myosins, actin-based motor proteins. Unconventional myosin genes underlie some forms of
syndromic and non-syndromic hearing impairment (discussed in Section 5.3.1.2).
Furthermore, it has been shown that a kinesin protein can suppress a myosin defect in yeast
(Lillie & Brown, 1992), (discussed in Section 5.3.1.3). This information suggested that the
novel kinesin-like EST that maps to the DFNB9 interval was a good candidate deafness gene
for further investigation.
R4 3 9 8 8 GTAGAAATTTACTTATC—ACTTGAGATACCTAGAGACATTTTGGGCCATCACAAAGGAA 71
KIF3B GCTGAAACTCAAGCATCTTATTATAGAAAACTTTATCCCTCTGGA AGAAAAAAGTAA 1960
R43988 GGTAAGGAGTATCCCCCT AGGAACCAATTTGCGTAACTAGTGAATAAAG 120
KIF3B AATTATGAATAGAGCCTTCTTTGATGAAGAGGAAGATCATTG-GAAACTACATCCTATAA 2 019
R43988 GATCTATTGTCAACAAAATAATACCTTAAAGATGCAATTCAGAAACAGGGG TAACAG 177
KIF3B CCAGACTGGAGAACCAGC—AGATGATGAAGCGGCCAGTCTCAGCCGTGGGATATAAGAG 2077
R4 3 9 8 8 GCAA AGCTGGNAA—AAGATTGTGCCTGGGCTTCTGTTTCCTGTGACAGATGAAGGG 232
KIF3B ACCATTGAGCCAGCACGCAAGAATGTCCATGATGATTCGTC-CAGAGGCCCGATACAGGG 213 6






Figure 5.3 Sequence comparison ofEST R43988 sequence with KIF3B (Genbank accession
number NM_004798). Numbering refers to database entry numbering.
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5.3.1.2 Role of unconventional myosin genes in non-syndromic hearing
impairment
Myosins are molecular motors that use the energy from ATP hydrolysis to generate force
and move along actin filaments (Mooseker & Cheney, 1995). Whereas conventional
myosin, or myosin 2, has the specialised ability to form bipolar filaments that form an
essential component for the process ofmuscle contraction, unconventional myosins are
non-filament forming (Hasson, 1997). Unconventional myosins are primarily found within
non-muscle cells, share structurally conserved heads (the motor domain), and have divergent
tails presumably to move different macromolecular structures relative to actin filaments.
Phylogenetic analysis of the conserved head domain allow the myosin protein family to be
divided up into 15 classes, 9 of which are present in mammals (reviewed in Sellers, 2000).
These nine classes (1-7, 9, 10, and 15) can contain multiple members and to date, 26
different myosin genes (10 conventional and 16 unconventional) have been identified.
In addition to the motor domain, myosins contain regulatory or light-chain-binding domains
and distinctive C-terminal tail domains. In the unconventional myosins studied so far, the
regulatory domain has served as a binding site for calcium binding proteins such as
calmodulin, which have been shown to regulate the motor activity in a calcium-dependent
fashion (Houdusse et al., 1996). The tail domain is unique to each myosin, functioning in
protein-protein, protein-membrane interactions, dimerisation and subcellular targeting
(Bement et al., 1994). One of the functions ofunconventional myosins is to transport cargo
within the cell and it is the tail domain that is thought to bind vesicles containing the cargo
(Prekeris & Terrian, 1997).
The involvement of unconventional myosins in the pathogenesis of deafness was first
demonstrated by the analysis ofmice with hearing impairment. Both Snell's waltzer and
shaker-1 mice (Deol, 1956; Mikaelin, 1964) exhibit head tossing, hyperactivity and circling
behaviour, which are due to vestibular dysfunction, and rapid progressive hearing loss
accompanied by neuroepithelial degeneration (Deol & Green, 1966; Green, 1960).
Positional cloning techniques revealed that both these mouse phenotypes were caused by
mutations in two unconventional myosin genes. The deafness genes Myo6 (Avraham et al.,
1995)andMyo7a (Gibson et al., 1995) were identified in the Snell's mouse and in the
shaker-1 mouse, respectively. Although both these genes are expressed in the inner ear, their
exact function is unknown.
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Recent research has shown that unconventional myosins are expressed in the stereocilia of
hair cells, the sensory cells of the inner ear (Hasson et al., 1995). Stereocilia are actin-based
projections on the apical surface of hair cells, which are required to convert mechanical
forces such as sound waves and gravity into electrical signals (Figure 5.1 (c)). A specialised
linkage, the tip link, joins the tip of the shorter stereocilia to the adjacent taller stereocilia to
form a stereocilium bundle. Stretching of this linkage on bundle deflection leads to the
opening or closing of stretch-gated transduction channels. Opening of transduction channels
causes an influx of endolymphatic K and Ca2+ ions, which leads to depolarisation of the hair
cell and neurotransmitter release. After opening, the channels are reset, in a process termed
"adaptation", whereby the tension on the tip link is modulated by movement of the
transduction apparatus up or down the actin filaments of the stereocilium. It has been
suggested that both myosin 6 and myosin 7a are components of the adaptation motor
(Avraham et al., 1995; Hasson et al., 1995).
Recent studies of the inner ear epithelia by indirect immunofluorescence and
immuno-electron microscopy techniques have suggested that it is another unconventional
myosin, myosin 1 (1, that is a better candidate for the adaptation motor and thatmyosin 6 and
myosin 7a perform other functions in the inner ear (Hasson et al., 1997). Myosin 1 (3 protein
was found to be enriched at the tips of the stereocilia, the site of the adaptation process and
myosin 7a was found along the length of the stereocilia associating with the linkages that
join adjacent stereocilia to their neighbours. However, myosin 6 was found outwith the
stereocilium and located in the cuticular plate, an actin rich region below the stereocilium
bundle in the apical domain of the hair cell (Hasson et al., 1997). The location of the
unconventional myosins lb, 7a, and 6 in the hair cell and stereocilium of the inner ear is
summarised in Figure 5.4.
It is thought that myosin 6 plays a role in anchoring the stereocilia bundle into the cuticular
plate. In addition, all three unconventional myosins were localised to a new subcellular
domain of the hair cell, termed the "pericuticular necklace" (Hasson et al., 1997). Found
between the zona adherens and the cuticular plate, the pericuticular necklace is rich in
membrane vesicles and is the site ofmicrotubule ends. It has been suggested that the
pericuticular necklace may represent a release point for vesicles carrying cargo such as
myosins in transit between the microtubule arrays in the cell body and the actin arrays in
either the cuticular plate or stereocilium. Both myosin 6 andmyosin 7a are implicated in
membrane trafficking, so, perhaps it is these actin based movements that are truly essential
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Figure 5.4 Location of unconventional myosins (myosins lb, 7a, and 6) in the hair cell and
stereocilium of the inner ear.
So far, the screening of unconventional myosin genes in humans with non-syndromic
hearing impairment has implicated two myosin genes: MY07A as the gene corresponding to
both the recessive DFNB2 and dominant DFNA11 loci (Liu et al., 1997), and MY015 at the
DFNB3 locus (Wang et al., 1998). The MY07A gene has also been determined to be
responsible for Usher syndrome Type lb, a recessively inherited disease characterised by
congenital deafness, vestibular dysfunction and retinitis pigmentosa (Weil et al., 1995).
There are three other unconventional myosins that are candidates for human deafness genes,
the recently clonedMY06 and myosin ip (MYOIC) genes, and myosin ID (MYOIF).
While MY06 does not map to any previously identified human deafness loci, MYOIC does
map to the DFNB3 interval and MYOIF potentially maps to the DFNB15 locus. The cloning
ofnew unconventional myosin genes will undoubtedly provide more candidates for deafness
genes.
5.3.1.3 Suppression of a myosin defect by a kinesin-related gene
Yeast studies revealed that the SMY1 gene, a member of the kinesin superfamily (see Section
5.3.1.4), when present at high-copy number would suppress the defects in a temperature-
sensitive myosin mutant (myo2-66) in S. cerevisiae (Lillie & Brown, 1992). At the
restrictive temperature the myo2-66mutation does not impair DNA, RNA, or protein
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biosynthetic activity, but produces unbudded, enlarged cells (Johnston et ah, 1991). In an
experiment to look for "multicopy suppressors" for the myo2-66 mutant phenotype, that is,
heterologous genes that, when over expressed, could correct the temperature sensitivity of
the myo2-66 mutant, one suppressor was identified (SMY1). This gene encoded a predicted
polypeptide sharing sequence similarity with the motor portion of proteins in the kinesin
superfamily. In SMY1 deletion mutants, no obvious defects were observed, therefore the
function of Smylp must either be redundant or non-essential under the conditions used.
However, a cross of the myo2-66 mutant with the SMY1 deletion mutant produced no live
double mutants. This "synthetic lethality" was evidence that Smylp, a putative microtubule
based motor, can interact or substitute forMyo2p, a putative actin based motor. The exact
function ofMyo2p is unknown, but Yeast studies involving the temperature-sensitive
mutation (myo2-66) have implicated the Myo2 protein (Myo2p) in the process ofpolarised
secretion in S. cerevisiae (Johnston et al., 1991). Possible functions that have been suggested
include that Myo2p could organise or stabilise the actin cytoskeleton, or that Myo2p attaches
to secretory vesicles and carries them along actin filaments to the bud (Johnston et al., 1991;
Lillie & Brown, 1992). If the Myo2p mutant causes a defect in vesicle transport, the Smylp
might correct this by carrying the vesicles along microtubules. However this is unlikely as it
has been demonstrated in yeast that microtubules are not required for delivery of secretory
vesicles to the bud, nor do they substitute in actin mutants. One possibility might be that the
microtubules could normally provide a minor pathway that could compensate for a partial
defect in myosin at the nominally permissive temperature. Such transport of vesicles along
microtubules by Smylp would represent the first clear-cut example of functional redundancy
between actin and microtubules. Another possibility is that Smylp suppresses the myosin
defect by carrying vesicles along actin filaments. Again this seems unlikely, given the
sequence similarity of Smylp to kinesin.
Analysis of the microtubule interaction site of a kinesin motor using alanine-scanning
mutagenesis, reveals that the microtubule-interacting residues are located in three loops that
cluster in a patch on the motor surface (Woehlke et ah, 1997). Crystallographic studies have
also shown that the core of the microtubule-binding interface corresponds topologically to
the major actin-binding domain ofmyosin. The nucleotide binding pockets of kinesin and
myosin also show similarity to the corresponding region ofG proteins, a group of "molecular
switches" that exhibit nucleotide-dependent binding interactions with a variety of target
proteins (Sack et ah, 1999). This evidence suggests that kinesin and myosin and possibly G
proteins evolved from a common ancestral protein. The similarity between the kinesin and
myosin binding sites for microtubules and actin respectively may support the idea that there
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could be some functional redundancy between kinesin like proteins and myosins, for
example Myo2p and Smylp.
To summarise, the kinesin-like gene located on chromosome 2p23.3 can be considered a
good candidate deafness gene because l)defects in othermolecularmotor proteins have been
shown to play a role in the pathogenesis of hearing impairment, 2) both kinesins and atypical
myosins have an intraneuronal transport function, and 3) genetic defects in some atypical
myosins and kinesins can cross-complement in yeast (Lillie & Brown, 1992).
5.3.1.4 The kinesin superfamily
The kinesin superfamily was defined by the motor protein kinesin, which was first found in
the axoplasm of squid where it is thought to play a role in axonal transport (Brady, 1985;
Vale et al., 1985). Subsequent research has shown that kinesin is but one member of an
extended superfamily ofmicrotubule motor proteins that all share in common a motor
domain of approximately 350 amino acids (for either anterograde or retrograde transport), a
putative ATP-binding site and a microtubule-binding site.
Characterisation of the kinesin superfamily first began with a systematic search for novel,
putative motors for organelle transport by cloning and sequencing cDNAs encoding both
ATP-binding and microtubule-binding consensus sequences homologous to the kinesin
heavy chain domain from a murine cDNA library (Aizawa et al., 1992). Three types of
kinesin superfamily proteins (KIFs) have been defined: N-terminal-motor-domain type, such
as KIF1, KIF3, K1F4, KIF5, central-motor-domain type, such as KIF2, and
C-terminal-motor-domain type such as KIFC1, KIFC2 and KIFC3 (reviewed in Goldstein,
1993). The kinesin superfamily manage to carry out a wide range of functions by
differences in its members' direction of transport, velocity, tissue expression and type of
organelle transported. It has also been found that while some KIFs can function as
monomeric motors (KIF1A and KIF1B), others work as homodimers (kinesin, KIF2, KIF4,
and KIF5), and heterodimeric motors (KIF3A and KIF3B) with associated proteins, for
example KAP3. Further research is required to understand how these changes in
configuration might alter function but it has been suggested that changes in KIF
configuration may be important in determining the nature of the cargo and rate of organelle
transport.
While tissue expression can give an indication ofKIF function, the identification of the
cargo transported by the KIFs is required for a better understanding of their cellular function.
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Binding domains unique for each individual KIF protein are thought to specify the type of
cargo they attach to, for example organelles like mitochondria and vesicles. Working out
KIF function will depend on identification of their cargoes and in the case of vesicles, what
they carry within. This can be carried out by subcellular fractionation and
immunoprecipitation experiments. Additional functional information can be obtained by
using antisense oligonucleotides to suppress expression of individual KIF in cell cultures
(Ferreira et al., 1992), microinjection of blocking antibodies in other cell types, and
"knock-in" and "knock-out" mouse mutants, including the introduction of point mutations
within binding domains of the KIF protein. The effects on cellular morphology can be
examined and the KIF function deduced.
In understanding the function ofKIFs, the issue of functional redundancy must be
considered. One clear example of functional redundancy is shown between the kinesin
superfamily CIN8 and KIP1 genes in S. cerevisiae. Deletion of either gene causes little or no
phenotype on its own, but the double mutant is lethal (Hoyt et al., 1992; Roof et al., 1992).
This situation becomes even more complex when KAR3 mutations are introduced, which
suppress the CIN8 KIP1 abnormalities (Hoyt et al., 1993).
Direct redundancy might involve two different motors attaching to, and moving the same
cargo to the same destination. "Bypass redundancy" might involve a logic similar to that of
metabolic pathways or bypass suppressors. Bypass redundancy could occur ifmore than one
pathway or movement could achieve the same outcome as far as the cell is concerned. If the
cargo and destination for each motor can be ascertained, exploitation of functional
redundancy could become very useful as a treatment for diseases caused by a malfunctioning
KIF. By switching on an alternative pathway, it may be possible to bypass a faulty gene
product and therefore restore the healthy phenotype. In the analysis of disease phenotypes, it
should be considered that the phenotype exhibited in each tissue could be dependent on gene
expression for that tissue and whether there is any functional redundancy between the
proteins that are present in each different tissue. Why eukaryotes have functional
redundancy is unknown but in the case of yeast, it may give an evolutionary advantage for
survival in certain extreme environmental conditions (Thomas, 1993). In complex
organisms, the movement of organelles for specialised cellular functions for example in the
human inner ear, might require many different KIFs and although there is some functional
redundancy, each KIF may retain its own specialised function.
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Although much progress has been made recently concerning how KIFs generate directional
force from the chemical energy in ATP, there is still much to learn about what dictates how
any specific individual cargo is transported to a specific destination and the mechanisms
controlling the bidirectional transport of organelles by KIFs within the cell.
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5.3.2 Methods
5.3.2.1 cDNA cloning and sequencing
Two strategies were employed to obtain the full length KIF3C cDNA sequence:
1/ The EMBL and Genbank DNA sequence databases were searched using the EST sequence
from IMAGE cDNA clone 28784 (Lennon et al., 1996) that contained stSG4150 (Genbank
accession number R43988), to look for overlapping cDNA clones. This process was
continued until no new overlapping clones were found. The longer cDNA clones that
spanned the whole cDNA contig were chosen for sequencing on both DNA strands (IMAGE
clone numbers 261794, 261794, and 28784).
2/ Oligonucleotides were designed from the sequence of IMAGE clone 28784
(5'-dGGAGATCCAGGACCAGCATG-3' and 5'-dGCTTGTCCAATCGCATGAGCC-3')
and a 442 bp cDNA probe (corresponding to nucleotides 1953 to 2394 of human K1F3C;
Figure 5.6) was amplified by PCR, radiolabeled using a random primer DNA labelling kit
(Boehringer) and used to screen a human fetal brain cDNA library (Clontech). Sequence
analysis of a clone containing a 4 kb insert revealed the cDNA to be a hybrid of an unrelated
human sequence fused to a kinesin-like open reading frame (Figure 5.6, nucleotides
874-2320). To determine the 5' end of the KIF3C cDNA sequence, the method ofRACE
amplification was used -see Chapter 6, Section 6.2.3.3.
The products of 5' RACE reactions were analysed by Southern blot hybridisation with
"P-labelled primer (5'-dGGAGAGAGGCCTAAGGAAG-3'; Figure 5.6, nucleotides
1003-1021) and an 820 bp product was cloned into the TA vector (Invitrogen) and
sequenced with vector- and kinesin-specific oligonucleotide primers. Multiple PCR-derived
cDNA clones were used to check for errors in the nucleotide sequence produced by
amplification procedures. The remaining 357 bp from the 5' end and 1181 bp from the
3'-end of the gene were sequenced from PAC genomic DNA. DNA sequencing was
performed on both strands of cloned cDNA using either the Thermosequenase cycle
sequencing kit (Amersham) or AmpliTaq cycle sequencing kit (Perkin Elmer) and the ABI
Prism 377 DNA sequencer.
The BLAST algorithm (Altschul et al., 1990) was used to search for homologies or identities
between sequences identified and sequences entered in the Genbank database. The cDNA
sequence has been submitted to Genbank and assigned the accession number AF035621.
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5.3.2.2 Isolation of genomic clones
The stSG4150 primer pair (5'-dCCTAGAGACATTTGGGCCA-3' and
5'-dTTGCCTGTTACCCCTGTTTC-3'; Figure 5.6, nucleotides 3678-3697 and 3557-3576
respectively) was used to PCR screen the ICIYAC genomic library (Anand et al., 1990) and
the PAC human genomic library RPCI1 (obtained from the HGMP Resource Centre,
Hinxton, U.K.). Standard PCR conditions were used (1.5 mM MgCl2) with the hot start PCR
program 94°C, 5min; 40 x (94°C,45 s; 58°C,45 s; 72°C, 1 min). Four positive genomic
clones containing KIF3C were obtained: two YAC clones 14IC3 and 35FIB12 and the two
PAC clones 14H17 and 97K3.
5.3.2.3 Structural analysis
To determine the K1F3C genomic structure, oligonucleotides were designed from the cDNA
contig and used to sequence directly from the PAC clones 14H17 and 97K3. The
exon-intron boundaries were sequenced across from both directions and the exact junctions
determined by comparison of the cDNA sequence to the genomic sequence and looking for
the exon-intron consensus sequence. Sizes of introns were determined by amplification
across each intron using PAC genomic DNA as template and primers located within adjacent
exons. The fragments amplified were analysed on a 1.5 % agarose gel and sized against a
GibcoBRL 1 kb DNA ladder. Genomic sequences have been submitted to the EMBL
sequence database and assigned accession numbers AJ002223-AJ002229.
5.3.2.4 Interspecific backcross mapping
To determine the location of the mouse Kif3c gene, linkage analysis was performed using the
Jackson laboratory interspecific backcross panel - see Chapter 2, Section 2.1.6 for more
information about this backcross panel. Searching of the Genbank EST database with the
human K1F3C sequence revealed several ESTs showing significant similarity to the human
K1F3C sequence including EST W82835, highly similar to the 3'-untranslated region of
KIF3C (nucleotides 4349-4913, Figure 5.6). This suggests a high degree of sequence
conservation between human and mouse K1F3C. A 458 bp genomic fragment of the 3'UTR
corresponding to part ofEST W82835 was amplified fromMus spretus and C57BL/6J using
the primers MkinF (5'-dCTACCCTCACAGTCTTATAGC-3') and MkinR
(5'-dAAAGGCCTCCATCCTAAACCA-3'), but no variants were found on sequencing.
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The primers Kin3 (5 '-dGGAGATGCAGCAGGAGATG-3') and Kin2
(5'-dGGGTCTGCTCGTTCTGCG-3'), corresponding to nucleotides 1815-1833 and
2026-2009 respectively in Figure 5.6, were found to amplify fragments of~1.0 kb from
C57BL/6J andM. spretus DNA. Sequence analysis of this PCR product revealed that the
sequence from the Kin2 primer crosses the splice acceptor site of intron 3, and within this
intron a polymorphic (CT)n repeat region is found (see Figure 5.5). A third primer Mkin2R
(5'-dGCATTCCATCAGTTCTCTTTCAG-3'), on the other side of the (CT)n repeat was used
in conjunction with the Kin2 primer (annealing temperature 63 °C) to type this polymorphism
in 94 animals from the Jackson laboratory interspecific backcross panel: Mkin2R and Kin2
amplify a -350 bp fragment from C57BL/6J and -400 bp fragment fromM. spretus.
Kif3c Kif3c








Figure 5.5 Diagram showing polymorphic (CT)„ repeat region within C57BL/6J (B6) and
SPRET/Ei Kific intron 3. The primers Kin2 (black arrow) and Mkin2R (red arrow) were
used to PCR across the polymorphic (CT)n repeat region (blue box), amplifying products of
~350 and -400 bp from C57BL/6J and SPRET/Ei, respectively. This PCR assay was used to
type the Jackson Laboratory interspecific backcross panel (C57BL/6JEi x SPRET/Ei) x
SPRET/Ei).
5.3.2.5 Northern blot analysis
To examine expression of the human KIF3C gene, a multiple tissue Northern blot was
probed using a 32P-labeled 818 bp PCR product encoding the motor domain (nucleotides
360-1177, Figure 5.6), performed by Dr L. Telford. Approximately 1 pg of total RNA from
various adult human tissues (brain, salivary gland, oesophagus, trachea, heart, lung, and
stomach) was tested.
5.3.2.6 Fluorescence in situ hybridisation
To map KIF3C by FISH, ATFJC-containing YAC clones were identified by screening the
ICI YAC library by PCR with the stSG4510-specific primers. Two YACs were identified,
YAC 35HB12 and YAC 14IC3. The YACs 14IC3 and 35HB12 were shown by PCR to
contain the markerD2S2144. Total yeast DNA was extracted for the YAC 35HB12, and the
DNA labelled by nick-translation with digoxigenin-11-dUTP and used for FISH analysis
(Pinkel et al., 1986). FISH analysis was performed by Dr J. Leek.
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5.3.3 Results
5.3.3.1 Sequencing KIF3C cDNA
The human IMAGE clone 28784 (Genbank accession number R14361) displayed significant
sequence homology to the 68 kDa and the 95 kDa kinesin-like proteins ofDrosophila
melanogaster and the sea-urchin Strongylocentrus purpuratus respectively. Nucleotide
sequence analysis of the entire 1917 bp insert reveals that it contains a 720 bp open reading
frame encoding a kinesin-like carboxy-terminal tail domain and 1197 bp of 3TJTR sequence.
A composite full-length cDNA (4913 bp) was assembled from a human fetal brain cDNA
clone, from 5' RACE products which were generated from total fibroblast RNA, and from
cDNA clones identified by database searching (see Methods).
The full-length KIF3C cDNA is characterised by a single open reading frame of 2382 bp
encoding a predicted protein of 793 amino acids (Figure 5.6). The overall organisation of
the predicted protein is similar to members of the KIF3 family ofKRPs and contains an
amino-terminal motor domain (residues 1-389), a central rod domain (residues 390-599) and
a carboxy-terminal tail domain (residues 600-793). A putative polyadenylation signal is
located nucleotides 2354-2359 nucleotides downstream from the translation termination
codon. The cDNA clones have a poly(A) tail added 20 nucleotides downstream of this
(2378 nucleotides downstream of the termination codon; Figure 5.6).
At the time of cloning KIF3C, searching the Genbank sequence database revealed that
among the kinesin superfamily proteins described, this novel sequence was most similar to a
195 bp partial cDNA encoding the murine KIF3Cmotor domain (Genbank accession
number AB001433; corresponding to nucleotides 430-624 in Figure 5.6), the human and
partial mouse sequence sharing 91% and 98% identities in nucleotide and amino acid
sequence, respectively. The mouse and rat Kif3c genes have subsequently been cloned
(Genbank accession numbers AF013116 and AF083330, respectively). Comparison of
human KIF3C to the mouse and rat Kif3c genes reveals 89% identity at the nucleotide level
over the protein coding region. When compared to human KIF3C, the mouse and rat Kif3c
proteins exhibit 94% and 95% identity respectively.
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Figure 5.7 shows the human KIF3C amino-terminal motor domain and central rod domain
amino acid sequence compared to various KIF3-like proteins (KIF3A, KIF3B, Drosophila
melanogaster 68 kDa and Strongylocentruspurpuratus 95 kda kinesin-like proteins). This
reveals that the amino-terminal motor domain (residues 1-389) is highly conserved with
many positions showing a single, fully conserved residue. This includes the
ATP/GTP-binding motif and kinesin motor domain signature which are highly conserved
even between species. Comparison of the amino acid sequences ofKIF3 motor domains also
reveals that the human KIF3C sequence encodes a 24 amino acid glycine-rich domain which
is not conserved in human KIF3A, KIF3B, Drosophila melanogaster 68 kDa and
Strongylocentruspurpuratus 95 kda KIF3-like proteins (Figure 5.7, residues 255-292).
However, comparison of human, mouse and rat KIF3C sequences reveals that the
glycine-rich domain is conserved in these three proteins (Figure 5.8). Although it is not
known why KIF3C contains this glycine-rich domain, the fact that it is conserved in human,
mouse, and rat KIF3C proteins does suggest it to possess some functional significance.
Human kif3c (255-292) kagpnt.
Mouse kif3c (255-294) kagpn.
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Figure 5.8 Comparison ofKIF3C glycine-rich region in human, mouse, and rat (Genbank
accession numbers JC5831, 014782, and 055165 respectively. Glycine residues are shaded
and a consensus sequence is shown.
Although the central rod domain (residues 390-599) is not so highly conserved, a high
proportion of residues are fully conserved between these five proteins. The carboxy-terminal
tail domain (residues 600-793, not shown in Figure 5.7) is the least conserved domain. An
explanation for the differences in sequence conservation for the three KIF protein domains in
various KIF3 proteins is the role each domain plays in KIF function. The motor and rod
domains are conserved because of their conserved functional role in KIF proteins (the motor
domain uses the energy from ATP hydrolysis to generate force and move along
microtubules, the rod domain is thought to be the region of dimerisation). The
carboxy-terminal domain shows little similarity between different KIF proteins because it is
where accessory polypeptides and/or vesicles containing KIF-specific cargo are attached.
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5.3.3.2 Structural organisation of the human KIF3C gene
To detennine the exon-intron structure of the novel KIF3C gene, PAC clones containing
KIF3C were isolated and analysed by direct sequencing and exon-to-exon PCR. The results
of sequence analysis ofPAC clones are summarised in Figure 5.10 and Table 5.2. The
human KIF3C gene spans approximately 12 kb of genomic DNA and consists of 8 exons and
7 introns, the exons ranging in size from 2472 bp to 109 bp. The first methionine codon of
the open reading frame is located in exon 1, whereas the stop codon and poly(A) addition
signal (Gil et al., 1987) are located in the last exon, exon 8. Exon 8 contains 2378 bp of
untranslated sequence. All introns have the consensus sequence (C/T/A)AG-exon-GT(G/A)
at their boundaries (Table 5.2).
The present gene structure is the first described for any kinesin family member. The
ATP/GTP-binding site motif and the kinesin motor domain signature (nucleotides
(nucleotides 442 to 465 and 871 to 906 respectively, Figure 5.6) are both located in exon 1.
This exon includes the whole of the N-terminal motor and over halfof the rod domain.
Exons 2 and 3 encode the remaining part of the rod domain and exons 4-8 the C-terminal
tail.
5.3.3.3 Expression of human KIF3C
The tissue distribution of human KIF3C mRNA was determined by analysis of a multi-tissue
northern blot (see Figure 5.9). A transcript of approximately 5.0 kb in size was found to be
expressed in brain but could not be detected in any of the other tissues tested (salivary gland,
oesophagus, trachea, heart, lung, and stomach). Smaller transcripts of approximately 1.5 kb,
1.3 kb, and 1.0 kb were identified in all tissues with similar levels of expression.
1 2 3 4 5 6 7
Figure 5.9 Northern blot analysis ofKIF3C expression in different human tissues.
Approximately 1 jig of total RNA from various adult human tissues were loaded: brain (lane
1), salivary gland (lane 2), oesophagus (lane 3), trachea (lane 4), heart (lane 5), lung (lane 6),
stomach (lane 7). The size of the 28S (4.8 kb) and 18S (1.8 kb) ribosomal RNA subunits are
shown. The largest transcript, expressed only in brain is marked with an asterisk. This
Northern blot was performed by Dr L. Telford.
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5.3.3.4 Mapping of human KIF3C
Following hybridisation of the KIF3C-containing YAC (35HB12) to normal human
chromosomes, doublet signals on the short arm of chromosome 2p23 were observed in 25
cells (Figure 5.11). The distribution on 2p was as follows: 1(4), 2(21), 3(0), 4(0) chromatids
per cell. This FISH result independently confirms the KIF3C localisation obtained by
radiation hybrid mapping of stSG4510 to chromosome 2p23.3 by the Sanger Centre. STS
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Figure 5.11 Chromosome mapping ofhuman K1F3C by fluorescence in situ hybridisation.
A signal is present on both chromatids of chromosome 2 at a location corresponding to p23.
This experiment was performed by Dr J. Leek.
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5.3.3.5 Mapping of mouse Kif3c
The Kif3c gene was genotyped as described in the Methods section. The products from the
PCR assay used to type the alleles from the Jackson interspecific backcross mapping panel
were visualised by electrophoresis through agarose gel (Figure 5.12). Mapping ofmurine
Kif3c using the Jackson laboratory interspecific backcross panel placed the murine gene on
chromosome 12 between D12MU44 and D12Mitl82 (Figure 5.13). The mouse ApoB gene
also maps to this interval. (Human APOB is localised to chromosome 2p23-24).
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Figure 5.12 Kific allele typing. The typing of each interspecific backcross animal is indicated
above each gel image (B:heterozygote C57BL/6JEi / SPRET/Ei type; S: homozygous
SPRET/Ei type. Lane 1A contains parental C57BL/6JEi homozygous alleles (BB) and lane IB
contains parental SPRET/Ei homozygous alleles (SS). The size of each allele is shown
















D12Mit44 ■ □ □ ■ □ ■ □ ■
kific ■ □ ■ □ □ ■ □ ■
syndl ■ □ ■ □ ■ □ □ ■
D12Mitl6 ■ □ ■ □ ■ □ ■ □
40 46 1 0 0 1 2 0
Figure 5.13 Localisation ofKific on mouse chromosome 12.
A) Map figure showing the proximal part of chromosome 12, with markers linked to Kific.
The map is depicted with the centromere (black circle) toward the top. The gene order
and relative positions ofmarkers used in this study are shown. Map distances in
centimorgans are shown on the left. The proposed positions of loci in human
chromosomes are shown to the right of the chromosome map.
B) Haplotype figure showing loci linked to Kific on chromosome 12. Loci are listed in
order with the most proximal on top. The black boxes represent the C57BL/6J allele,
and the white boxes the SPRET/Ei allele. The number of animals with each haplotype is
given at the bottom of each column of boxes.
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5.3.4 Discussion
5.3.4.1 Cloning of KIF3C
This section describes the cloning, structural analysis, expression and localisation of a novel
human kinesin-like gene, K1F3C. The KIF3C gene is highly conserved between human,
mouse and rat, showing 89% identity at the nucleotide level within the protein coding region.
Comparison of human KIF3C with mouse and rat kif3c protein sequences reveals 94% and
95% identity. The KIF3C protein is most similar to members of the KIF3 subfamily of
kinesins which includes the sea urchin 95 kDa (Cole et al., 1993), Drosophila 68 kDa
(Stewart et al., 1991), mouse Kif3a (Kondo et al., 1994), mouse Kif3b (Yamazaki et al.,
1995), human KIF3A (Kondo et al., 1994), and human KIF3B (Yamazaki et al., 1995). The
overall identity of these proteins with the human sequence is 59%, 43%, 45% 67%, 44%, and
66% respectively, and that relative to the motor domain (amino acid residues 1-389, Figure
5.6) increases to 69%, 51%, 57%, 72%, 57% and 72%.
A striking feature ofK1F3C with respect to the other KIF3 family members is the insertion
of a 24-residue glycine-rich stretch in the otherwise conserved amino-terminal domain
(Figure 5.7). Comparison ofKIF3C glycine-rich region between human, mouse, and rat
reveals that this insertion is conserved (Figure 5.8). This insertion immediately precedes the
LI 1 loop (Sablin et al., 1996), a region that is thought to play a crucial role in microtubule
binding, forming an arm that protrudes into the groove between microtubule protofilaments
(Sosa et al., 1997). As discussed below, experiments studying KIF3 proteins in the rat, have
revealed Kif3c, Kif3b and Kif3a to form heterodimers (Muresan et al., 1998). Therefore,
whether the structural difference between KIF3C proteins and other KIF3 family members is
of functional significance might be ascertained by comparing the microtubule and nucleotide
binding kinetics ofKIF3C to KIF3A and KIF3B.
5.3.4.2 The KIF3 superfamily
Although genes of the kinesin family are ubiquitously expressed, some of its members
display a restricted tissue distribution, including Kifl, Kif3 and Kif5, which are expressed
almost exclusively in murine brain (Aizawa et al., 1992), suggesting that certain kinesins
may perform a role in tissue-specific functions. Northern blot analysis, using a probe
encoding the KIF3Cmotor domain, identified a transcript of approximately 5.0 kb which
was expressed in brain but not in any of the other tissues tested. This is in agreement with
studies showing mouse Kif3c to be expressed mainly in neural tissues such as brain, spinal
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cord and retina (Yang & Goldstein, 1998). The fact that RACE products from near the 5'
end of the gene could be generated from total fibroblast RNA suggests a basal level of
expression of the full-length transcript in tissue other than brain which is detectable by RT-
PCR but not Northern hybridisation. Smaller transcripts of 1.0 kb, 1.3 kb and 1.5 kb appear
clearly in this Northern blot after stringent wash conditions and were expressed at
comparable levels in all tissues. It is possible that these smaller transcripts represent cross-
reacting kinesin related proteins (KRPs).
KIF3 subfamily proteins have been reported to be plus-end-directed microtubule motors with
roles in anterograde axonal transport for membraneous organelles in neurons (Kondo et ah,
1994). Immunoprecipitation assays have shown that some members, including mouse Kif3a
and Kif3b, assemble heterotrimeric complexes comprising two homologous but distinct
KRPs associated with a non-kinesin polypeptide subunit which has been proposed to
function as an adapter for cargo attachment (Cole et ah, 1993; Yamazaki et ah, 1995).
Immunoprecipitation experiments have now shown that rat Kif3c associates with Kif3a but
not Kif3b, but also that a significant fraction ofKif3c is not in association with Kif3a,
suggesting that rat Kif3c is part of two different motor complexes (Muresan et ah, 1998).
Proteins with which human KIF3C interact and the nature of the cargo that it transports have
yet to be determined. A recent study found that KIF3C expression was upregulated in
several cell lines undergoing growth arrest, suggesting a possible functional correlation of
KIF3C with growth control (Cabibbo et al., 1998).
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5.3.4.3 KIF3C as a candidate DFNB9 gene
The localisation of the human KIF3C gene to the genomic interval for sensorineural non-
syndromic recessive deafness, DFNB9 (Chaib et al., 1996), suggested KIF3C as a good
candidate gene for DFNB9. This was supported by the fact that non-syndromic deafness at
the DFNB2 locus (1 lql3) and the syndromic form of deafness Usher syndrome lb result
from mutations of the myosin 7A (MY07A) gene (Weil et al., 1997). MY07A encodes an
atypical myosin which like kinesins, has an intraneuronal transport function. Genetic defects
of some atypical myosins and kinesins can even cross-complement in yeast (Lillie & Brown,
1992). As KIF3C is also mainly expressed in neural tissues including the cochlea, this gene
could play an important intraneuronal transport role within the inner ear. Further
investigation ofKIF3C expression within the inner ear, the proteins it may interact with, and
the cargo that this kinesin-like protein may transport, might give clues as to KIF3C function.
However, the identification ofOTOF as the DFNB9 gene has eliminated K1F3C from further
consideration in the context ofDFNB9.
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5.4 The CRMP1 gene
5.4.1 Introduction
Genes that co-localise with Gckr and Khk on mouse chromosome 5 may also map to the
region of conserved synteny on human chromosome 2p23 and this may be a useful approach
to identifying possible candidate DFNB9 genes. A search of the mouse chromosome 5
region surrounding the Gckr and Khk locus for genes that could encode proteins with
functions within the inner ear identified the collapsin response mediator protein-1 gene
(Crmpl).
The Crmpl gene was cloned during the analysis of cDNA clones obtained by the subtraction
of a 2-day-old mouse cochlear cDNA library by mouse liver cDNA (Cohen-Salmon et al.,
1997b) and was found to be specifically expressed in the brain, retina, and in the cochlea,
mainly during the development of the nervous system. The Crmpl gene was also later found
to be expressed in the testes and was mapped to mouse chromosome 5 near the Gckr and Khk
locus (Taketo et al., 1997).
Sequence analysis reveals Crmpl to show 87% homology to its human homologue, CRMP1.
CRMP1 had been cloned during a study to identify genes that encode proteins related to
dihydropyrimidase (Hamajima et al., 1996). CRMP1 was shown to be highly expressed in
the brain. Crmpl is also related to the chick CRMP-62 gene and C. elegans Unc-33 gene, a
nematode gene involved in the co-ordination of axonal outgrowth (Hedgecock et al., 1987;
Li et al., 1992; Mclntire et al., 1992). This family of proteins is thought to play a role in
mediating "collapsin" activity during neuronal development. Collapsin, a member of the
semaphorin family, is involved in the development of the nervous system by acting as a
repulsive cue toward specific neuronal populations (Luo et al., 1995; Puschel et al., 1995).
The investigation of collapsin signalling identified chick CRMP-62, a gene expressed
exclusively in the developing chick nervous system (Goshima et al., 1995). Introduction of
anti-CRMP-62 antibodies into dorsal root ganglion neurons blocked collapsin-induced
growth cone collapse, suggesting CRMP-62 to be one of the components of the signaling
cascade initiated by the fixation of collapsin to an yet unidentified receptor (Goshima et al.,
1995).
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The mapping ofCrmpl to the same region ofmouse chromosome 5 as Gckr and Khk
suggests that its human homologue CRMP1 might map, like GCKR and KHK, to the region
of conserved synteny on human chromosome 2p23.3. If CRMP1 did map to human
chromosome 2p23 like GCKR and KHK, it could be considered an excellent candidate
DFNB9 gene because of its role in regulating neuronal growth and its high expression levels
during innervation of the developing cochlea.
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5.4.2 Methods
To map the human homologue ofCrmpl, an STS was designed from the partial human
CRMP1 gene sequence (Genbank accession number U17278) and used to screen a
monochromosomal somatic cell hybrid DNA panel (supplied by HGMP). The primers
CRMP1F (5 '-dTTAGTTTGGTGCTGATGGAG-3') and CRMP1R
(5'-dTCTGAGTGTGAACCTGGCT-3') were used to amplify a PCR product of size 657 bp
using the hot start PCR program 94°C, 5min; 30x(94oC,45s;58°C,45s;72°C,lniin), 50ng of
template and standard PCR buffer (1.5 mM MgCl2). PCR products were run on a 1.5%
agarose gel.
5.4.3 Results
Screening of the monochromosomal somatic cell hybrid DNA panel (Kelsell et al., 1995) for
CRMP1 gave positive results for chromosome 4 and chromosome 20 (Figure 5.14).
Examination of the data sheet for the DNA panel revealed that the chromosome 20 cell
hybrid also contained part of chromosome 4 therefore it is most likely that CRMP1 resides
on human chromosome 4. Since CRMP1 does not map to chromosome 2p23, its structure
was not further investigated.
1 2 34 5678 9 10 11 12 H M Ha ■ 13 14 15 16 17 18 19 20 21 22 X Y HM Ha¬
lt * ' ft :|s
W' Sp7°';f
Figure 5.14 PCR screening of a monochromosomal somatic cell hybrid DNA panel. First
half of gel sample order: 1 kb ladder; cell hybrid chromosomes 1-12; human; mouse;
hamster; negative control; 1 kb ladder. Second half of gel sample order: lkb ladder; cell
hybrid chromosomes 13-22, X, Y; human; mouse; hamster; negative control; 1 kb ladder.
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5.4.4 Discussion
The genes surrounding Gckr and Khk locus on the proximal part ofmouse chromosome 5
map to three regions of conserved synteny within the human genome: Gbxl and En2 map to
human chromosome 7q36; Gckr and Khkmap to human chromosome 2p23; Htr5a, Hmx 1
and Msx 1 map to human chromosome 4 (Msxl maps to chromosome 4p26), gene order
starting closest to the centromere Gbxl/En2 - GckrlKhk-Htr5alHmxl/Msxl. Mapping of
CRMP1 to human chromosome 4 (Figure 5.14) suggests that it too will most likely reside
close to the Hmxl andMsxl genes, possibly on chromosome 4pl6. The result discounts its
candidacy as a DFNB9 gene. Nonetheless, other research carried out to investigate Crmpl
expression in 2-day old mouse cochlea by in situ hybridisation revealed a highly specific
signal in the spiral ganglia, which contain the neurons innervating the sensory hair cells of
the organ ofCorti (Cohen-Salmon et al., 1997a). The high expression of Crmpl during
innervation of the developing cochlea suggests that although the CRMP1 gene is not the
DFNB9 gene, it remains an excellent candidate deafness gene.
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5.5 The KCNK3 gene
5.5.1 Introduction
5.5.1.1 Chromosomal mapping of KCNK3
During the search for candidate DFNB9 genes, ESTs that map to chromosome 2p23 by
radiation hybrid mapping (see http://www.ncbi.nlm.nih.gov/genemap) were used to PCR
screen the YAC physical contig constructed at the DFNB9 interval (See Chapter 3, Figure
3.5). One EST was found to be positive for YAC 7DD11, a YAC that maps within the
DFNB9 interval. This EST had been designed from the 3'UTR of the human potassium ion
channel gene KCNK3 (TASK), Genbank accession number AF006823. The mapping of
KCNK3 to within the DFNB9 interval, added to the important role that potassium ion
channels play in the ear (discussed later in this section), makes KCNK3 a good candidate
deafness gene.
5.5.1.2 Potassium channels
Potassium channels represent the largest and most diverse group of ion channels (Rudy,
1988). This diversity originates partly from the large number of genes coding for K+ channel
principal subunits, but also from other processes such as alternative splicing, heteromeric
assembly ofdifferent principal subunits, and as possible RNA editing and post-translational
modifications. By determining and modulating the membrane potential, potassium channels
play a major role in neuronal integration, muscular excitability and hormone secretion
(Edwards & Weston, 1995).
It has recently been shown that mutations in potassium channel genes are responsible for a
number of inherited human diseases. Heterozygous mutations in KCNQ1 cause autosomal
dominant long QT syndrome (LQTS) (Wang et al., 1996). LQTS is electrocardiographically
characterised by a prolonged QT interval and polymorphic ventricular arrhythmias (Romano,
1963; Ward, 1964). These cardiac arrhythmias may result in recurrent syncope, seizures, or
sudden death. Mutations in KCNQ1, when present on both alleles, were also shown to
underlie Jervell and Lange-Nielsen (JLN) syndrome (Neyroud et al., 1997), whose
symptoms include deafness in addition to cardiac arrhythmias. Mutations in a second gene,
KCNE1, have also been shown to result in JLN syndrome (Schulze-Bahr et al., 1997).
KCNE1 encodes a transmembrane protein known to associate with KCNQ1, together
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forming a delayed rectifier potassium channel (Barhanin et al., 1996; Sanguinetti et al.,
1996).
Mutations in either KCNQ2 or KCNQ3, cause benign familial neonatal convulsions (Biervert
et al., 1998; Charlier et al., 1998; Singh etal., 1998). KCNQ2 and KCNQ3 encode
potassium ion channel subunits that can associate with each to form functional potassium ion
channels. Interestingly, KCNE1 which is mutated in JLN syndrome, can also associate with
KCNQ2 and KCNQ3 (Yang et al., 1998). Mutations in another potassium ion channel gene,
KCNQ4, can cause autosomal dominant deafness in DFNA2-affected families (Kubisch et
al., 1999).
The role of potassium channels in deafness is not surprising as in the cochlea, the
transduction current through the sensory cells is carried by potassium and depends on the
high concentration of that ion in the endolymph (Delpire et al., 1999). The presence of
potassium channels in most cell types suggests that mutations in these genes will lead to
deafness by various mechanisms. Indeed, it has been shown that mutations in KCNQ1 cause
deafness by affecting endolymph secretion (Neyroud et al., 1997) but that the mechanism
leading to KCNQ4-related hearing loss is intrinsic to the outer hair cells (Kubisch et al.,
1999). Further evidence for the importance ofK+ in the inner ear is the finding that
mutations in the gene for connexin 26, which encodes a gap-juctional protein, are
responsible for a surprisingly large fraction of non-syndromic human deafness (Estivill et al.,
1998; Kelsell et al., 1997). Gap junctions could have a vital role in the maintenance ofK+
homeostasis, as it has been suggested that K+ ions are recycled from endolymph through the
sensory epithelium and back to the stria vascularis by moving from cell to cell through gap
junctions.
5.5.1.3 The KCNK3 gene
The KCNK3 (TASK) gene encodes a potassium ion channel that is part of the same family of
potassium channel proteins as TWIK-1 and TREK-1 (Duprat et al., 1997). Although these
three potassium channels have different functional properties, they all possess four
transmembrane segments and two P domains (a motif that forms an essential element of the
potassium ion-selective filter of the aqueous pore). TWIK-1 gives rise to weakly inward
rectifier potassium ion currents (Lesage et al., 1996) while TREK-1 produces outward
rectifier potassium ion currents (Meadows et al., 2000). The outward rectification seen in
the KCNK3 channel is a result of asymmetric concentrations of potassium ions on both sides
of the membrane suggesting that it lacks intrinsic voltage sensitivity (Duprat et al., 1997). In
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other words, KCNK3 behaves like a potassium ion selective "hole". Therefore, KCNK3 can
be classified as a "background" potassium ion channel.
Background potassium ion channels are open at all membrane potentials and probably play a
pivotal role in the control of the resting membrane potential and in the modulation of
electrical activity of both neurons and cardiac cells. KCNK3, the first mammalian potassium
ion channel to be identified as a background potassium ion channel (Duprat et al., 1997), is
extremely sensitive to extracellular pH, fully opening or closing within a range of only 0.5
pH unit around the physiological pH (7.4). The sensitivity ofKCNK3 to external protons
probably has important implications for the physiological function of the KCNK3 channel,
for example in modulating neuronal activity.
The mapping ofKCNK3 to chromosome 2p23 , the role of other potassium channel genes in
the pathogenesis of deafness, for example KCNQ1, KCNQ4, and KCNE1, and the high
sensitivity ofKCNK3 to pH in cells like neurons, make this an excellent candidate DFNB9
gene. To confirm KCNK3 as a candidate DFNB9 gene, a more precise localisation of
KCNK3 was performed to see if this gene indeed mapped to the DFNB9 interval.
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5.5.2 Methods
5.5.2.1 Isolation of genomic clones
The primer pair (5'-dGTCCTCAGAGACCCTGCTG-3' and
5'-dCTCCAGTGCGACCATTCTGC-3'), designed from the KCNK3 3'UTR sequence
(Genbank accession number AF006823), amplifies a PCR product of 376 bp. This primer
pair was used to PCR screen the ICI human genomic YAC library (Anand et al., 1990) and
other YACs that had been used to construct a physical contig spanning the DFNB9 interval
(see Chapter 3, Figure 3.5). To identify other genomic clones containing KCNK3, the same
primer pair was used to screen a human genomic PAC library (RPCI1) - see Chapter 3
Methods section for details ofPAC library screening strategy. Standard PCR conditions
were used, with an annealing temperature of 58°C.
5.5.2.2 Radiation hybrid mapping
The primer pair (as described above) was used to PCR screen the Genebridge 4 (GB4)
radiation hybrid DNA panel (Gyapay et al., 1996), supplied by the HGMP Resource Centre,
Hinxton. Radiation hybrid mapping makes use of a panel of somatic cell hybrids, with each
cell line containing a random set of fragments of irradiated human genomic DNA in a
hamster background. For the GB4 panel, the X-ray dosage was 3000 rad. The GB4 panel
consists of 93 somatic cell hybrids, with an average fragment size of 25 Mb and an effective
resolution of 1Mb.
The results were analysed using the Radiation Hybrid Mapping Environment (RhyME)
bioinformatics application based at the HGMP resource centre. RhyME takes the results of
the typed marker and analyses the typing data in relation to the 1998 International Gene Map
(NCBI) using the RADMAP program (HGMP). The marker in question is assigned to the




5.5.3.1 Mapping to genomic clones within physical contig
PCR screening of the ICIYAC library identified two KCNK3-containing YAC clones,
7DD11 and 1CA11. Further PCR screening of the YAC physical contig spanning the
DFNB9 interval also revealed KCNK3 to map to the CEPH mega-YAC 964D8 (see Chapter
3, Figure 3.5). PCR screening of the RPCI1 PAC library identified one PAC containing
KCNK3, 249B24. All three KCNK3-containing YACs were also positive for the
microsatellite marker D2S174. These genomic clones were placed on the physical contig
(see Chapter 3, Figure 3.5).
5.5.3.2 Radiation hybrid mapping
The Genebridge 4 radiation hybrid mapping panel was PCR screened using the
AYWAG-specific primer pair and the PCR products were analysed on 1.5% agarose gels
(Figure 5.15). The presence of a PCR product was scored as a "+" for positives, for
negatives and "2" for unknowns/uncertains.
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Figure 5.15 Radiation hybrid mapping ofKCNK3. PCR samples 1 to 95 correspond to the
Genebridge 4 radiation hybrid panel, 96 well plate format. Samples 94 (Ha) and 95 (Hu) are
hamster and human genomic DNA respectively. The presence of a PCR product was scored
as a "+" for positives, for negatives and "2" for unknowns/uncertains. Circles indicate a
missing sample (not supplied) and these were also scored as unknowns. The outer lanes
contain 1 kb ladder; the sizes of the DNA fragments are indicated.






506bp\M — — —
396 bp-y
344 op y "
298 bp/










The "scored" data (or "vector") was analysed using the RADMAP program. Two markers
are considered linked if they have vectors of statistically significant similarity (defined as a
LOD score), and a measure of their separation is obtained from the analysis of the degree of
difference between two vectors. A LOD score >3 is statistically significant. Table 5.3
shows a list of the chromosome 2 markers that vector analysis has determined to be
statistically linked to the KCNK3 marker. This reveals KCNK3 to be most highly linked to
D2S392 on the GB4 radiation hybrid map. The location ofKCNK relative to other markers
in the Genebridge 4 radiation hybrid panel is shown in Figure 5.16.
Marker Theta LOD
AFM347ya5 (D2S392) 0.326 7.964
AFM234ya9 (D2S165) 0.390 6.717
AFM296vg9 (D2S352) 0.422 5.956
AFM242yd8 (D2S171) 0.437 5.741
AFM267zc9 (D2S177) 0.469 5.060
Table 5.3 Chromosome 2 markers linked to KCNK3.
2p
Figure 5.16 Ideogram of human G-banded chromosome 2p. The location ofKCNK3
(indicated by an arrowhead) is shown relative to markers in the Genebridge 4 radiation




Potassium ion channel genes have a proven role in underlying human syndromes including,
long-QT syndrome (Wang et al., 1996), Jervell and Lange-Nielsen (JLN) syndrome(Neyroud
et al., 1997), and autosomal dominant deafness (DFNA2) (Coucke et al., 1999).
Furthermore, high levels of potassium ions within the inner ear suggest that potassium ion
channels are essential for proper functioning of the inner ear. The location ofKCNK3, a
potassium channel gene mapping to chromosome 2p23, suggested that it would be a good
candidate DFNB9 gene.
The aim of this section was to determine whether the KCNK3 gene resided within the
DFNB9 interval and therefore could be considered a candidate DFNB9 gene. This was
carried out by physical mapping of A"CAW3-containing genomic clones and by radiation
hybrid mapping. Three YAC clones (7DD11, 1CA11, and 964D8) and one PAC clone
(249B24) were shown to contain KCNK3 by PCR screening using ACTVAG-specific primers.
The three YACs were used to form part of the physical YAC contig located on chromosome
2p23.3. Further PCR screening revealed that the microsatellite marker D2S174 also mapped
to these YACs. The DFNB9 interval is delimited by the markers D2S2303 and D2S174 at
2p23.1, so that this physical mapping data places KCNK3 close to the DFNB9 region.
Radiation hybrid mapping places KCNK3 between the chromosomal markers D2S392 and
D2S165 on chromosome 2p23 in the Genebridge 4 (GB4) radiation hybrid mapping panel
(Figure 5.16). This mapping data confirms the assignment ofKCNK3 to human chromosome
2p23, and also confirms FISH studies that locate KCNK3 to chromosome 2p23.3. (Leek,
1998 unpublished). The data agrees with other radiation mapping data carried out while
these studies were in progress (Lesage & Lazdunski, 1998). Recently, FISH analysis has
again confirmed the location ofKCNK3 on chromosome 2p23 (Manjunath et al., 1999).
Physical mapping ofKCNK3 also shows this gene to map close to D2S165 (Chapter 3,
Figure 3.5).
The assignment to the proximal region ofmouse chromosome 5 of a mouse cardiac two pore
background potassium channel gene (Kcnk4) (Fujita et al., 1998) that was highly similar to
KCNK3 (79% and 93% at the nucleotide and amino acid level respectively), suggests that
Kcnk4 is the mouse orthologue ofKCNK3. The Kcnk4 gene has now been renamed Kcnk3
and analysis by FISH confirms this mouse gene to map to chromosome 5 (Manjunath et al.,
1999). This shows KCNK3 to be further example of a gene residing in the region of
conserved synteny that lies on human chromosome 2p23 and mouse chromosome 5.
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The mapping data described in this section place KCNK3 very close to the DFNB9 interval.
However, the KCNK3 gene was not further investigated as a DFNB9 candidate, since the
identity ofDFNB9 with a gene encoding another novel protein was established by others
(Yasunaga, 1999). With the proven role of potassium channel genes in human diseases such
as LQTS, JLN syndrome and both syndromic and non-syndromic deafness, however, further
research into the role ofKCNK3 within the heart and inner ear is nonetheless warranted.
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5.6 The DFNB9 gene
5.6.1 Cloning of OTOF
A combination of the candidate gene and positional cloning strategies was employed to
identify the gene underlying DFNB9 (Yasunaga et al., 1999). The segregation of the DFNB9
locus in a consanguineous family living in northern Lebanon led to the initial assignment of
the DFNB9 gene to a 2 cM interval delimited by D2S2303 and D2S174 (Chaib et al., 1996).
Further linkage studies in families with profound senorineural prelingual hearing loss led to
the identification of three additional unrelated consanguineous DFNB9-affected families
from Lebanon and this allowed the refinement of the DFNB9 interval to between D2S158
and D2S174 (in a region of~1 cM).
With the construction of a physical contig from YACs, BACs, and PACs covering the
DFNB9 interval, Yasunaga et al. estimated the size of the DFNB9 interval to be less than
700 kb. This contig allowed the assignment of genes and ESTs to the candidate region. Two
genes mapping to the DFNB9 interval including HADHB (encoding trifunctional protein (3
subunit) and CENPA (encoding centromeric protein A) were not considered as candidate
genes for deafness due to the putative functions of their encoded proteins. Several novel
ESTs that were mapped to the DFNB9 region were submitted to rounds of 5' RACE on total
fetus mRNA and the predicted amino acid sequences they encoded were compared to other
amino acid sequences derived from clones that had been isolated from two subtracted mouse
cochlear cDNA libraries (Cohen-Salmon et al., 1997b; Verpy et ah, 1999). One of the
clones (RH12053) predicted 89.7% amino acid identity and 97.1% similarity to a mouse
clone, suggesting that they were orthologous genes. The full length cDNA was constructed
by 5' RACE and an open reading frame encoding 1230 amino acids was identified. Due to
sequence homology between the predicted amino acid sequence and the C. elegans
spermatogenesis factor FER-1 (Achanzar & Ward, 1997), the human protein was named
otoferlin (OTOF).
5.6.2 Mutation detection
The screening of all 28 OTOF exons from the four DFNB9-affected families identified one
stop mutation in exon 18 that would lead to a truncated protein of 729 amino acids in the
affected patients. This mutation was homozygous in all affected individuals (21
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individuals), heterozygous in their parents (11 individuals) and not detected in any of the
unaffected controls screened (106 individuals from Lebanon). These results identified
OTOF as the causative gene for DFNB9.
5.6.3 Function of OTOF
A search for proteins showing homology to OTOF revealed that apart from the C. elegans
FER-1 protein, the human protein dysferlin (DYSF) also showed significant similarity. The
DYSF gene has been reported to underlie Miyoshi myopathy (MM) and limb-girdle muscular
dystrophy type 2B (Bashir et al., 1998; Liu et al., 1998). Inspection of the amino acids
sequence reveals that both these proteins have a highly hydrophobic C-terminus and further
sequence analysis suggests that both are C-terminal membrane-anchored cytosolic proteins
containing C2 elements (two four-stranded (3 sheets thought to bind calcium ions).
The exact function of the FER-1 like family is unknown but clues have been drawn from C.
elegans Fer-1 mutants. During the maturation of spermatids to motile spermatozoa, large
vesicles called membranous organelles fuse with the spermatid plasma membrane. In Fer-1
mutants, the fusion between the large vesicles and the spermatid plasma membrane is found
to be defective (Achanzar & Ward, 1997).
It is also known that C2 domain-containing proteins interact with phospholipids and proteins
(Rizo & Sudhof, 1998), so it has been hypothesised that otoferlin is involved in Ca2+-
triggered vesicle membrane fusions. With in situ hybridisation ofmouse Otof in the inner ear
revealing expression in the inner hair cells and vestibular type I sensory hair cells, a possible
function of otoferlin maybe in synaptic vesicular trafficking within the synapses of these
cells.
5.7 Summary
During this study, three candidate genes: MPV17, K1F3C and KCNK3, were identified that
all map close to, or within the DFNB9 interval on human chromosome 2p23 and encode
proteins with potentially important functions within the inner ear. However, the gene
underlying DFNB9 was eventually identified as OTOF (Yasunaga et al., 1999), cloned from
an EST mapping to within the DFNB9 interval. Mutation screening of the OTOF gene
reveals it to contain the same nonsense mutation in four unrelated families of Lebanese
origin affected with non-syndromic prelingual deafness.
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In the autosomal DFNA2 families, the DFNA2 gene has been mapped to chromosome lp34,
and fine mapping using different DFNA2 families indicates non-overlapping candidate
regions (Van Hauwe et al., 1999). It is now thought that there are two (possibly three)
deafness genes that map to the same locus. Therefore, in the case ofDFNB9, if the mutation
screening of further DFNB9 families reveals no mutations in OTOF, the other candidate
DFNB9 genes identified in this Chapter would have to be reconsidered for mutation
screening. It is now important to screen all families with non-syndromic prelingual deafness




6 Summary and future research
6.1 Introduction
This chapter summarises the work carried out in previous chapters and discusses how the
genes identified as part of this research could now be subjected to further biochemical and
genetic analysis. Also included in this chapter is a brief discussion concerning the impact of
recent advances in the Human Genome Project and new technologies on the type of research
that is described in this thesis.
6.2 Summary of research and future work
6.2.1 Aim
The candidate type 2 diabetes genes GCKR and KHK and the gene underlying
non-syndromic recessive sensorineural deafness DFNB9 map to the same genomic region of
chromosome 2p23.3. As GCKR and KHK have previously been shown to encode
metabolically connected proteins (see Chapter 1), this raised the possibility that other genes
encoding functionally related proteins to GKRP and KHK might also map to the
GCKR-KHK intergenic region. Further circumstantial evidence for the possibility of GCKR
and KHK co-ordinate regulation was obtained by the mapping of both Gckr and Khk to
mouse chromosome 5, even though the surrounding genes on either side of the GCKR-KHK
genomic region map to mouse chromosome 12 (see Chapter 2). This thesis describes the
characterisation of human chromosome 2p23.3 to search for novel candidate genes for type 2
diabetes mapping to the GCKR-KHK intergenic region and also the identification of
candidate DFNB9 genes within the DFNB9 interval.
6.2.2 Assembly of a physical contig
To confirm the intimate co-localisation ofGCKR and KHK to a 500 kb genomic region on
chromosome 2p23.3, that had previously been suggested by fluorescent in situ hybridisation
(Hayward et al, 1996), and to aid the search for novel transcripts within the GCKR-KHK
genomic region, a physical contig consisting ofYAC, BAC, PAC, and cosmid clones was
constructed using a combination of STS/EST mapping and cosmid (see Chapter 3). The
GCKR-KHK physical contig showed that GCKR and KHK were indeed -500 kb apart. As
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the DFNB9 interval was known to map close to the GCKR-KHK genomic region, the
GCKR-KHK physical contig was extended to include the DFNB9 interval.
The complete physical contig on chromosome 2p23.3 was estimated to span ~2 Mb (see
Figure 3.5) and the search for transcripts by sequence analysis and PCR screening for cDNA
markers identified 14 known genes and 15 ESTs that mapped to this contig (described in
Chapter 3). The high gene density on chromosome 2p23.3 posed a dilemma as to which
genes to further investigate. To prioritise genes for further investigation, candidate type 2
diabetes genes were chosen based on the possibility of involvement in biochemical pathways
relating to carbohydrate metabolism (described in Chapter 4), and candidate deafness genes
were chosen based on their location within the DFNB9 interval and potential function of the
encoded protein in the inner ear (described in Chapter 5).
6.2.3 Transcripts located within the GCKR-KHKgenomic region
In Chapter 4, three genes were identified for further investigation: EIF2B4, encoding the
delta subunit of the initiation factor eIF2B - a protein complex known to play a key role in
the regulation ofprotein synthesis, the activity ofwhich has been shown to be stimulated by
both glucose and sugar phosphates; a novel gene called KIAA0064 that was shown to be
intimately located in a "head to head" arrangement with EIF2B4\ and RBSK, the gene
encoding the human ribokinase protein - a member of the same kinase family as KHK.
After mapping and cDNA cloning of these transcripts, the genomic structures for these genes
were elucidated.
In the case ofEIF2B4, two isoforms were identified that differed at their 5' ends.
Investigation of the EIF2B4 isoform expression by RT-PCR showed that both isoforms were
expressed in brain, heart, liver, and muscle. However, alternative splice forms ofEIF2B4
were identified only in the brain. Although the function of the two EIF2B4 isoforms and
brain specific alternative splice forms is unknown, their existence might correlate with a
complex regulatory system that acts on the eIF2B complex and control of protein synthesis.
The function of the two EIF2B4 isoforms and the brain isoforms requires further
investigation.
Possible ways to investigate the EIF2B4 isoform function in the eIF2B complex would be to
remove expression of one isoform and examine the effect on eIF2B activity to external
cellular stimuli such as glucose. This experiment could be conducted using anti-sense RNA
oligonucleotides that can block expression of one of the EIF2B4 isoforms in cell tissue
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culture. Activity of the endogenous eIF2B complex could be compared to activity of the
eIF2B complex lacking one of the EIF2B4 isoforms. Whereas in the past, phosphorothioate
based anti-sense RNA oligonucleotide experiments have suffered from degradation by
nucleases, unpredictable targeting, poor sequence specificity, and multiple non-antisense
activities, the use of "morpholino" based anti-sense RNA oligonucleotides has been found to
be resistant to nucleases, has predictable targeting, excellent sequence specificity and
minimal non-antisense activity. (Reviewed in Summerton and Weller, 1997). The advances
in antisense RNA oligonucleotide design make it an attractive tool for blocking mRNA
translation especially in tissue culture but has also been shown to work effectively in
Xenopus laevis andDario rerio.
An investigation into the functionality of the brain EIF2B4 alternative splice forms could be
carried out by cloning the individual splice forms into a protein expression vector and
co-expressing each splice form with the other four eIF2B subunits. Comparison of the
guanine nucleotide exchange activity each eIF2B protein complex containing the different
brain EIF2B4 splice forms could give an indication of the difference in functionality of each
brain EIF2B4 splice form.
To assess whether eIF2B4 is a legitimate candidate type 2 diabetes gene, a genetic screen for
polymorphisms and mutations in the EIF2B4 gene in individuals with type 2 diabetes should
be carried out. Any polymorphisms or mutations identified could be introduced into
recombinant EIF2B4 protein and the effect examined on eIF2B activity in response to
presence and absence of glucose. This experiment would utilise the same protein expression
system described for the investigation of the function ofEIF2B4 brain splice forms.
With the identification of the KIAA0064 transcript adjacent to the EIF2B4 gene in a intimate
"head to head arrangement", these two genes could share promoter elements. Although
previous work suggests KIAA0064 to be ubiquitously expressed (Nomura et al, 1994), it
would be of interest to investigate whether the expression ofKIAA0064 and EIF2B4 are in
some way linked, for example, by up-regulation through glucose presence. This experiment
could be conducted in tissue culture cells, for example the rat insulin secreting (INS-1) cell
line which was established from cells isolated from an x-ray-induced rat transplantable
insulinoma and which behave similarly to pancreatic [3-cells (Asfari et al, 1992). It would
also be of interest to perform in situ hybridisation experiments for both EIF2B4 and
KIAA0064 to investigate whether these genes share any subcellular localisation. As
KIAA0064 has no known function, a yeast two hybrid experiment could be conducted to
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isolate any proteins that interact with KIAA0064, which may provide clues as to the function
ofKIAA0064 itself.
The ribokinase gene (RBSK) was identified as a transcript on chromosome 2p23.3 for further
investigation because RBSK belongs to the same kinase family as KHK (see Chapter 4,
Section 4.4). If evidence could be gathered that suggested RBSK and KHK to have evolved
from a common ancestral gene, it would provide an interesting insight to the evolutionary
history of the genomic region on chromosome 2p23.3. Although the peptide sequences of
both RBSK and KHK do show similarity, investigation and comparison of the genomic
structures for the RBSK and KHK genes revealed distinct genomic structures. This suggests
that the RBSK and KHK genes had not evolved from a common ancestral gene. Another
indication as to whether RBSK and KHKmay have evolved from a common ancestral gene
could be gained by performing X-ray crystallography on purified RBSK and KHK protein.
This would allow the comparison of the tertiary protein structures for RBSK and KHK and
give an alternative insight into the evolutionary history of the genes encoding these two
proteins.
6.2.4 Candidate DFNB9 genes
The search for candidate deafness genes located in the DFNB9 interval identified three
genes: MPV17, KIF3C, and KCNK3 (see Chapter 5), before the actual DFNB9 gene was
identified to be Otoferlin (OTOF) by Yasuga et al., 1999. MPV17 was chosen for further
investigation because the Mpvl7 (-/-) mouse has abnormalities in the inner ear similar to
Alport's syndrome and is a mouse model for both deafness and renal disease (Meyer zum
Gottesberge, 1996). Although mutation screening ofMPV17 revealed no mutations in two
individuals with deafness and glomerulosclerosis, a much larger number ofpatient samples
is required for mutation screening to give a better indication as to whether any mutations
exist in this gene that cause deafness and/or renal disorder.
The KIF3C was chosen for further investigation because it is an intracellular motor protein,
having a similar function to myosin proteins which have a proven role in the pathogenesis of
deafness (Hasson, 1997). Expression analysis ofKIF3C revealed a brain specific 5 kb
transcript suggesting a intraneural function for KIF3C. To further investigate the function of
KIF3C, an interesting experiment would be to identify the cargo that is attached to KIF3C.
This could be carried out by immunoprecipitation experiments in which antibodies raised
against KIF3C are used to pull down KIF3C and its cargo. Proteins found to be associated
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with KIF3C could be separated by two dimensional electrophoresis and micro-sequenced to
reveal the protein's identity.
The KCNK3 gene, encoding a potassium channel protein, was mapped to the DFNB9
interval by physical and radiation hybrid mapping. This KCNK3 gene was a good candidate
deafness gene because of the high concentration of potassium ions in the endolymph of the
inner ear and the proven role of other genes encoding potassium ion channels in the
pathogenesis of deafness (Neyroud, 1997). Although this gene was not further investigated
since the DFNB9 gene had been identified as OTOF, the proven role of potassium channel
genes in diseases such as long QT syndrome, Jervell and Lange-Nielson syndrome, and
autosomal dominant deafness (DFNA2), makes KCNK3 an interesting gene for further
investigation. Any polymorphisms in KCNK3 identified by genetic screening of the general
population could be introduced into recombinant KCNK3 proteins and the effect on KCNK3
function investigated by use of the patch clamp technique (Neher et al, 1978). The patch
clamp technique can measure the current flowing through a single ion channel and give an
indication to when the ion channel is open or closed, and ifmutations affect the normal
function of the ion channel.
The DFNB9 gene was identified as otoferlin (Yasunaga et al, 1999), a gene encoding a
protein of unknown function. Flowever OTOF does show similarity to the C. elegans FER-1
protein (see Chapter 5, Section 5.6). Clues to the function ofOTOF have been drawn from
the C. elegans Fer-1 mutants, which show defects in the process of vesicle fusion with the
spermatid plasma membrane (Achanzer & Ward, 1997). As OTOF is a C2
domain-containing protein (the C2 domain often interacts with phospholipids and other
proteins, and has also been shown to bind Ca2" ions), it has been hypothesised that OTOF is
involved in Ca2 ion triggered vesicle membrane fusions.
Mutations in OTOF underlie neurosensory non-syndromic recessive deafness 9 (DFNB9) in
humans. Therefore it would be ofmuch interest to understand the function of this protein,
the role it plays in the inner ear, and how mutations in this gene are involved in the
pathogenesis of deafness. An insight into the pathogenic mechanism of deafness caused by
mutations in OTOFmight be gained by use of a model organism such as the mouse.
Antibodies to OTOF could be used in in situ hybridisation and immunocytochemistry
experiments, carried out using inner ear tissue from normal mice to determine when and
where Otofand its encoded protein are expressed. The production of a mouse Oto/knock¬
out would allow further insight into Otof function. Firstly, the auditory function ofOtof(-/-)
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mice can be examined which should confirm that mutations in Otofcan cause deafness. An
Cto/ knock-out mouse would facilitate the investigation ofwhat actually happens in-vivo
when no Otof protein is present. Electron microscopy ofmouse inner ear tissue from the
mutant mouse should indicate whether Otof is actually involved in the process of vesicle
fusion and if it is, an investigation into the vesicle components could be carried out.
6.3 Impact of the Human Genome Project and technological
advances on functional genomics
6.3.1 Use of the Human Genome Sequence
The first draft human genome sequence has now been deposited in the sequence databases
and the expected date for completion of the entire human genome is 2003. With over 30
fully sequenced genomes already in the public domain, the emphasis of genome research is
now shifting from description of genome sequence to assignment of gene function and how
the proteins encoded by genes interact, for example in the organisation and control of genetic
pathways that come together to make up the physiology of an organism. This section
discusses how the Human Genome Project, in addition to advances in new technologies for
investigation of gene function that are available to the research scientist, has changed the
methodology for the type ofproject that is described in this thesis.
This thesis describes the characterisation of the genomic region surrounding the genes
GCKR and KHK on chromosome 2p23.3. This was carried out by creating a physical contig
of genomic clones spanning the genomic region of interest and identifying transcripts by
sequence analysis and PCR screening for EST sequences. This is a time consuming and
labour intensive process. Therefore one obvious advantage of the Human Genome Project is
the availability of sequence data for the whole genome. This means that once a genomic
region of interest has been identified, the complete annotated DNA sequence for that region
will be available in the sequence database. With ESTs and transcripts already mapped to the
DNA sequence, the investigator can immediately make a decision on what genes require
further investigation.
The sequencing ofmany genomes from different organisms has facilitated the development
of computational methods for establishing functional linkages between proteins. One such
method is the production of a phylogenetic profile for a particular gene. The presence of a
gene sequence can be searched for in genome sequences from different organisms and the
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presence or absence of that gene sequence is used to produce a phylogenetic profile. If two
genes are found to have identical phylogenetic profiles, their encoded proteins might have a
functional link and could be engaged in a common pathway or complex. As the number of
genomes sequenced from different organisms increases, the phylogenetic profile method will
become more accurate for establishing functional linkages.
The mapping of transcripts to chromosome 2p23.3 identified 14 known genes and 15 EST
sequences. The examination of putative functions of the encoded proteins identified no
obvious functional links for these transcripts. Therefore, the method of phylogenetic
profiling for the genes mapping to the GCKR-KHK genomic region might identify functional
links between the encoded proteins that were not apparent by homology searching.
Another computational method that can reveal functional linkages from genome sequences is
the gene neighbour method (Overbeek et al, 1999). As more complete genome sequences
are deposited in databases, genes that lie in regions of conserved synteny in many different
organisms might indicate functional linkages between the encoded proteins. This method
has proven very successful in prokaryote genomes, where operons are common, and may
also be applicable to eukaryote genomes. As described in Chapter 2, both GCKR and KHK
were both mapped to the same region ofmouse chromosome 5. IfGCKR and KHK are
shown to be adjacent to each other in other genomes, this might suggest a functional link
between their encoded proteins.
6.3.2 DNA arrays
Computer analysis of genome sequences can only infer a functional linkage between two
proteins and it should be pointed out that computer predictions should always be backed up
with genetic and biochemical experimental evidence. One way to gain an insight into the
function of a protein is to examine when, where and to what extent its encoding gene is
expressed. Whereas in the past, the expression of a gene would be examined by RT-PCR or
Northern blotting, the recent advances in DNA array technology now allow expression
analysis to be carried out on a genome-wide scale. Significant numbers of arrays can now be
made which have 250,000 different oligonucleotide probes or 10,000 different cDNAs per
square centimetre (Lipshutz et al, 1999). The small size of an array means that only a small
amount of probe, for example mRNA from a specific cell type, is required to perform the
screen. A great advantage ofDNA arrays is the ability to monitor the expression of
thousands of known and novel genes in response to altering environmental stimuli,
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development, and in disease. In this way, links between genes can be found that would
never have been found by analysing the expression of genes one at a time. In addition,
analysis of the multi-gene expression patterns can provide clues about regulatory
mechanisms, broader cellular functions, and biochemical pathways.
6.3.3 Proteomics
The investigation of gene expression can be highly informative about cell state and the
activity of genes, but mRNA is only an intermediate on the way to a functional protein
product. Although in many cases, gene expression correlates with the translation ofmRNA
into a functional protein, in the functional genomic era, it is important to investigate where a
protein is expressed, its abundance and whether it is functional.
Although the analysis of proteins has proven more difficult, less sensitive, and lower
throughput than RNA-based methods, recent technological advances have allowed the large
scale analysis of proteins. This field which has been termed "proteomics", can be divided
into three main areas: 1) the characterisation of proteins and their post-translational
modifications, 2) "differential display" proteomics for the comparison ofprotein levels with
the potential application in a wide range of diseases, and 3) studies ofprotein-protein
interactions using techniques such as mass spectrometry (Shevchenko et al, 2000) or the
yeast two hybrid system (Fields and Song, 1989). The advances in techniques like mass
spectrometry of gel purified proteins has revolutionised proteomics. The purification and
analysis ofproteins and protein complexes, and the identification of interacting proteins will
be essential in the ultimate goal of understanding cellular physiology and the pathogenic
mechanisms of disease processes.
6.3.4 Identification of genetic determinants
Whereas the identification of single gene genetic disorders has proven fruitful, it has become
apparent that methods used to identify genes that underlie polygenic diseases are inadequate.
An example of this is the search for genes that underlie type 2 diabetes. Using the positional
gene method which utilises linkage analysis for DNA markers with the disease allele in
families with the genetic disorder, five genes have so far been identified that underlie the
monogenic MODY form of type 2 diabetes (discussed in Chapter 1). However, linkage
analysis ofpolygenic disorders have so far been largely unsuccessful. Genome-wide screens
to identify markers associated with the disease allele in sib pairs have only identified three
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loci for late-onset type 2 diabetes. This lack of success has been attributed to the polygenic
nature of the disease and also to different factors having more important affects in different
ethnic populations.
One method that has offered hope for identifying the genetic determinants in polygenic
disorders has been the identification and utilisation of single nucleotide polymorphisms
(SNPs). SNPs are present throughout the human genome with an average frequency of
approximately 1 per 1000 bp (Brookes, 1999). Much effort is being put into the
identification of SNPs, with the SNP consortium aiming for a target of over 300 000 SNPs.
The resultant SNP map will enable disease genes to be mapped by linkage disequilibrium
(Kruglyak, 1998). This works on the basis that linkage disequilibrium occurs when
haplotype combinations of alleles at different loci occur more frequently than would be
expected from random association; the linkage disequilibrium will decay over generations in
proportion to the recombination fraction between the loci. Therefore, consecutive SNP
variations that are in linkage disequilibrium and associated with a disease phenotype can
"mark" the position on the chromosome where a susceptibility gene is located.
Once enough SNPs have been identified and a cost effective high throughput method for
SNP screening has been obtained, the accurate assignment of chromosomal regions
containing susceptibility genes for polygenic disorders can be carried out (Zhao et al, 1998).
However, until a high density SNP map (one SNP every 10 kb) is available, the time
consuming and expensive individual testing ofmultiple candidate genes found to be located
within a linkage interval for a disease will continue. The benefits of SNP mapping can be
demonstrated using as an example the search for the gene underlying non-syndromic
sensorineural deafness DFNB9 (see chapter 5). The DFNB9 gene had been mapped by
linkage to a 2cM region of chromosome 2p23.3 (Chaib et al, 1996) that was shown to
contain a large number of transcripts. To identify the DFNB9 gene, candidates had to be
chosen formutation analysis based on expression analysis and putative function of the
encoded protein. This is a very time consuming and haphazard method. The DFNB9 gene
was eventually identified as encoding a novel protein called OTOF (Yasunaga et al, 1999)
but many other candidate gene had to be examined before its identification. This time
consuming process could have been much shorter if SNP mapping had been available. SNP
mapping in the 2 cM DFNB9 interval in the DFNB9 families would have identified a much
smaller genomic region showing SNP linkage disequilibrium associated with the DFNB9
phenotype. The genomic region could be relatively quickly sequenced and a much smaller
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number of candidate DFNB9 genes identified by sequence analysis. Therefore SNP mapping
would have beenmuch less time consuming and more cost effective.
Looking to the future, SNP mapping might have an important role in pharmacogenetics. This
is the study of how genetic differences influence the variability in patients responses to
drugs. An SNP profile might correlate to a good or bad response to a drug for a certain
disease (McCarthy and Hilfiker, 2000). By identifying patients who will respond to drug
treatments will provide better treatments for the patient in addition to much cost saving on
wasted treatments.
6.4 Summary
As discussed in this chapter, the progress of the Human Genome Project has resulted in
greater research emphasis on functional genomics. With the recent technological advances
in the field ofmolecular biology and proteomics for example DNA arrays and mass
spectrometry, in projects such as described in this thesis, a much more in depth analysis of
gene function, protein function, and in vivo protein interactions can now be performed. The
use of SNP maps and linkage disequilibrium should allow genes underlying both monogenic
and polygenic disorders to be elucidated, for example in the identification of type 2 diabetes
DFNB9 loci. Functional genomics will play an essential role in working out the pathogenic
mechanisms of these genetic diseases and in the long term, identify targets for disease




7 Materials and Methods
7.1 Materials
7.1.1 Chemicals and reagents
All chemicals for general use were supplied by Sigma (Sigma-Aldrich Company Ltd) or
BDH (Merck Ltd) unless otherwise stated, and were ofmolecular biology grade. Bacterial
media were supplied by Difco U.K. Ltd.
7.1.2 Radiochemicals
The radioactive isotopes [a32P] dCTP at a specific activity of 3000 Ci/mmol and [y12P] ATP
at a specific activity of 1415 Ci/mmol were supplied by Amersham Life Science. The four
Redivue™ 33P-labelled dideoxynucleotide terminators were also supplied by Amersham Life
Science.
7.1.3 Enzymes
Restriction enzymes, polynucleotide kinase and T4 DNA ligase were supplied either by
Gibco BRL Life Technologies or New England Biolabs. Klenow fragment ofE. coli DNA
polymerase I was provided with the Rediprime™ DNA labelling kit (Amersham Life
Science). Desiccated proteinase K and RNase A were supplied by Sigma. Taq DNA
polymerase was supplied at a concentration of 5 U/pl by Gibco BRL Life Technologies.
Thermo Sequenase™ DNA polymerase (a site-directed mutant of Taq polymerase with
improved affinity for dideoxynucleotides) was included with the Thermo Sequenase™
radiolabelled terminator cycle sequencing kit (Amersham Life Science) and AmpliTaq™
DNA polymerase was supplied with the ABI PRISM® BigDyeTM terminator cycle
sequencing kit (PE Applied Biosystems).
7.1.4 Nucleic acids, vectors and markers
Salmon sperm DNA was supplied by Sigma Chemical Company Ltd. pBluescript™ was
purchased from Stratagene. Subcloning-Efflciency™ DH5a™ competent E. coli cells were
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purchased from Gibco BRL Life Technologies. The 1 kb ladder DNA marker was obtained
from Gibco BRL Life Technologies.
7.1.5 Electrophoretic and DNA transfer materials
Standard grade agarose was supplied by Sigma Chemical Company Ltd. Acrylamide / bis-
acrylamide in proportions 19:1 were supplied as a 40% solution by BDH chemicals.
Hybond-N and HybondN+ hybridisation membranes were supplied by Amersham Life
Science. Hyperfilm MP™ X-ray film was supplied by Amersham Life Science.
7.1.6 Solutions and buffers
Unless otherwise stated, solutions and buffers were prepared using distilled and deionised
water and were stored at room temperature (i.e. between 15 and 25°C). Sterilisation was by
autoclaving at 15 psi 121°C (30 min). The components of general solutions and buffers are
presented in appendix 6.A. 1.
7.1.7 Fluorescent in situ hybridisation (FISH) materials and
solutions
All solutions for fluorescent in situ hybridisation (FISH) were prepared using distilled and
deionised water and stored at room temperature (unless otherwise stated). For YAC probes,
the clone was propagated on synthetic dextrose (SD) medium to obtain a pure, single colony
which was grown to saturation in SD broth. A total yeast DNA extract was obtained using
standard techniques. The probe was labelled by nick-translation with digoxigen-11 -dUTP
and 200 ng was used for FISH analysis as described by (Pinkel et al., 1986). Chromosomes
were identified with 4,6-diamidino-2-phenylindole-dihydrochloride (DAPI). Microscopy
was performed using a Zeiss Axioskop fluorescence microscope coupled to a CCD camera
and image analysis system (Vysis, UK).
FISH analysis was carried out by Dr Judy Fantes and Dr Jack Leek.
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7.2 Standard Methods
This section details the generalised methods for the molecular biology techniques used as
part of the work presented in this thesis. More specialised methodologies are described in
the chapters of this thesis where they have been used to generate the data described in those
sections.
7.2.1 Preparation of closed circle DNA from bacteria
The general method of alkaline lysis (Birnboim & Doly, 1979) was used for the preparation
ofplasmid DNA (including cosmids, PACs, and PI clones) from bacteria. For small scale
preparation (mini-prep) of plasmid and cosmid DNA, the following method was used:
A single colony was used to inoculate 10 ml ofLB-broth (see appendix 6.A.2), containing
the appropriate antibiotics (appendix 6.A.3). This culture was incubated overnight at 37°C
with vigorous shaking (225 rpm). The cells were pelleted by centrifugation at 13000 g (5
min) and resuspended in solution I (100 pi) to create a completely homogenous suspension.
Freshly made solution II (200 pi) was added and the mixture gently mixed by swirling.
Solution III (150 pi) was added and the mixture shaken vigorously. The lysate was spun at
13000 g (10 min), and the supernatant removed. An equal volume of saturated
phenol/chloroform was added and the tube shaken vigorously (1 min). The phases were
separated by centrifugation at 13000 g (5 min), and the bottom layer discarded. This process
was repeated once with saturated phenol/chloroform and again with chloroform. The DNA
was recovered by addition of absolute ethanol (3 vol.) and centrifugation at 13000 g (20 min,
room temperature). The supernatant was discarded and the DNA pellet washed with 70%
ethanol. The pellet was dissolved in TE (50 pi, pH8.0) and stored at -20°C.
The quality ofDNA produced by this method was adequate for sequencing using the 33P
cycle sequencing method (Amersham, see section 6.2.17). However, it was found that for
automated cycle sequencing, use of the S.N.A.P.™ (a simple nucleic acid prep) kit
(Invitrogen) gave better quality DNA as well as being a quicker method when handling large
numbers of samples. For large scale preparation of plasmid and cosmid DNA, the Qiagen
plasmid maxi kit was used according to supplied instructions.
For the isolation of high quality PAC DNA, a modified version of the alkaline lysis method
was used:
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A single colony was used to inoculate LB (5 ml) containing kanamycin (25 pg/ml) and
incubated at 37°C for 4-7 hr with vigorous shaking (225 rpm). The cells were pelleted by
centrifugation at 6000 g (20 min) and the supernatant discarded. The pellet was resuspended
in Solution I (5 ml) and left at room temperature (5 min). The cells were lysed by addition
of Solution II (5 ml) with gentle mixing and incubated at room temperature (10 min).
Solution III (5 ml) was added and mixed before placing on ice (10 min). The cell debris was
removed by centrifugation at 13000 g (20 min, 4°C) in Corex™ tubes. The supernatant was
filtered through cheese cloth into fresh Corex tubes and ice cold isopropanol (0.6 vol.)
added. Aftermixing well, the mixture was centrifuged at 13000 g (20 min). The supernatant
was poured off and the pellet washed with 70% ethanol. After air drying, the pellet was
resuspended in TE (1.5 ml, pH8.0). Ice cold 5 M LiCl (1.5 ml) was added and aftermixing,
the mixture was centrifuged at 13000 g (15 min, 4°C). The supernatant was transferred into
fresh Corex tubes and an equal volume of isopropanol added. After mixing, the mixture was
centrifuged at 13000 g (20 min) and the supernatant discarded before washing the pellet
with 70% ethanol. After air drying, the pellet was resuspended in TE (250 (ill, pH8.0)
containing RNAse A (20 pg/ml) and incubated at room temperature (30 min). To this
solution, 1.6 M NaCl containing 13% (w/v) polyethylene glycol (250 pi) was added and after
mixing, the PAC DNA recovered by centrifugation at 13000 g (15 min, 4°C). The
supernatant was removed by aspiration and the pellet resuspended in TE (200 pi, pH8.0).
To determine the concentration of the DNA, the absorption at 260 nm (A26o) was measured.
The spectrophotometer was first blanked using TE before the plasmid DNA sample (5-10 pi
of the miniprep) absorbance was measured. The formula below was used to estimate the
DNA concentration:
[DNA] = (A260)(0.05 mg/ml) x D
where D is the dilution factor.
7.2.2 Preparation of RNA from tissue culture cells - Guanidinium
Thiocyanate Method
The medium was removed from the culture dish and 0.5 ml of solution D (see Appendix A)
was added directly to the dish before scraping the cells into 2 ml tubes. (At this point the
cells can be frozen at -70°C if necessary). The cells were homogenised by passing the lysate
10 times through a 1 ml pipette tip. The following solutions were sequentially added: 2 M
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sodium acetate (0.05 ml), phenol (0.5 ml), chloroform isoamyl alcohol mixture 24:1 ratio
(0.1 ml). The mixture was mixed thoroughly by inversion after addition of each reagent.
After shaking vigorously for 10 s, the mixture was cooled on ice (15 min) before
centrifuging at 10,000 g at 4°C (20 min). The aqueous phase (containing the RNA) was
transferred to a fresh tube and mixed with isopropanol (0.5 ml) and cooled at -20°C for at
least 1 hr. After centrifuging at 10,000 g (20 min), the supernatant was removed and the
pellet redissolved in solution D (0.3 ml) and transferred to a 1.5 ml Eppendorf tube. The
RNA was precipitated with 1 volume of isopropanol and cooled at -20°C (1 hr) before
centrifuging at 4°C (10 min). The pellet was resuspended in 75% ethanol and centrifuged.
The pellet was vacuum dried (15 min) and dissolved in 0.5% SDS (50 jal) before incubating
at 65°C (10 min). The purified RNA was stored at -70°C.
7.2.3 The polymerase chain reaction (PCR)
7.2.3.1 Oligonucleotides
Oligonucleotide primers were generally designed by selecting a sequence of about 20
nucleotides, with approximately equal [G+C] to [A+T] content, taking care to ensure that the
two primers' 3' ends were not complementary. The primers were checked using the
"PRIMER" computer programme (PRIMER is copyright 1991 by The Whitehead Institute
for Biomedical Research) to ensure that they were not chosen from sequences which are
likely to be repetitive, and that they have approximately equal predicted melting
temperatures. Oligonucleotides were purchased from Sigma-Genosys and were supplied as
lyophilised products at a nominal synthesis scale of 0.03 pmol. The oligonucleotide
sequences used and their respective annealing temperatures are described in their respective
chapters.
7.2.3.2 The polymerase chain reaction (PCR)
The PCR reactions were carried out in a Hybaid Omnigene™ Thermal Cycler. The Gilson
pipettes, tips, and 0.5 ml PCR tubes were kept separate from those used in other experiments.
Reactions were also set up in a separate room to the one used for electrophoresis ofPCR
products. These precautions minimised the possibility of extraneous DNA contamination.
PCR was carried out in 1 x PCR buffer, with 200 pM deoxynucleoside triphosphates
(dNTPs), 15 pmol primers, template DNA (0.1 pg genomic DNA, 0.1-1 ng plasmid DNA),
and a concentration ofMg2+ particular to each set ofprimers (usually 1 -3 mM) in a volume
of 50 pi. After a denaturation step of 95°C (5 min) and the addition of 0.25 units Tag
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polymerase, the PCR conditions were 94°C for 1 min, the appropriate annealing temperature
for 1 min, and 72°C for 1 min (if product is <500 bp), 3 min (if product is >500 bp). The
number of cycles depended on the type ofDNA template: 25 cycles for plasmid, 30 cycles
for cosmid, 35 cycles for PAC, and 40 cycles for YAC and human genomic DNA. Reaction
mixes were overlaid with 50-75 pi mineral oil. The annealing temperatures used are
described along with oligonucleotide sequences in the respective chapters of this thesis.
7.2.3.3 RT-PCR and 5' RACE
For RT-PCR, the GibcoBRL RT-PCR kit was used.
In chapter 5, the method of 5' RACE (Frohman et al., 1988) was used to generate cDNA
sequence for the 5' end ofKIF3C. Briefly, 5 pg of total RNA from human fibroblasts was
mixed with the reverse KIF3C-specific primer (5'-dGGCCCCAGTGTGGCTACC-3'; Figure
5.6, nucleotides 1167-1184) and reverse transcribed with 200 U Superscript II™ reverse
transcriptase (GibcoBRL) at 42°C for 50 minutes. A poly(dA) tail was added to the 3'-end
of the cDNA and tailed cDNA was amplified with a (dT) n-adapter primer and the reverse
primer (5'-dGTGTGGCTACCATGATGGTC-3'; Figure 5.6, nucleotides 1158-1177). The
products of 5' RACE reactions were analysed by Southern blot hybridisation with 32P-
labelled primer (5'-dGGAGAGAGGCCTAAGGAAG-3'; Figure 5.6, nucleotides
1003-1021) and an 820 bp product was cloned into the TA vector (Invitrogen) and
sequenced with vector- and kinesin-specific oligonucleotide primers. Multiple PCR-derived
cDNA clones were used to check for errors in the nucleotide sequence produced by
amplification procedures.
7.2.3.3.1 First strand cDNA synthesis
In a 30 pi reaction volume, the following components were added to a nuclease-free
microcentrifuge tube: 5 pi RACE 2 primer (3 pM), 1-5 pg total RNA, sterile, distilled water
to 12 pi. The mixture was heated at 80°C (3 min) and chilled quickly on ice. The contents of
the tube were collected by brief centrifugation before adding: 6 pi 5 x first strand buffer (250
mM Tris-HCl, pH 8.3, 375 mM KC1, 15 mM MgCl2), 3 pi DTT (0.1 M), 3 pi 20 mM dNTP
mix (20 mM each dATP, dGTP, dCTP and dTTP at neutral pH).
The contents of the tube were mixed gently and incubated at 42°C (60 min) before adding 1
pi (200 units) of Superscript II and mixing by pipetting gently up and down. After
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incubation at 25°C (10 min), the mixture was incubated at 42°C (50 min) before inactivating
the reaction by heating at 70°C (15 min).
NOTE: The cDNA can now be used as a template for amplification in PCR. However,
amplification of some PCR targets (those >1 kb) may require the removal ofRNA
complementary to the cDNA. To remove RNA complementary to the cDNA, 1 pi (2 units)
ofE. coli RNase H is added, followed by incubation at 37°C for 20 min.
7.2.3.3.2 PCR Reaction
10% of the first strand reaction was used for PCR (adding larger amounts of the first strand
reaction may not increase amplification and may result in decreased amounts ofPCR
product). The PCR reaction was set up as described in section 6.2.3.2 and PCR performed
by following the PCR program: 5 min, 94°C, 40 x (94°C, 1 min; X°C, 1 min; 72°C, 2 min) -
where X is the annealing temperature for the specific primer pair used in the reaction.
7.2.4 Restriction enzyme digestion of DNA
Restriction endonuclease digestions were performed under the appropriate conditions as
recommended by the manufacturers, and with the buffers supplied with the enzymes. In
general, 5 pg of genomic DNA was mixed with 4pl lOx restriction enzyme buffer and 30
units of enzyme, in a total volume of 40 pi (made up with sterile water) and incubated (5-16
hr) at the optimal temperature for the enzyme. Restriction enzyme digestion ofplasmid,
cosmid and PAC DNA was generally carried out using 2-5 jig ofDNA in a volume of 20 pi.
If the DNA was to be used for another manipulation, the enzyme was heat inactivated (if
heat labile) at 65 °C (15 min) or phenol/chloroform extracted and ethanol precipitated.
7.2.5 Agarose gel electrophoresis
Digested DNA was size-fractionated by agarose gel electrophoresis with gels prepared to
concentrations ofbetween 0.8 and 1.5% w/v agarose (unless stated otherwise) in the
appropriate volume of 1 x TAE or 0.5 x TBE buffer (Appendix 6.A. 1). Prior to
electrophoresis, DNA samples were combined with one-tenth volume DNA loading buffer.
Electrophoresis was performed at 50-150 V until dye markers had migrated an appropriate
distance, depending on the size ofDNA to be visualised. Estimation of the size of
fractionated DNA was achieved by running 0.5 pg of 1 kb ladder (Gibco BRL Life
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Technologies) alongside the DNA samples. DNA was visualised by viewing under
ultraviolet (UV) transillumination and photographed using an electronic imager (Appligene).
7.2.6 Phenol/chloroform extraction of DNA
An equal volume ofbuffer-saturated phenol/chloroform/isoamyl alcohol (25:24:1) was
added to the DNA solution. Aftermixing well (most DNA solutions can be vortexed for 10
s, except for high molecular weight DNA, which should be gently rocked), the mixture was
microcentrifuged (3 min). The aqueous layer was carefully removed (being careful to avoid
the interface) and placed in a new tube. This phenol/chloroform extraction can be repeated
until an interface is no longer visible. To remove traces ofphenol, an equal volume of
chloroform was added to the aqueous layer and the mixture microcentrifuged (3 min). The
aqueous layer was removed placed in new tube before ethanol precipitating the DNA.
7.2.7 Ethanol precipitation of DNA
The volume of the DNA sample was measured and the salt concentration adjusted by adding
1/10 volume of sodium acetate (3 M; pH 5.2), or an equal volume of ammonium acetate (5
M). Aftermixing well, 2 to 2.5 volumes of cold 100% ethanol (calculated after salt addition)
was added and again mixed well. If small amounts ofDNA were to be recovered, 5-10 jag
tRNA was added to increase recovery from dilute DNA solutions. The mixture was placed
on ice or at -20°C for >20 minutes. After spinning at maximum speed in a microfuge (10-15
min), the supernatant was carefully decanted off. The pellet was washed in 70% ethanol (1
ml) and spun briefly. The supernatant was carefully decanted off before air drying or briefly
vacuum drying the pellet and resuspending in the appropriate volume ofTE (pH8.0) or
water.
7.2.8 Method for purifying DNA from agarose gels
The DNA band of interest was excised from a TAE gel and its volume estimated by
weighing the gel slice. After dissolving the gel slice in 3 volumes ofNaI/Na2S03 solution by
heating at 65 °C for 5 min or until the gel dissolved, 8 ul of glass milk (thoroughly vortex
glass milk before use) was added and the tube placed on ice (15 min). The mixture was
microcentrifuged and the pellet washed with ice cold ethanol (200 p.1). The mixture was
again microcentrifuged and the supernatant discarded. This washing process was repeated a
further two times before resuspending the glass milk in 20 |il TE. After heating at 50°C (10
212
min), the mixture was microcentrifuged at full speed (30 sec) and TE removed (now
containing eluted DNA). This elution process was repeated by addition of a further 20 pi of
TE, heating at 50°C (10 min) and microcentrifuging at full speed (30 sec).
7.2.9 Subcloning
7.2.9.1 Restriction digestion and dephosphorylation of DNA
Restriction enzyme digestion of plasmid DNA was carried out essentially as described in
section 6.2.4, using 2-5 pg ofDNA in a reaction volume of 20 pi. The terminal phosphate of
linearised vector DNA was removed using calf intestinal phosphatase (CIP) to prevent self-
ligation of the ends in subsequent cloning experiments. The vector DNA (2-5 pg of
pBluescript™; Pharmacia) was digested with the restriction enzyme of choice in the
appropriate buffer for the enzyme. CIP (0.2 units) was added and incubated at 37°C (1 hr)
after which the CIP was inactivated by heating at 85°C (15 min). The CIP was removed by
phenol / chloroform extraction and the DNA was recovered by ethanol precipitation. The
pellet was washed in 70% ethanol, dried and resuspended in a suitable volume ofTE.
7.2.9.2 Ligation of DNA
The insert DNA was digested with the appropriate restriction enzyme and ligated to the
appropriate cut and phosphatased vector in a volume of 20 pi. A three fold molar excess of
insert DNA : vector DNA was used for most cloning experiments. Reactions were
performed in 1 x T4 DNA ligase buffer and 1 unit ofT4 DNA ligase at 14°C overnight.
7.2.9.3 Preparation of competent E. coli
Competent cells were prepared using the calcium chloride procedure as described by
Sambrook et al. (1989). The host cells used in the cloning process were the E. coli strain
DH5a. These cells are a restriction-deficient strain ofE.coli, which are also endonuclease
deficient and recombination deficient, ensuring stability of any inserts cloned within the
system. This bacterial strain contains the F' episome and also a defective copy of the lacZ
gene. The latter can be activated to generate an active (3-galactosidase enzyme by
a-complementation from a peptide encoded on many common cloning vectors. These
plasmid vectors' cloning sites interrupt the peptide coding region, so that
a-complementation is lost by ligation of an insert. On a medium containing the
chromogenic lactose analogue 5-bromo-4-chloro-3-indolyl-(3-D-galactopyranoside (X-gal),
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and the lac operon inducer isopropyl-(3-D-galactopyranoside (IPTG), colonies carrying
uninterrupted plasmids are blue. Most insert-bearing plasmids fail to complement the
defective lacZ and are white (or pale blue).
7.2.9.4 Transformation of competent E. coli
For transformation, generally up to 10 pi ligation reaction (50-100 ng) was added to a 200 pi
aliquot of competent cells, cooled on ice (40 min), heat shocked at 42°C (90 sec) and cooled
on ice (2 min). LB-medium (500 pi) without antibiotic was added to the transformation
reaction and the mixture incubated at 37°C (1 hr), to allow for pre-expression of the
antibiotic resistance. The transformation mix was then plated onto LB-agar plates with the
appropriate antibiotic and incubated at 37°C overnight. When using the blue/white selection
screening, 50 pi ofX-Gal (2% solution in dimethylformamide) and 20 pi of 100 mM IPTG
were added to the LB-agar before pouring the plates. The transformation efficiency was
tested by transforming with 10 ng of undigested vector DNA. The efficiency of the CIP
reaction was examined by transforming with a control ligation performed using
dephosphorylated vector without insert DNA.
7.2.9.5 Electrotransformation of competent E. coli
For transformation, generally 1-2 pi ligation reaction (50-100 ng) was added to a 40 pi
aliquot of competent cells in an electroporation cuvette. The Gene Pulser apparatus
(Bio-Rad) was set to 25pF, 2.5kV, 200Q. The cells were pulsed to a time constant of 4.5-5
msec and immediately resuspended in 1ml of ice-cold LB-medium. The cell suspension was
transferred to a 17 x 100 mm polypropylene tube and incubated at 37°C, 225rpm for 1 hour.
The transformation mix was subsequently treated according to the method described above.
7.2.10 Cosmid Fingerprinting
Fluorescent fingerprinting was performed using the method described by Carrano et al.,
1989. A single reaction mixture was used to restriction digest the cosmid DNA and ligate
fluorescent primers to the restriction fragment ends (see Chapter 3, Section 3.2.2). The
mixture consisted of: 1 pg cosmid DNA, 1 pi fluorescent dye labelled universal primer (ratio
ofprimer to insert ends, 0.5-2), 1 pi complementary synthetic oligonucleotide (at the same
ratio as the dye primer), 10 units of restriction enzyme, lpl lOx restriction enzyme buffer, 2
pi T4 DNA ligase (0.5 unit/pl), 1 pi 8.8 mM ATP, 1.4 pi lOOmM DTT, and water to bring
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the total volume to 10 ul. The mixture was incubated at 37°C overnight (12-14 hr) before
addition of 1 pi Hinfl restriction enzyme (40 units/|Lll) and a further 4 hr incubation at 37°C.
Each tube was cooled on ice, and 0.5 jlxI of 500 mM EDTA added. The sample was
precipitated with ammonium acetate (0.75 M), glycogen (lpl of 20 mg/ml stock, and 2.5 vol.
95% ethanol). The precipitate was washed in ethanol and resuspended in 4 pi ofTE buffer
(10 mM Tris-HCl, 1 mM EDTA, pH 7.4). After at least 60 min of resuspension, 4 pi of de-
ionised formamide and 0.5 pi size standard (GENSCAN TAMRA 500) were added. The
DNA was denatured at 95°C for 5 min before loading 2.5 pi into a single lane of a
denaturing (8 M urea) polyacrylamide gel and run using the Genscan software package on
the ABI 377 Fluorescent DNA sequencer. The cosmid fragments were sized by comparison
to the internal lane size standard and the cosmids assembled into a contig according to the
number of shared fragments of equal size.
7.2.11 Southern blotting
Transfer ofDNA from agarose to nylon membrane was performed according to the method
originally described by Southern, 1975. Prior to DNA transfer, the gels were treated in
depurination solution (10 min, room temperature) with gentle agitation (this step is necessary
if target sequences are greater than 10 kb in size), denaturation solution (25 min, room
temperature) with gentle agitation, and neutralisation solution (30 min, room temperature)
with gentle agitation. The DNA was transferred from the gel to a Hybond-N ' nylon
membrane using capillary blotting apparatus that consisted of a reservoir of 10 x SSC (the
transfer buffer), Whatman 3MM paper wicks and a blotting platform. The DNA was
allowed to transfer for at least 16 hr. After transfer, the membrane was rinsed four times
with 2 x SSC (5 min). The membrane was either baked at 80°C (2 hr) or UV cross-linked to
fix the DNA to the membrane.
7.2.12 Northern blotting
RNA agarose gels must be run in gel tanks specifically for RNA work. The gel tank was
washed with 0.1% SDS and rinsed well with Nanopure™ water before using. The RNA gel
was prepared by first autoclaving agarose (1.5 g), 20 x MOPS (5 ml), and water (80 ml).
After boiling and allowing to cool to ~60°C, formaldehyde (15 ml of a 37% solution) was
added (this procedure was carried out in a fume cupboard). The RNA samples were
prepared using 10-20 pg RNA = 1 volume + 3 volume loading buffer. After heating the
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samples at 65°C (10 min), the samples were loaded onto the gel and electrophoresed at 100
V for 4 hrs in 1 x MOPS buffer. Then the RNA gel was washed in water before washing in
20 x SSC. The gel was blotted onto Hybond-N nylon membrane using 20 x SSC as transfer
buffer (the blotting apparatus consisted of the same set-up as described for Southern blotting
- section 6.2.11). The blot was washed in 50 mM sodium phosphate (pH 7.2) and baked at
80°C (1 hr). The filter was pre-hybridised in Church buffer for at least 1 hr before
hybridising in 10 ml of Church buffer with a labelled probe overnight. After hybridisation,
the filter was washed three times (30 min per wash) at 65°C in 50 mM sodium phosphate,
pH 7.2 / 1% SDS. The filter was air dried, sealed in a polythene bag and exposed overnight
to x-ray film.
To examine expression of the human KIF3C gene, a multiple tissue Northern blot (Clontech)
was hybridised at 65°C overnight in a solution consisting of 0.5M sodium phosphate, 1%
BSA, 7% SDS, ImM EDTA and 50)Lig/ml denatured herring sperm DNA. The probe was a
32P-labelled 818 bp PCR product encoding the motor domain (nucleotides 360-1177, Figure
5.6). Following hybridisation, the blot was washed twice in 2 x SSC, 0.1% SDS at 65°C for
40 minutes.
7.2.13 Use of Radiolabeled DNA probes
7.2.13.1 Radiolabelling DNA probes
Probes were labelled by the random hexanucleotide priming method (Feinberg & Vogelstein,
1983) using the Rediprime™ DNA labelling system (Amersham) and with [a32P] dCTP
(3000 Ci/mmol) as the radioisotope. The DNA probe (25 ng) was made up to 45 jxl volume
using distilled deionised water and denatured by boiling (5 min). Klenow enzyme, random
9mer primers and a buffered solution of dATP, dGTP, and dTTP were all supplied in a
single tube in a dried stabilised form (1 per reaction) in the labelling kit. Following
denaturation of the probe and snap cooling on ice, the probe was centrifuged at 13000 g (30
sec) and the DNA added to the tube of labelling mix. Following the addition of 20 pCi
[a32P] dCTP (2 |ul) the reaction was incubated at 37°C for 30 min and then centrifuged
through a Sephadex G-50 column at 1500 g (1 min) to remove unincorporated nucleotides.
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7.2.13.2 Hybridisation of DNA probes to Hybond N+ nylon membranes
Hybridisations were performed at 65 °C in hybridisation bottles in a volume of 15 ml
hybridisation buffer per 20 x 20 cm filter. Hybond N+ nylon membranes were pre-hybridised
in hybridisation buffer at 65°C (1 hr). Radiolabelled probes were first denatured along with
sonicated salmon sperm DNA (250 |ll lOmg/ml solution per 10 ml of hybridisation buffer)
by boiling (5 min). Probe and salmon sperm were added directly to the hybridisation bottle
containing the membrane and pre-hybridisation buffer, and hybridised at 65°C (16-24 hr).
7.2.13.3 Post-hybridisation washing and radioactive signal detection
Following hybridisation, residual non-specifically bound probe was removed by washing
twice in 2 x SSC (10 min, room temperature), followed by two washes in 2 x SSC / 0.1%
SDS at 65°C (15 min). When greater stringencies were required, membranes were washed
with 0.1 x SSC / 0.1% SDS at 65°C for varying lengths of time. For radioactive signal
detection, membranes were exposed to autoradiographic X-ray film (Hyperfilm; Amersham)
in light proof cassettes at -70°C with intensifying screens for between 16 hours and 14 days.
7.2.13.4 Removal of radiolabelled probe
To remove radiolabelled probes for subsequent hybridisation experiments, membranes were
submerged in boiling 0.1 x SSC / 0.1% SDS in a plastic sandwich box, and left to cool to
room temperature. Membranes were exposed to autoradiographic film as previously




Sequencing ofDNA was performed using either the Thermo Sequenase™ radiolabeled
terminator cycle sequencing protocal (Amersham Life Science) or the BigDye™ terminator
cycle sequencing protocol (PE Applied Biosystems). It was found that the radioactive
Thermo Sequenase protocol worked well for DNA templates such as PCR products, plasmid,
cosmid and PAC, but that the automated BigDye™ terminator cycle sequencing protocol
worked well only for only PCR products and plasmid template. However, the automated
fluorescent method was more efficient and less time consuming for sequencing large
numbers of samples.
7.2.14.2 Thermo Sequenase radiolabeled terminator cycle sequencing
7.2.14.2.1 Method for sequencing clones or plasmid
One reaction mixture was prepared for each sequencing primer consisting of: reaction buffer
(2|ill), template DNA (25-250 fmol), primer (2pmol), H20 (to adjust total volume to 20 pi),
and Thermo Sequenase polymerase (2pl) which was added last. Note: in most cases, half
reaction volumes produced adequate results.
7.2.14.2.2 Sequencing of PCR products
Before sequencing, PCR products were treated with a combination of exonuclease I and
shrimp alkaline phosphatase (SAP). The exonuclease I removes residual single-stranded
primers and any extraneous single stranded DNA produced by the PCR. The shrimp alkaline
phosphatase removes the remaining dNTPs from the PCR mixture to prevent any
interference with the sequencing reactions. The reaction mix consisted of: 5 pi PCR product,
1 pi exonuclease I, and 1 pi SAP. The reaction was incubated at 37°C (15 min) before
inactivating the enzymes at 80°C (15 min). The treated PCR product (1 pi; equivalent to 10-
100 fmol) can now be used directly for sequencing using the Thermo Sequenase
radiolabelled terminator cycle sequencing kit.
7.2.14.3 BigDye™ terminator cycle sequencing
The BigDye™ terminator cycle sequencing reaction mixes were set up in PCR tubes (0.5 ml)
and consisted of: terminator ready reaction mix (4 pi), primer (3.2 pmol), template DNA
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(single-stranded DNA: 25-50 ng; double-strandedDNA: 100-250 ng; PCR product DNA:
15-45 ng), and deionised water (total volume: 10 pi). (Note: before sequencing PCR
products, the PCR products were cleaned by using the Qiagen PCR product clean up system
according to manufacturers instructions.) The reaction mix was mixed well and
microcentrifuged briefly. The PCR tubes were transferred to a thermal cycler (MJ225) and
25 cycles of the following program run: rapid thermal ramp (l°C/sec) to 96°C, 96°C for 30
sec, rapid thermal ramp to 50°C, 50°C for 15 sec, rapid thermal ramp to 60°C, 60°C for 4
min, rapid thermal ramp to 4°C and held until ready to purify. The contents of the tubes
were spun down in a microcentrifuge and the sequencing products purified by ethanol
precipitation. After drying, the pellets can be stored at -20°C or resuspended in loading dye
(3 pi) in preparation for sample loading. Samples were denatured at 95°C (5 min) prior to
loading 2 pi of sample onto an ABI sequencing gel.
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7.A Materials and Methods Appendices








5 x T4 DNA ligase buffer
50 x Denhardt's solution










10 x PCR buffer
5 x Long range PCR buffer #1
10 mM Tris-HCl, ImM EDTA, pH 8.0.
0.4 M Tris, 10 mM EDTA, 9 ml/L glacial acetic acid.
1 M Boric acid, 1 M Tris, 20 mM EDTA.
10% w/v sodium dodecyl sulphate.
0.2 M MOPS, 0.05 M sodium acetate, 0.01 M EDTA.
3 M NaCl, 0.3 M trisodium citrate.
3.6 M NaCl, 0.2 M sodium phosphate, 0.02 M EDTA pH7.0.
250 mM Tris-HCl pH7.6, 50 mM MgCl2, 5 mM ATP, 5 mM
DTT, 25% w/v polyethylene glycol 8000.
1% w/v BSA, 1% w/v Ficoll, 1% w/v polyvinylpyrrolidone.
28.5% acrylamide, 1.5% N,N' - methylenebisacrylamide.
0.5 M sodium phosphate pH7.2, 7% SDS, 1 mM EDTA.
1.5 M NaCl, 0.5 MNaOH.
250mM HC1.
0.25% bromophenol blue, 15% Ficoll.
50% ethanol, 0.1 M NaCl, 10 mM Tris-HCl pH7.5, 1 mM
EDTA. Store at-20°C.
Mix Silica, 325 Mesh (a powdered flint glass obtainable
from ceramic stores) with TE buffer and store as a 50%
slurry.
10% w/v dextran sulphate, 6 x SSC, 4 x Denhardt's solution,
0.5% SDS, 1% PPi.
Dissolve 90.8 g Nal and 1.5 g Na2S03 in 100 ml H20. Filter
through Whatman paper before adding 0.5 g Na2S03.
Solution should be saturated. Store in the dark.
1.5 M NaCl, 0.5 M Tris-HCl, pH adjusted to 7.5.
500 mM KC1, 250 mM Tricine, 125 mM KOH, 15 mM
MgCl2, pH 8.3.
425 mM Potassium acetate, 125 mM Tricine (pH8.7), 40%
glycerol, 5% DMSO, 6 mM MgCl2.
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0.7 M Tris-HCl pH8.0, 0.1 M MgCl2, 50 mM DTT.
5 x SSC, 2.5 x Denhardt's solution, 0.1% SDS, 0.1% PPi.
20 x MOPS (50(1.1), formamide (500ul), 37% formaldehyde
(150|_il), 10 mg/ml ethidium bromide (3)0,1), DNA loading
buffer (lOOjol).
10 mg/ml RNase Ain lOmM Tris-HCl pH7.5, 15 mM NaCl.
Boil the solution for 15 minutes to destroy DNase activity
and allow to cool slowly to room temperature.
Store at -20°C.
4M guanidinium thiocyanate, 25 mM sodium citrate, pH7;
0.5% sarcosyl, 0.1 M 2-mercaptoethanol.







50 mM glucose, 25mM Tris-HCl pH8.0, lOmM Na2EDTA
pH8.0, 100 pg/ml RNase A. Filter sterilise. Store at 4°C.
0.2 M sodium hydroxide, 1% SDS. Filter sterilise. Store at
room temperature.
5 M potassium acetate (60ml), glacial acetic acid (11.5ml).
Make up to 100ml. Autoclave. Store at 4°C. (The resulting
solution III is 5 M with respect to acetate and 3 M with
respect to potassium).
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Appendix 7.A.2 Growth media for bacterial cultures
Luria-Bertani (LB) Medium 10 g/1 Bacto-tryptone, 5 g/1 Bacto-yeast extract, 5 g/1 NaCl.
LB agar 10 g/1 Bacto-tryptone, 5 g/1 Bacto-yeast extract, 5 g/1 NaCl,
15 g/1 Bacto-agar.
Appendix 7.A.3 Antibiotics
Ampicillin 50 mg/ml in H20 stock solution, 20 |U.g/ml working
concentration.
Kanamycin 10 mg/ml in H20 stock solution, 10 pg/ml working
concentration.
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Fig. 1. Co-localization of Gckr and Khk on mouse Chr 5. The gene order
and relative positions of markers used in this study are shown. Map dis¬
tances in centimorgans are shown on the left.
Loci names: Glucokinase regulatory protein and ketohexokinase
Loci symbols: Gckr and Khk
Map position: Gckr and Khk map to the proximal part of Chro¬
mosome (Chr) 5, cosegregating with a number of other loci in¬
cluding D5MU149. D5Mitl-3A9 ± L81-£>5B;>5-1.06 ± 1.06-
Nos3/Dpp6/Fgl2-\.06 ± \.06-Htr5a/Gbxl/En2/Nkxl-l/Plk-psl/
D5Mitl49/D5Wsul 78e/D5Xrf391/D5Bir6/Znt3/Gckr/Khk-1.06 ±
1,06-D5Mit351/D5Xrf47-\ .06 ± 1 X)6-Crmpl/D5Bir7/Msxl-2.13
± 1.49-Bapxl (Fig. 1).
Method of mapping: Using The Jackson Laboratory Backcross
DNA Panel Mapping Resource, 94 backcross animals from the
interspecific cross (C57BL/6JEi x SPRET/Ei) x SPRET/Ei were
typed with a PCR/restriction digest assay to reveal the variants.
Database deposit information: Typing data is deposited under
accession number MGD-JNUM-37599 at http://www.jax.org/
resources/documents/cmdata.
Molecular reagents: For Gckr, a ~4-kb fragment corresponding to
human exons 2-8 [1] was amplified, and the PCR product ends
were sequenced. The C57BL/6 and Mus spretus sequences diverge
145 bp upstream of the IVS7-exon 8 splice junction, where a
poly(A) sequence (on the sense strand) is found in C57BL/6J
but the start of a B1 repetitive element-like sequence is present
in M. spretus. (The C57BL/6J PCR product is also 200-300 bp
larger than that ofM. spretus.) A single nt variant 55 bp upstream
of the splice junction alters a XcmI cutting site (present in
M. spretus but absent in C57BL/6). A new primer GreSB (5'-
dCTTGGTTGAGGAATCTATTTCTAG-3') within intron 7 was
used with the exon 8 primer Gre7R (5'-dGCTCACTGGATT-
GAAGCCAACC-3') to type the polymorphism by PCR with stan¬
dard buffers (1.5 mM MgCL) and an annealing temperature of
55°C. For Khk, primers KhkM4 (5'-dTGAGGGGCTTGTA-
CAGTCGAG-3') and KhkR9 (5'-dCCACCTGGCACCC-
GAATCTC-3'), designed from the sequences of rat [2] and mouse
[3] Khk cDNA, were used to amplify a ~400-bp genomic fragment
corresponding to exons 6-8, with an annealing temperature of
64 °C.
Allele detection: GreSB and Gre7R amplify a ~200-bp Gckr frag¬
ment that, if derived from an M. spretus allele, cuts with Xcml to
yield fragments of size -150 bp and -50 bp. Mbol digestion of the
Khk ~400-bp genomic fragment produces a fragment of 300 bp
from the C57BL/6J Khk allele and 220 bp from M. spretus.
Previously identified homologs: Human GCKR and KHK co-
localize to Chr. 2p23.2-23.3 [4],
Discussion: Gckr encodes the regulatory protein of glucokinase,
which binds to and inhibits glucokinase in liver and probably
pancreatic islet [5,6], This inhibitory interaction is promoted by
fructose-6-phosphate and relieved by fructose-1-phosphate, the
product of ketohexokinase (KHK). The postulated metabolic link
between KHK and GCKR therefore makes the co-localization of
their genes in human, and as shown here also in mouse, notewor¬
thy. YAC contig mapping indicates the phosphatase gene PPP1CB
to lie <400 kb from human KHK (gene order PPP1CB-KHK-
GCKR) [1,4]. However, the mouse homolog of human PPP1CB
maps, like several other human genes located on 2p, to mouse Chr
12D [7], The co-localization of Gckr and Khk despite their non-
syntenic relationship with PPP1CB, which is adjacent in human,
adds circumstantial support to the possibility of co-ordinate regu¬
lation of Gckr and Khk.
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We report the cloning and characterization of a
novel human kinesin-like gene with strong homology
to the mouse kinesin Kif3c. The full-length cDNA con¬
tains an open reading frame of2382 nucleotides encod¬
ing a predicted 793 amino acid peptide that includes
a 389 amino acidmotor domain conserved amongother
kinesins. PCR and DNA sequence analysis of PAC
clones containing the humanKIF3C sequence revealed
that the gene contains 8 exons. All introns have the
conserved GT and AG dinucleotides present at their
donor and acceptor sites, respectively. We have local¬
ized KIF3C to chromosome band 2p23 by fluorescence
in situ hybridization. © 1998 Academic Press
Kinesin heavy chain and kinesin-related proteins
(KRPs) constitute a superfamily of molecular motors
that utilize energy derived from the hydrolysis of ATP
to translocate vesicles and organelles along microtu¬
bules (for review see ref 1). They thus play important
roles in various intracellular transport events. Kinesin
is a tetramer composed of two identical heavy chains
(110-120KD) and two identical light chains (60-70KD)
(2-3). Members of the KRP family share a similar struc¬
ture which can be subdivided into three domains (4).
The globular amino-terminal region forms a motor do¬
main, which contains consensus sites for putative ATP-
and microtubule-binding. The central region folds into
a long a-helical coiled coil and forms the rod domain
which allows heterodimerization (5). Finally, the car-
boxy-terminal globular domain interacts with the light
chains and possibly other cytoplasmic components.
1 Corresponding author. Fax: 044 113 2444475. E-mail: mmeeart@
stjames.leeds.ac.uk.
This is assumed to be the binding site for specific
"cargo" proteins. Amino acid sequence analysis of dif¬
ferent KRPs from a variety of species revealed that
the motor domain is highly conserved, usually 35-45%
identical between all kinesin superfamily members (6),
whereas the rod and tail domains are more divergent.
Phylogenetic analysis of the conserved motor domains
groups the kinesin proteins into a number of subfami¬
lies, the members of which have more closely related
motor domain sequences, exhibit sequence similarity
outside of the motor domain and share common molecu¬
lar organization and cellular function (7).
Here we report the isolation, characterisation, pat¬
tern of tissue expression and chromosomal localiza¬
tion of a novel human gene that encodes a protein
similar to members of the KIF3 family of kinesin-re¬
lated proteins.
METHODS
cDNA Cloning and sequencing. An I.M.A.G.E clone 28784 (8) con¬
taining sequence from EST stSG4510 was obtained from Research
Genetics and sequenced. Oligonucleotides were synthesized from this
sequence (dGGAGATCCAGGACCAGCATG; dGCTGTCCAATCGCA-
TGAGCC, respectively) and a 442 bp cDNA probe (corresponding to
nucleotides 1953 to 2394 of human KIF3C; Figure 1) was amplified
by PCR, radiolabeled using a random primer DNA labeling kit (Boeh-
ringer) and used to screen a human fetal brain cDNA library (Clon-
tech). Sequence analysis of a clone containing a 4kb insert revealed
the cDNA to be a hybrid of an unrelated human sequence fused to
a kinesin-like open reading frame (Figure 1, nt 874-2320).
To determine the 5' end of the cDNA sequence RACE amplifica¬
tions were performed as previously described (9). 5/jg of total RNA
from human fibroblasts was mixed with the reverse R7F3C-specific
primer (dGGCCCCAGTGTGGCTACC, nt 1167-1184) and reverse
transcribed with 200U Superscript II reverse transcriptase (Gibco
BRL) at 42°C for 50 minutes. A poly(A) tail was added to the 3'-end
of the cDNA and tailed cDNA was amplified with a d(T)-adapter
407 0006-291X/98 $25.00
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13 54 GGGAAGCGGCCCCGGAGGAAGAGCAGCCGCAGGAAGAAGGCCGTGTCCGCCCCGCCTGGG 1413
401 GKRPRRKSSRRKKAVSAPPG
1414 TACCCTGAGGGCCCAGTGATTGAGGCTTGGGTGGCAGAAGAGGAGGATGACAACAACAAC 1473













































































FIG. 1. The complete K1F3C cDNA sequence and its putative translation product. The termination signal is marked with an asterisk
and the polyA addition signal is underlined. The conserved ATP/GTP-binding motif and kinesin motor domain signature are boldface. The
first base of exons 2-8 is underlined.
primer and the reverse primer (dGTGTGGCTACCATGATGGTC, nt
1158-1177). The products of 5' RACE reactions were analysed by
Southern blot hybridization with 32P-labelled primer (dGGAGAGAG-
GCCTAAGGAAG, nt 1003-1021) and an 820 bp product was cloned
into the TA vector (Invitrogen) and sequenced with vector- and
kinesin-specific oligonucleotide primers. Multiple PCR-derived
cDNA clones were used to check for errors in the nucleotide sequence
produced by amplification procedures. The remaining 357 bp from
the 5' end and 1181bp from the 3' end of the gene were sequenced
from PAC genomic DNA.
DNA sequencing was performed on both strands of cloned cDNA
using either the Thermosequenase cycle sequencing kit (Amersham)
or AmpliTaq cycle squencing kit (Perkin Elmer) and the ABI Prism
377 DNA sequencer.
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mokif3b MSKLKSSESV RVWRCRPMN GKEKAASYDK WDVDVKLGQ VSVKNPKGTS HEMPKTFTFD AVYDWNAKQF ELYDETFRPL VDSVLQGFNG
S.pur95K MSK.KSAETV KVWRCRPMN SKEISQGHKR IVEMDNKRGL VEVTNPKGPP GEPNKSFTFD TVYDWNSKQI DLYDETFRSL VESVLQGFNG
hukif3c M ASKTKASEAL KWARCRPLS RKEEAAGHEQ ILTMDVKLGQ VTLRNPRAAP GELPKTFTFD AVYDASSKQA DLYDETVRPL IDSVLQGFNG
mokif3a MPINK SEKPESCDNV KWVRCRPLN EREKSMCYRQ AVSVDEMRGT ITV.HKTDSS NEPPKTFTFD TVFGPESKQL DVYNLTARPI IDSVLEGYNG
Dros68D MSAKSRRPGT GSSQTPNECV QVWRCRPMS NRERSERSPE WNVYPNRGV VELQNWDGN KEQRKVFTYD AAYDASATQT TLYHEWFPL VSSVLEGFNG

































































mokif3b IEHVMNVGNQ NRSVGATNMN EHSSRSHAIF VITIECSEVG LDGENHIRVG KLNLVDLAGS ERQAKT GAQGERLKEA
S.pur95K IEHVMTVGNN NRSVGSTNMN EHSSRSHAIF IITIECSELG VDGENHIRVG KLNLVDLAGS ERQAKT GATGDRLKEA
hukif3c IEHVMNLGNQ TRAVGSTHMN EVSSRSHAIF IITVECSERG SDGQDHIRVG KLNLVDLAGS ERQNKAGPNT AGGAATPSSG GGGGGGGSGG GAGGERPKEA
mokif3a MDRIMTLGHK NRSVGATNMN EHSSRSHAIF TITIECSEKG VDGNMHVRMG KLHLVDLAGS ERQAKT GATGQRLKEA
Dros68D MIKVMQVGNK NRTVGFTNMN EHSSRSHAIF MIKIEMCDTE T...NTIKVG KLNLIDLAGS ERQSKT GASAERLKEA



































































FIG. 2. Comparison of the human KIF3C motor domain with homologous KIF3 proteins; mouse KIF3A (P28741), KIF3B (D26077), sea
urchin 95K (P46871), and Drosophila 68D(P46867). The ATP/GTP-binding motif and kinesin motor domain signature are again boldface.
The BLAST algorithm (10) was used to search for homologies or
identities between sequences identified and sequences entered in the
GenBank database.
The cDNA sequence has been submitted to GenBank and assigned
accession number AF035621.
Structural analysis. A PAC human genomic library (obtained
from the HGMP Resource Centre, Hinxton, U.K) was screened by
PCR using the stSG4510-specific primers (dCCTAGAGACATTTG-
GGCCA and dTTGCCTGTTACCCCTGTTTC; nt 3678-3697 and
3557-3576 respectively) and two positive clones were obtained. Oligo¬
nucleotides were designed from the cDNA and used to obtain se¬
quence data across the exon/intron boundaries from PAC genomic
DNA. Sizes of introns were determined by amplification across each
intron using PAC genomic DNA as template and primers located
within adjacent exons. The fragments amplified were analysed on a
1.5 % agarose gel and sized against a GibcoBRL 1 kb DNA ladder.
Genomic sequences have been submitted to the EMBL sequence
database and assigned accession numbers AJ002223-AJ002229.
Northern blot analysis. To examine expression of the human
KIF3C gene, a multiple tissue Northern blot was hybridized at 65°C
overnight in a solution consisting of 0.5M sodium phosphate buffer
pH 7.2, 1% BSA, 7% SDS, ImM EDTA and 50pg/ml denatured her¬
ring sperm DNA with a 32P-labeled 818 bp PCR product encoding
the motor domain (nt 360-1177, Figure 1). Following hybridization,
the blot was washed twice in 2 X SSC, 0.1% SDS at 65°C for 40
minutes.
Fluorescence in situ hybridization. YAC clones containing the hu¬
man KIF3C sequence were identified by screening the ICI YAC li¬
brary (11) by PCR with the stSG4510-specific primers. These YACs,
141 C3 and 35H B12, were shown also to contain the marker
D2S2144. Clone 35H B12 was propagated on synthetic dextrose (SD)
medium to obtain a pure, single colony which was grown to satura¬
tion in SD broth. A total yeast DNA extract was obtained using
standard techniques. The probe was labeled by nick-translation with
Digoxigenin-ll-dUTP and 300ng used for FISH analysis as described
(12). Chromosomes were identified with 4,6-diamidino-2-phenylin-
dole-dihydrochloride (DAP1). Microscopy was performed using a
Zeiss Axioskop fluorescence microscope coupled to a CCD camera
and image analysis system (Vysis, UK).
Interspecific backcross mapping. Primers Kin3: dGGAGATGC-
AGCAGGAGATG; and Kin2 : dGGGTCTGCTCGTTCTGCG were
used to amplify fragments of — 1.0 kb from C57BL/6J and M. spretus
DNA. A polymorphic (CT)n repeat was found adjacent to the Kin2
(exon 4) end of this fragment. A third primer MKin2R (dGCATTCCA-
TCAGTTCTCTTTCAG), on the other side of the (CT)n repeat was
used in conjunction with Kin2 to characterize this polymorphism:
MKin2R and Kin2 amplify a —350 bp fragment from C57BL/6J and













Exon 6 Exon 7
109 bp 173 bp
Exon 8
2472 bp
0.6 kb 1.3 kb
oon
2.6 kb 1.5 kb 0.4 kb 0.231 kb
FIG. 3. Genomic organization of KIF3C. Exons are shown as shaded boxes, coding regions darker than untranslated regions. The
diagram is not to scale; exact exon sizes (bp) and approximate intron sizes (kb) are indicated.
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TABLE 1
KIF3C Exon/Intron Splice Junction Sequences
Exonl-TGCTTGCGGCCAAGTACAAGgtaagggccccagaggagct 1.0 kb acccctctgtgtgtccccagGCCATGGAGAGCAAGCTCCT-Exon2
Exon2-GGCAGGAGATTGCCGAGCAGgtagggcctccaggtgccag 0.6 kb actgcccgtccttggcctagAAACGTCGTGAGCGGGAGAT-Exon3
Exon3-AAACCAAGAAACTCAAGAAGgtgagacgctgcagcaggac 1.3 kb tggcacctgtccccacccagCTCTACGCCAAGCTGCAGGC-Exon4
Exon4-ACCCGCGAACTCAAGCTCAAgtagggcccgcagctctttt 2.6 kb tccttcattcctgctcccagGTACCTAATCATCGAGAACT-Exon5
Exon5-CCACTGGTGCCAGCCGGCGTgtagtctctaacccagctgt 1.5 kb atatagcctctttcctacagCAGTAGCAGCCAGATGAAGA-Exon 6
Exon6-GGTCCCACCCCAGGTACAGGgtaagaagcggagaggggag 0.4 kb tggcatgatattcccaccagGCTGAAAACATAATGTTTCT-Exon7
Exon7-GTCCGAAAGTCCAGATCCTGgtcagtacctccatggtccc 0.231 kb ctgcgtcatctcccctgcagGTGCCAGAGTCCTCAGCGGC-Exon8
Note. Intron sequences are in lowercase and exon sequences in capital letters.
RESULTS
Sequencing KIF3C cDNA
The human EST clone 28784 (GenBank Accession
No. R14361) displayed significant sequence homology
to the 68D and the 95K kinesin-like proteins of Dro-
sophila melanogaster and Strongylocentrus purparatus
respectively. Nucleotide sequence analysis of the entire
1917 bp insert revealed a 720 bp ORF encoding a
kinesin-like carboxy-terminal tail domain and 1197 bp
of 3'UTR sequence. A composite full-length cDNA
(4913 bp) was assembled from a human fetal brain
cDNA clone, from 5' RACE products which were gener¬
ated from total fibroblast RNA and from genomic se¬
quence of the large 3 'UTR-containing exon. (This latter
genomic sequence was shown to consist of a single exon
by comparison to a large cDNA contig assembled from
dbEST sequences spanning the whole region.)
The full-length cDNA is characterized by a single
open reading frame of 2382 bp encoding a predicted
protein of 793 amino acids (Figure 1). The overall orga¬
nization of the predicted protein is similar to members
of the KIF3 family of KRPs and contains an amino-
terminal motor domain (residues 1-389), a central rod
domain (residues 390-599) and a carboxy-terminal tail
domain (residues 600-793). A putative polyadenylation
signal is located 2354-2359 nucleotides downstream
from the translation termination codon. The cDNA
clones have a poly(A) tail added 20 nucleotides down¬
stream of this (2378 bp downstream of the termination
codon; see Figure 1).
Among the kinesin superfamily proteins described
thus far, this novel sequence is most similar to a 195
bp partial cDNA encoding the murine KIF3C motor
domain (GenBank Accession No AB001433; corre¬
sponding to residues 93-257 in Figure 1), the human
and mouse sharing 91% and 98% identities in nucleo¬
tide and amino acid sequence respectively.
Comparison of the amino acid sequences ofKIF3 mo¬
tor domains revealed that the human KIF3C sequence
encodes a 24 amino acid glycine-rich domain which is
not conserved in other KIF3 proteins (Figure 2).
Structural Organization of the Human KIF3c Gene
The results of DNA sequence analysis of PAC clones
are summarized in Figure 3 and Table 1. The human
KIF3C gene spans approximately 12 kb of genomic
DNA and consists of 8 exons and 7 introns, the exons
ranging in size from 2472 bp to 109 bp. The first methi¬
onine codon of the open reading frame is located in
exon 1, whereas the stop codon and poly(A) addition
signal are located in the last exon-exon 8. Exon 8 con¬
tains 2378 bp of untranslated sequence. All introns
have the consensus sequence C/T/A/AG-exon-GT(G/A)
at their boundaries (Table 1).
The present geiie structure is the first described for
any kinesin family member. The ATP/GTP-binding site
motif A (442 to 465 nt) and the kinesin motor domain
signature (871 to 906 nt) are both located in exon 1.
This exon includes the whole of the A-terminal motor
and over half of the rod domain. Exons 2 and 3 encode




FIG. 4. Northern blot analysis of KIF3C expression in different
human tissues. Approximately 1/ig of total RNA from various adult
human tissues were loaded: brain (lane 1), salivary gland (lane 2),
oesophagus (lane 3), trachea (lane 4), heart (lane 5), lung (lane 6),
stomach (lane 7). The size of the 28S (4.8 kb) and 18S (1.8 kb) ribo-
somal RNA subunits are shown. The largest transcript, expressed
only in brain is marked with an asterisk.
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FIG. 5. Chromosome mapping of human KIF3C by fluorescence in situ hybridization. A signal is present on both both chromatids of
chromosome 2 at a location corresponding to p23.
Expression ofHuman KIF3C
The tissue distribution of human KIF3C mRNA was
determined by analysis of a multi-tissue Northern blot
using an 818 bp motor domain PCR fragment as a
probe. A transcript of approximately 5.0 kb in size was
expressed in brain but could not be detected in any of
the other tissues tested (Figure 4). Smaller transcripts
of approximately 1.5, 1.3 and 1.0 kb were identified in
all tissues with similar levels of expression.
Chromosomal Mapping ofHuman and Mouse KIF3C
Following hybridization of a digoxigenin-labeled
KIF3C probe to normal human chromosomes, doublet
signals at human chromosome 2p23 were observed in
25 cells (Figure 5). The distribution on 2p was as fol¬
lows: 1(4), 2(21), 3(0), 4(0) chromatids per cell. This
FISH result independently confirms the KIF3C local¬
ization obtained by radiation hybrid mapping of
stsG4510 and by the co-localization with D2S2144 in
YACs 141 C3 and 35H B12.
To determine the location of the corresponding
mouse gene, linkage analysis was performed. A data¬
base search was performed to identify a murine cDNA
clone (W82835) highly similar to the 3' untranslated
region (nt 4349-4913) ofKIF3C. A 458 bp genomic frag¬
ment corresponding to part of this clone was amplified
from Mus spretus and C57BL/6J, but no polymorphic
differences were seen on sequencing. Therefore, prim¬
ers designed against the human KIF3C exon 3 and exon
4 sequences, were used to amplify fragments of ~1.0
kb from C57BL/6J and M. spretus DNA and the PCR
products' ends sequenced. The sequence from the Kin2
primer end crossed the splice acceptor site of intron 3
and within this intron a polymorphic (CT)n repeat re¬
gion was found. Using the Jackson Laboratory Back-
cross DNA Panel Mapping Resource, 94 animals from
the interspecific cross (C57BL/6JEi X SPRET/Ei) X
SPRET/Ei were genotyped. The resulting linkage data
placed the murine gene on chromosome 12 between
D12Mit44 and D12MH182. The mouse ApoB gene also
maps to this interval. (Human APOB is localized to
2p23-p24). Therefore, KIF3C/Kif3c map to a region of
conserved human-mouse synteny.
DISCUSSION
In this report we describe the cloning, structural analy¬
sis, expression and localization of a novel human kinesin-
like gene. The protein encoded is most similar to members
of the KIF3 subfamily of kinesins which includes the sea
urchin 95K, Drosophila 68D, and mouse Kif3a and Kif3b
KRPs (13-16). The overall homology of these proteins with
the human sequence is 64%, 47%, 48% and 72% respec¬
tively and that relative to the motor domain (amino acid
residues 93-251, Figure 1) increases to 80%, 56%, 63% and
82%. The strongest homology was to a sequence encoding
65 amino acids of the mouse Kif3c motor domain (17-18).
The mouse and human peptides share 98% identity and
differ only at a single residue. DNA and protein sequence
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homology and localization of the human kinesin-like gene
to chromosome 2p23, a region syntenic with mouse chro¬
mosome 12, suggests that the novel gene described in this
paper is the human homologue ofmouse KifSc.
Although genes of the kinesin family are ubiqui¬
tously expressed, some of its members display a re¬
stricted tissue distribution, including Kifl, Kif3 and
Kif5, which are expressed almost exclusively in murine
brain (19), suggesting that certain kinesins may per¬
form tissue-specific functions. Northern blot analysis,
using a probe encoding the KIF3C motor domain, iden¬
tified a transcript of approximately 5.0 kb which was
expressed in human brain but not in any of the other
tissues tested. This is in agreement with studies show¬
ing mouse Kif3c to be expressed mainly in neural tis¬
sues such as brain, spinal cord and retina (18). The
fact that RACE products from near the 5' end of the
gene could be generated from total fibroblast RNA sug¬
gests a basal level of expression of the larger transcript
in tissue other than brain, which is detectable by RT-
PCR but not Northern hybridization. Smaller tran¬
scripts of approximately 1.0, 1.3 and 1.5 kb appear
clearly in this Northern blot after stringent wash condi¬
tions and were expressed at comparable levels in all
tissues. It is possible that these smaller transcripts
represent cross-reacting KRPs.
KIF3 subfamily proteins have been reported to be
plus-end-directed microtubule motors with roles in an¬
terograde axonal transport for membraneous organ¬
elles in neurons. Immunoprecipitation assays have
shown that some members, including mouse Kif3a and
3b, assemble heterotrimeric complexes comprising two
homologous but distinct KRPs associated with a non-
kinesin polypeptide subunit which has been proposed
to function as an adapter for cargo attachment (13,
16). Proteins with which mouse Kif3c interacts and the
nature of the cargo that it transports have yet to be
determined. However, localization of a gene for sensori¬
neural non-syndromic recessive deafness, DFNB9, to
the same chromosomal region, 2p22-23 (20), as the hu¬
man KIF3C gene suggests KIF3C as a good candidate
gene for DFNB9. This is supported by the fact that
both non-syndromic deafness at the DFNB2 locus
(llql3) and the syndromic form of deafness Usher syn¬
drome IB result from mutations in the myosin VIIA
(MY07A) gene (21-25). MY07A encodes an atypical
myosin which like kinesins, has an intraneuronal
transport function. Genetic defects of some atypical
myosins and kinesins can even cross-complement in
yeast (26). Investigation of the possible role ofKIF3C in
human sensorineural deafness is currently in progress.
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